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SUMMARY 
Malignant gliomas are the most frequent primary brain tumors in adults and have a poor 
prognosis, despite advances in the conventional treatment involving neurosurgery, 
followed by radiation- and chemotherapy. Hence, there is a great need for the 
development of novel therapeutic approaches. Gene therapy based on viral vectors 
represents an interesting alternative or adjuvant to conventional cancer therapies. The 
oncotropic and oncolytic properties of rodent autonomous parvoviruses, together with 
their low pathogenicity make them particularly attractive candidates as viral vectors for 
cancer gene therapy.  
Gliomas are highly vascularized tumors that induce a strong immunosuppressive 
environment. Therefore, our laboratory has recently investigated the antitumor effects of 
parvoviral vectors delivering human interferon inducible protein-10 (hIP-10) and mouse 
tumor necrosis factor-α (mTNF-α), cytokines known to have both immunostimulatory 
and antiangiogenic properties, in a syngeneic mouse glioma model. These recombinant 
viruses strongly inhibited the growth of murine GL261 glioma cells grafted 
subcutaneously in immunocompetent mice. Complete tumor regression was observed 
when glioma cells were coinfected with both vectors, demonstrating synergistic 
antitumor effects (Enderlin et al., 2008). 
In the present study, the mechanisms sustaining subcutaneous tumor inhibition by  
TNF-α- and IP-10-encoding parvoviral vectors were investigated. Parvoviral-transduced 
TNF-α increased the mRNA expression and protein secretion of endogenous IP-10 in 
GL261 cells in vitro. When both viruses were used in combination, the IP-10 levels may 
thus reach a critical threshold that could account for the synergistic antitumor effects 
observed in vivo. The analysis of the cellular immune response upon peritumoral 
injections of recombinant parvoviruses in established subcutaneous GL261 tumors 
showed a decreased infiltration of CD4+ and CD8+ T lymphocytes compared to PBS-
treated tumors. More strikingly, the infiltration of CD4+ T lymphocytes was dramatically 
decreased in tumors treated with cytokine-encoding vectors and inversely correlated 
with the tumor growth in vivo. We hypothesize that the antitumor effects could be due to 
a decrease of CD4+ T regulatory cells, known to suppress immune responses. In 
agreement with this, we could show that in vitro infection of GL261 cells with cytokine-
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encoding vectors led to a decrease of TGF-β that strongly correlated with the infiltration 
of CD4+ T cells.  
Next, the antitumor effects of parvoviral vectors transducing mTNF-α and hIP-10 were 
investigated on GL261 implanted intracranially in syngeneic C57BL/6 mice. The tumor 
growth and survival of mice implanted with GL261 cells in vitro infected with parvoviral 
vectors were monitored. Wild-type parvovirus and the vector devoid of transgene had 
only a slight antitumor effect, similarly to the results obtained subcutaneously. In 
contrast, in the intracranial setting, TNF-α-, but not IP-10-encoding vector significantly 
delayed the tumor growth of GL261 glioma and prolonged the survival of tumor-bearing 
mice. No synergy between TNF-α and IP-10 could be observed in this setting. 
Immunohistochemical analysis on brain tumor samples showed that parvoviral infection 
induced a moderate infiltration of CD4+ and CD8+ T lymphocytes. The TNF-α-
transducing parvoviral vector decreased tumor microvascularization as well as the 
infiltration of CD68+ macrophages/microglia, and these effects are likely responsible for 
the antitumor effects observed.  
The monocyte chemotactic protein (MCP)-2 and -3 are known to be potent 
immunoactive cytokines, recruiting a broad range of leukocytes. Parvoviral vectors 
delivering MCP-3 were shown to inhibit the tumor growth in several animal tumor 
models. This prompted us to compare the effects of parvoviruses delivering MCP-2 and 
MCP-3 in the GL261 intracranial glioma model to those obtained with parvoviral vectors 
transducing TNF-α and IP-10. No effects on tumor growth and animal survival could be 
observed, suggesting a possible processing of MCP-2 and MCP-3 by GL261 cells, 
leading to their inactivation.  
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ZUSAMMENFASSUNG 
Maligne Gliome sind die am häufigsten bei Erwachsenen auftretenden Hirntumor. Trotz 
großer Fortschritte in der konventionellen Behandlung, die aus Neurochirurgie, gefolgt 
von Strahlen- und Chemotherapie besteht, haben maligne Gliome eine sehr schlechte 
Prognose. Daher bedarf es dringend einer Entwicklung neuer therapeutischer Ansätze. 
Die virale Gentherapie stellt eine interessante Alternative oder auch Adjuvans zur 
konventionellen Krebstherapie dar. Die autonomen Nagetierparvoviren sind aufgrund 
ihrer onkotropischen und onkolytischen Eigenschaften, sowie ihrer niedrigen 
Pathogenität besonders attraktive Kandidaten für die Entwicklung viraler Vektoren für 
die Gentherapie gegen Krebs. 
Gliome sind hochvaskularisierte Tumore, die ein stark immunsuppressives Milieu 
erzeugen. Daher wurde in unserem Labor vor kurzem die antitumoralen Effekte 
parvoviraler Vektoren, die das humane Interferon-γ-induzierte Protein-10 (hIP-10) und 
den murinen Tumornekrosefaktor-α (mTNF-α) transduzieren, in einem syngenen, 
murinen Gliom-Modell untersucht. IP-10 und TNF-α sind Zytokine, die für ihre 
immunostimulatorischen und antiangiogenischen Eigenschaften bekannt sind. Diese 
rekombinanten Viren konnten das Wachstum von murinen GL261-Gliomzellen, die 
subkutan in immunkompetente Mäuse appliziert wurden, signifikant hemmen. Die 
Koinfektion der Gliomzellen mit beiden Vektoren führte zu einer kompletten 
Tumorregression, was auf einen synergistischen antitumoralen Effekt schließen lässt 
(Enderlin et al., 2008). 
In der vorliegenden Arbeit wurden die Mechanismen, die zu einer Hemmung des 
Tumorwachstums durch TNF-α- und IP-10-kodierende parvovirale Vektoren führten, 
untersucht. Parvoviral transduziertes TNF-α verstärkte die mRNA-Expression und 
Proteinsekretion von endogenem IP-10 in GL261-Zellen in vitro. Die Kombination von 
beiden Viren könnte auf diese Weise in IP-10-Mengen resultieren, die oberhalb eines 
kritischen Schwellenwertes liegen und so zu den in vivo beobachteten synergistischen 
antitumoralen Effekten führen. Die Analyse der zellulären Immunantwort nach 
peritumoraler Applikation der rekombinanten Parvoviren in etablierte, subkutane GL261 
Tumore zeigte eine verringerte Tumorinfiltration von CD4+ und CD8+ T-Lymphozyten im 
Vergleich zu PBS behandelten Tumoren. Auffallend war die drastisch verringerte 
Tumorinfiltration von CD4+ T-Lymphozyten durch die Behandlung mit den Zytokin-
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kodierenden Vektoren, die mit dem Tumorwachstum in vivo umgekehrt korrelierte. Wir 
vermuten, dass die antitumoralen Effekte auf einer Verringerung der CD4+ 
regulatorischen T-Zellen beruhen, welche eine Suppression von Immunantworten 
verursachen. Zudem konnten wir zeigen, dass die in vitro Infektion von GL261-Zellen 
mit Zytokin-kodierenden Vektoren zu einer Verringerung an TGF-β führte, welche stark 
mit der Infiltration von  CD4+ T-Lymphozyten korrelierte.  
Desweiteren wurden die antitumoralen Effekte der mTNF-α- und hIP-10-
transduzierenden parvoviralen Vektoren auf GL261-Zellen untersucht, die intrakranial in 
syngene C57BL/6 Mäuse implantiert wurden. Hierzu wurden das Tumorwachstum der 
mit parvoviralen Vektoren präinfizierten GL261-Zellen sowie die Überlebensrate der 
behandelten Mäuse beobachtet. Wildtyp Parvovirus und der virale Vektor ohne 
Transgen zeigten nur einen schwachen antitumoralen Effekt. Dies gleicht den 
Resultaten aus dem subkutanen Tumorversuch. Im Gegensatz hierzu, konnte TNF-α-, 
jedoch nicht IP-10-kodierende parvovirale Vektoren im intrakranial Tierversuch zu einer 
signifikanten Verzögerung des Tumorwachstums der GL261 Gliome sowie zu einem 
verlängerten Überleben der tumortragenden Mäuse führen. Zudem wurde kein 
synergistischer Effekt zwischen TNF-α und IP-10 beobachtet. Immunohistochemische 
Untersuchungen der Hirntumorproben zeigten, dass die parvovirale Infektion zu einer 
mäßigen Infiltration von CD4+ und CD8+ T-Lymphozyten führte. Der TNF-α-
transduzierende parvovirale Vektor verringerte die Vaskularisierung des Tumors und die 
Infiltration von CD68+ Makrophagen/Mikroglia. Dies scheint für die beobachteten 
antitumoralen Effekte verantwortlich zu sein. 
Die Monozyten chemotaktisches Proteine (MCP)-2 und -3 sind potente immunaktive 
Zytokine, die eine Vielzahl an Leukozyten rekrutieren. Es konnte gezeigt werden, dass 
MCP-3-transduzierende parvovirale Vektoren das Tumorwachstum in verschiedenen 
Tiermodellen hemmen. Dies veranlasste uns die Effekte von MCP-2- und MCP-3-
transduzierenden vektoren im intrakranialen GL261-Gliom-Modell mit denen von     
TNF-α und IP-10 zu vergleichen. Es konnten jedoch keine Effekte auf Tumorwachstum 
und Überlebensrate beobachtet werden. Wir vermuten, dass MCP-2 und MCP-3 in den 
GL261-Zellen prozessiert werden, was zu ihrer Inaktivierung führt. 
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1. INTRODUCTION 
1.1. Gliomas 
Gliomas are primary tumors of the central nervous system (CNS), originating from glial 
cells or their precursors. They are classified according to the glial cell types that 
predominate in the tumor mass as astrocytomas, oligodendrogliomas, mixed 
oligoastrocytomas and ependymomas. Gliomas are graded by the World Health 
Organization (WHO) on a scale from I to IV, based on the degree of malignancy, as 
determined by histopathological and genetic features. Astrocytomas are the most 
frequent intracranial neoplasm and account for more than 75% of all gliomas (CBTRUS, 
2004). They are graded as pilocytic astrocytomas (grade I, non malignant), diffuse 
astrocytomas (grade II, non malignant), anaplastic astrocytomas (grade III, malignant) 
and glioblastoma multiforme (GBM) (grade IV, malignant) (Louis et al., 2007). GBM is 
the most aggressive and most prevalent type of glioma (Louis et al., 2002). It accounts 
for 20% of all primary brain tumors and occurs at a frequency of about 5 cases per 
100 000 people (CBTRUS, 2004). GBMs typically affect adults and are preferentially 
located in the cerebral hemispheres. They are further subdivided into primary and 
secondary subtypes, based on the clinical presentation. Whereas primary GBMs 
develop de novo without antecedent history, secondary GBMs show evidence of 
malignant progression from previously diagnosed lower grade tumors (Kleihues and 
Ohgaki, 1999). Despite their distinct clinical histories, primary and secondary GBM have 
indistinguishable histopathologies and their prognosis is not significantly different.  
 
The main histopathological features of GBMs include aggressive growth, highly 
infiltrative properties, potent immunosuppression, and prominent vascularization 
(Brandes et al., 2008). These properties together with their anatomic location make 
malignant gliomas very challenging tumors to treat. Despite recent advances in the 
conventional treatment, involving surgery followed by adjuvant radio-and chemotherapy, 
the prognosis of patient with malignant gliomas remain poor, especially for GBM, with a 
median survival of less than a year after diagnosis (Stupp et al., 2005a). Thus, there is a 
great need for new therapeutics and gene therapy is emerging as a promising 
alternative to supplement the conventional therapies.  
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1.2. Glioma therapy  
1.2.1. Conventional treatment strategies 
The current standard treatment for gliomas involves surgical resection followed by 
adjuvant radiation therapy and chemotherapy. 
1.2.1.1 Surgery 
Surgery is commonly the initial therapeutic modality for newly diagnosed gliomas (Hsieh 
and Lesniak, 2005; Stupp et al., 2005b). The aim is to achieve maximum resection 
without causing any neurological defects. Despite improved surgical techniques, 
complete resection of the tumor is often hampered by the absence of defined tumor 
edges or localization of the tumor in critical areas of the brain. Even after apparent 
complete removal, there are almost invariably residual tumor cells infiltrated beyond the 
tumor margin defined and local recurrence is almost inevitable. Yet, tumor resection, 
even partial, relieves the increased intracranial pressure and improves the response to 
post-operative adjuvant treatments through disruption of the blood brain barrier (BBB). 
Biopsies are performed for inoperable tumors, providing histological confirmation of the 
diagnosis, required prior to alternative radiation or chemotherapy. 
1.2.1.2 Radiotherapy 
Post-operative radiation therapy has been shown to prolong the median survival of 
patients with glioblastomas and is the standard adjuvant therapy for high-grade gliomas 
after resection or biopsy (Fiveash and Spencer, 2003; Laperriere et al., 2002). The 
current treatment protocol involves conventional fractionated external-beam 
radiotherapy to total a dose of 60 Gy delivered in 30 daily fractions of 2 Gy. To limit 
irradiation of normal brain tissue, radiations are directed to a localized volume including 
the tumor bed and a 2-5 cm margin, where recurrence occurs in most of the cases 
(Brada, 2006). The main limitation to brain tumor radiotherapy is the radiation tolerance 
of normal brain tissue. Therefore, new techniques were developed to deliver more 
precise and higher dose of radiation, such as hyper-fractionation, stereotactic surgery or 
radiation sensitizers. However, until now, these alternative radiotherapies failed to 
demonstrate a survival benefit compared with conventional fractionated radiation 
therapy (Brada, 2006; Laperriere et al., 2002). 
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1.2.1.3 Chemotherapy  
Despite treatment of malignant gliomas with surgery followed by radiotherapy, most of 
the tumors recur and therefore additional therapies are required. Chemotherapy is 
currently a standard modality of treatment for gliomas, used either during or after 
radiotherapy. The most commonly used agents for glioma therapy are alkalyting agents 
including nitrosoureas (carmustine, lomustine), platinium-based drugs (cisplatin, 
carboplatin) and more recently temozolomide (Lonardi et al., 2005). The main limitations 
of chemotherapy are the blood-brain barrier and the development of chemorestistant 
cells within the tumor. The latter can be overcome through combination of multiple types 
of antitumoral drugs. The most common drug combination is the nitrosourea-based 
regime of procarbazine, lomustine, and vincristine (Stupp et al., 2005a). Nitrosoureas 
were long considered as the standard chemotherapy approach for malignant gliomas. 
However, their toxicity is not negligible and clinical studies have failed to demonstrate 
significant evidence of their benefits on patient survival (Lonardi et al., 2005; Stupp et 
al., 2005a). In contrast, concomitant and adjuvant chemotherapy with temozolomide 
was recently shown to increase patient survival with minimal additional toxicity, and has 
therefore become the standard treatment for newly diagnosed glioblastoma (Stupp et 
al., 2005a). 
 
Even after surgery followed by adjuvant radio- and chemotherapies, local recurrence 
occurs in more than 80% of the patients (Lonardi et al., 2005). The prognosis of patients 
with malignant gliomas remains poor, with a median survival of approximately one year 
after initial diagnosis (Stupp et al., 2005a).   
1.2.2. Gene therapy of glioma 
Gene therapy is defined as the transfer of engineered genetic material into cells for 
therapeutic purpose. Malignant gliomas remain mostly refractory to conventional 
therapies and therefore represent attractive targets for gene therapy. Moreover, their 
localization in an anatomically restricted area should allow local delivery of gene therapy 
vehicles without the risk of severe systemic toxicity. 
Currently there are two main approaches for gene transfer in the CNS, referred as in 
vivo and ex vivo strategies. In the in vivo approach, the genetic material is directly 
delivered into the target cells, either by systemic or local delivery into the brain. In the ex 
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vivo approach, the target cells are first removed from the patient, genetically modified by 
gene transfer in the laboratory, and subsequently re-implanted into the host.  
1.2.2.1 Gene therapy approaches 
Several gene therapy strategies were developed for malignant gliomas, including direct 
killing of tumor cells by correction of genetic defects, suicide genes, suppression of 
angiogenesis and immunotherapy. 
1.2.2.1.1 Correction of genetic defects 
This strategy, also referred to as replacement gene strategy, intends to transfer specific 
genes that are mutated or deleted in patients, such as tumor suppressor genes. 
Inactivation of p53, Rb and p16 suppressor genes is commonly found in glioma tumors, 
leading to a loss of cell cycle control. In this context, adenoviral vectors encoding wild-
type p53, p16 or Rb were evaluated in preclinical studies and were shown to inhibit 
glioma tumor growth both in vitro and in vivo (Chintala et al., 1997; Fueyo et al., 2000; 
Kock et al., 1996). Adenoviral vectors delivering p53 were further evaluated in a phase I 
clinical study in patients with glioblastoma. Although p53 transfer was observed in tumor 
cells, the effect was limited to a short distance from the injection site (Lang et al., 2003). 
1.2.2.1.2 Suicide genes: prodrug activating enzymes 
This approach involves the gene transfer of an enzyme which converts a prodrug, 
normally innocuous, into a toxic compound leading to cell death. Most of the gene 
therapy trials for malignant gliomas have been based on the delivery of the herpes 
simplex virus - thymidine kinase (HSV-TK) followed by systemic administration of the 
prodrug ganciclovir (GVC). The HSV-TK enzyme activates GCV, which in turns inhibits 
DNA synthesis and leads to cell death. Retroviral as well as adenoviral vectors 
encoding HSV-TK were tested both in preclinical and clinical studies of gliomas 
(reviewed in Aghi and Chiocca, 2006). Adenoviral vectors were found to be more 
effective compared to retroviral vectors and this could be assigned to the higher 
transduction efficiency of adenoviral vectors in human glioma cells (Sandmair et al., 
2000). Furthermore, there is a risk of insertional mutagenesis with retroviruses. 
However, the survival increase with adenoviral vectors was in most clinical trials non-
significant compared with the standard treatment (Aghi and Chiocca, 2006). 
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1.2.2.1.3 Suppression of angiogenesis 
Malignant gliomas are among the most highly vascularized tumors and thus 
angiogenesis represents an attractive therapeutic target. Two main strategies have 
been tested, namely the inhibition of endogenous angiogenic factors, and the delivery of 
natural antiangiogenic agents. Vascular endothelial growth factor (VEGF) and its 
receptors seem to be the central signaling pathway in glioma angiogenesis, but other 
pathways were also identified, involving for instance fibroblast growth factor (FGF) or 
epidermal growth factor (EGF). Inhibition of these pathways in glioma resulted in a 
reduced tumor vascularization and tumor growth in animal models (Tuettenberg et al., 
2006). Several antiangiogenic molecules have also shown antitumor effect in preclinical 
studies including angiostatin (Ma et al., 2002), endostatin (Peroulis et al., 2002) and 
platelet factor-4 (Bikfalvi, 2004). The results of preclinical studies are very encouraging 
and several clinical trials in glioma patients are ongoing using antiangiogenic molecules. 
Up to now, the most widely antiangiogenic molecules evaluated in clinical trials for 
malignant gliomas have been thalidomide, known to inhibit VEGF- and FGF-mediated 
angiogenesis and interferon (IFN)-α and -β, known to suppress FGF expression. 
However, both drugs gave variable results and induced severe side effects 
(Tuettenberg et al., 2006). 
1.2.2.1.4 Immunotherapy 
This strategy aims to stimulate the immune system to mount an effective immune 
response against glioma cells. Gliomas create a very immunosuppressive environment 
and commonly escape recognition by the immune system. Thus, immunotherapy 
represents an attractive strategy for glioma treatment. Several approaches have been 
tested in preclinical and clinical studies, including the transfer of immunostimulatory 
cytokines, and the ex vivo manipulation of immune cells. The transfer of several 
cytokines was shown to result in significant antitumor responses in animals models 
including interleukin-2, -4, -12 (IL-2, IL-4, IL-12), and granulocyte macrophage-colony 
stimulating factor (GM-CSF) (Benitez et al., 2008; Okada and Pollack, 2004). These 
cytokines mainly aim to enhance the activation of T lymphocytes. Another promising 
approach consists in the ex vivo manipulation of effector cells such as T lymphocytes or 
especially dendritic cells (DC), normally absent from the brain parenchyma (Barzon et 
al., 2006).   
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1.2.2.2 Gene transfer vectors 
To deliver the genes of interest into tumor cells, various viral and non-viral vectors were 
developed. Viral vectors are considered up to now as the most effective gene delivery 
system and are predominantly used in gene therapy trials. Most vectors are produced 
by replacement of one or more genes necessary for viral replication by the transgenes 
and are thus replication deficient.  
The main viral and non-viral vectors used for gene therapy purposes in malignant 
gliomas have been retroviral vectors and adenoviral vectors, although liposomes were 
also tested. Most clinical trials have been performed using retroviral and adenoviral 
vectors delivering the suicide gene HSV-TK, and adenoviral vectors encoding p53 
(Andreansky et al., 1996).  
Although the different gene transfer methods tested in gliomas have generally been 
proven to be safe and well tolerated, the clinical responses were rather disappointing 
compared to the preclinical results. This has been mainly assigned to the inefficient 
transduction of tumor cells and lack of selectivity of the vectors. Thus, continuous efforts 
in vector engineering are required to increase the selectivity and efficiency of tumor cell 
transduction.  
 
1.2.3. Oncolytic virotherapy 
Oncolytic viruses are replicating viruses able to selectively infect and lyses tumor cells, 
either naturally or through appropriate engineering. They are either used as direct killing 
agent or modified to be used as gene transfer vector, thus allowing highly selective 
delivery in tumor cells. 
Oncolytic viruses engineered from HSV type 1 (HSV-1) and adenovirus have been most 
intensively studied for glioma therapy, although naturally tumor-selective viruses like 
Newcastle disease, reovirus, poliovirus, vesicular stomatis virus and vaccinia virus are 
also under consideration.  
Oncolytic viruses derived from HSV-1 used in clinical trials for malignant gliomas 
include G207 and HSV1716. Both mutants harbor deletion in the neurovirulence gene 
γ34.5 and are thus replication-defective in neurons but replicate efficiently in 
transformed cells (Harrow et al., 2004; Markert et al., 2000; Papanastassiou et al., 
2002; Rampling et al., 2000). G207 and HSV1716 were tested in phase I clinical studies 
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in patients with malignant gliomas and gave promising results without any associated 
toxicity (Heise et al., 1997). 
Oncolytic virotherapy of malignant glioma with oncolytic adenoviruses was conducted 
using ONYX-015. ONYX-015 is an adenovirus mutant deleted in the E1B gene that 
preferentially replicates in p53 deficient cells, thus being more selective for cancer cells 
(Chiocca et al., 2004). The potential efficacy and safety was evaluated in a phase I 
clinical trial in patient with recurrent gliomas. Although no serious side effects were 
observed, no significant antitumor effect could be demonstrated (Berns, 1996).  
 
Autonomous parvoviruses are emerging as promising oncolytic viruses for cancer 
therapy. Indeed, they are endowed with intrinsic oncolytic but also oncotropic and 
oncosuppressive properties. Moreover, they show low pathogenicity in adult animals 
and prevalent cytotoxicity in transformed cells (Cornelis et al., 2004a).  
1.3. Autonomous parvoviruses  
Parvoviruses (latin parvus = small) are, with a diameter of approximately 20–25 nm, 
among the smallest, non enveloped icosahedral viruses, containing a linear single-
stranded DNA genome of 4 to 6 kb and belong to the Parvoviridae family (Berns, 1996).  
1.3.1. Taxonomy of Parvoviruses 
The Parvoviridae family is divided into two subfamilies on the basis of their host range: 
the Parvovirinae infecting birds and mammals, and the Densovirinae infecting insects 
and other arthropods (see Figure 1-1). The Parvovirinae subfamily is further divided in 
five genera: Parvovirus, Dependovirus, Erythrovirus, Amdovirus and Bocavirus and 
includes the known human viruses such as B19 (Erythrovirus) and the adeno-
associated viruses (AAV, Dependovirus). The erythrovirus B19, as well as the recently 
identified Human Bocavirus (HuBoca) are until now the only known human pathogenic 
members of the Parvoviridea (Anderson, 2007; Anderson et al., 1983).  
Dependoviruses, with the exception of the goose (GPV) and duck parvoviruses (DPV), 
are so called because they require the assistance of a helper virus, adenovirus, herpes 
virus or vaccinia virus, for efficient replication (Berns et al., 2000; Kerr et al., 2006). In 
contrast, other members of the Parvovirinae are able to replicate independently and are 
commonly described as autonomous parvoviruses (Kerr et al., 2006). 
INTRODUCTION 
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Family Subfamily Genus Species Host 
Parvovirus MVM, H-1 PV, FPV, KRV, LuIIIV,  MPV-1, PPV  
Vertebrates 
Dependovirus AAV, AAAV, BAAV, DPV, GPV Vertebrates 
Erythrovirus B19 Vertebrates 
Amdovirus AMDV Vertebrates 
Parvovirinae 
Bocavirus BPV-1, CnMV, HuBoca Vertebrates 
Densovirus JcDNV, GmDNV Invertebrates
Iteravirus BmDNV, CeDNV Invertebrates
Brevidensovirus AaeDNV, AalDNV Invertebrates
Parvoviridae 
Densovirinae 
Pefudensovirus PfDNV Invertebrates
 
 
Figure 1-1: Taxonomy of the Parvoviridae family 
MVM: Minute Virus of Mice; H-1 PV: H-1 parvovirus; FPV: Feline panleukopenia virus; KRV: Kilham rat 
virus; LuIIIV: LuIII virus; MPV-1: Mouse parvovirus 1; PPV: Porcine parvovirus; AAV: Adeno-associated 
virus; AAAV: Avian adeno-associated virus; BAAV: Bovine adeno-associated virus; DPV: Duck 
parvovirus; GPV: Goose parvovirus; B19: B19 virus; AMDV: Aleutian mink disease virus; BPV-1: Bovine 
parvovirus type 1; CnMV: Canine minute virus; HuBoca: Human bocavirus; JcDNV: Junonia coenia 
densovirus; GmDNV: Galleria mellonella densovirus; BmDNV: Bombyx mori densovirus; CeDNV: 
Casphalia extranea densovirus; AaeDNV: aedes aegypti densovirus; AalDNV: Aedes albopictus 
densovirus; PfDNV: Periplaneta fuliginosa densovirus. (Adapted from Kerr et al., 2006) 
The Parvovirus genus contains three distinct subgroups based on host range: Feline 
panleukopenia virus (FPV), Porcine parvovirus (PPV), and rodent viruses species 
including a mouse virus group with Minute Virus of Mice (MVM), and Mouse 
parvovirus 1 (MPV-1), as well as a rat virus group with H-1 virus (H-1 PV), Kilham rat 
virus (KRV), and LuIII virus (LuIIIV). 
MVM comprises two strains, the immunosuppressive (MVMi) strain and the prototype 
(MVMp) strain, used in this study. Although they are very similar, with only 3% 
divergence in their genome (Sahli et al., 1985), both strains display different in vitro 
tropism and in vivo pathogenicity. Whereas MVMp replicates in vitro preferentially in 
mouse fibroblast cell lines, MVMi replication is restricted to mouse T lymphocytes and 
hematopoietic precursors (Segovia et al., 1991). The two strains are therefore also 
commonly named fibrotropic or prototype (MVMp) and lymphohematotropic (MVMi). In 
vivo, MVMp infection of newborn mice is asymptomatic, while MVMi infection leads to 
severe growth retardation or death (Kimsey et al., 1986).  
 
In this study, the parvoviral vectors used are based on the MVM prototype strain MVMp 
and are referred as MVMp-based vectors. 
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1.3.2. Organization of the parvoviral genome 
Parvoviruses are composed of a small, linear, single-stranded DNA genome (minus 
strand) of approximately 5 kb, flanked at both ends by palindromic hairpins (Berns, 
1996). The genomic organization of MVM together with the corresponding transcripts 
and proteins are illustrated in Figure 1-2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-2: Genomic organization and transcription map of MVM  
A. Line diagram of the MVM genome showing the coding sequence and terminal hairpins. The position of 
the early promoter P4, driving the expression of the viral non-structural proteins (NS 1/2) and of the late 
promoter P38, driving the expression of the viral capsid proteins (VP 1/2) is indicated by the arrows.       
B. Schematic representation of MVM transcripts and corresponding proteins. The three transcripts 
classes (R1, R2, R3) are represented with their frequency (M: major, m: minor, r: rare) and size. The 
encoded proteins are listed on the right of each transcript. The large (1 and 3) and small (2) open reading 
frames are depicted together with their respective splicing sites (vertical caret), as well as Poly (A) tail 
(AAA), and eventual cleavage site (CS). 
The viral genome contains two large overlapping transcription units (Bodendorf et al., 
1999) controlled by two distinct promoters: the early promoter P4 and the late promoter 
P38, driving respectively the expression of viral non-structural (NS) and capsid (VP) 
proteins (Pintel et al., 1983). Three major mRNA species, R1, R2 and R3 are produced, 
all terminating at a single common polyadenylation site at the right end of the genome     
(Clemens and Pintel, 1987). Transcription of the left unit, under the control of P4, 
produces two classes of mRNAs transcripts, R1 and R2, which are alternatively spliced. 
While R1 encodes the non-structural proteins NS1, the R2M, R2m and R2r splice 
A 
B 
R1 (4.8 kb)
R2M (3.3 kb)
R2m (3.3 kb)
R2r (3.3 kb)
AAA3
AAA3 2 2
3 2 AAA
3 2 AAA3
R3M (2.8 kb)
R3m (2.8 kb) 1 AAA
AAA1
Transcripts Proteins
NS1
NS2-p
NS2-y
NS2-l
VP2 
VP13
P4 P38
NS1 / NS2 VP1 / VP2
3' 5'
CS
Genome 5149 bp
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variants code respectively for the NS2-p, -y, and -l isoforms. Transcription of right unit, 
under the control of P38, produces one mRNA transcript R3, and its two splice variants 
R3M and R3m code for the viral proteins VP1 and VP2. VP3 is produced by proteolytic 
cleavage of VP2. While the viral P4 promoter has a strong and constitutive activity, P38 
promoter activity is conditional and depends on NS1 for its transactivation (Rhode, 
1985). 
 
1.3.3. Parvoviral Proteins 
1.3.3.1 Non-structural proteins 
NS1 is a 83 kDa nuclear phosphoprotein, involved in viral DNA replication, 
transactivation of the P38 promoter and parvoviral-mediated cytotoxicity (Li and Rhode, 
1990). NS1 is essential for the viral replication and exerts its functions through helicase, 
adenosine triphosphatase (ATPase), nickase, endonuclease activities and site-specific 
DNA binding properties (Cotmore et al., 1995; Wilson et al., 1991). NS1 binding sites 
are reiterated at multiple sites throughout the viral genome, including the viral DNA 
replication origins and the transactivating region (TAR) upstream of the P38 promoter. 
Upon binding to the TAR region, NS1, endowed with a transcriptional activation domain, 
upregulates transcription from the P38 promoter, and thus stimulates the expression of 
viral capsid genes (Rhode, 1985). Besides its functions in viral replication and 
transcription, NS1 exerts cytotoxic properties and is considered as the major mediator 
of parvovirus-induced cytotoxicity (Caillet-Fauquet et al., 1990; Li and Rhode, 1990). 
However, the mechanisms of NS1-mediated cytotoxicity remain elusive. NS1 
oligomerization, as well as phosphorylation were shown to be essential for both the 
replicative and cytotoxic functions of NS1 (Corbau et al., 2000; Li and Rhode, 1990; 
Nuesch et al., 1998). 
 
NS2 is a 25 kDa phosphoprotein, predominantly cytoplasmic, present in three different 
isoforms (p, y, l). While MVM NS2 is required for a productive infection in its natural 
host, it seems to be non-essential in cells from other species (Naeger et al., 1990). In 
murine cells, NS2 appears to influence various steps of the parvovirus life-cycle 
including synthesis of DNA replication forms, capsid assembly (Cotmore et al., 1997) 
and efficient nuclear egress of progeny virions (Eichwald et al., 2002). NS2 might also 
be implied in parvoviral cytotoxicity (Brandenburger et al., 1990). The mechanism of 
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action of NS2 remains unclear. NS2 was shown to interact with different proteins, 
including proteins of the 14-3-3 family (Brockhaus et al., 1996), the survival motor 
neuron protein (SMN) (Young et al., 2002) and the chromosome region maintenance 
protein 1 (CRM1) (Bodendorf et al., 1999). The interaction between NS2 and CRM1 
was shown to be essential for active nuclear export of NS2 and viral egress from the 
nucleus (Eichwald et al., 2002; Miller and Pintel, 2002). Up to now, no distinct function 
could be attributed to the different NS2 isoforms. 
 
Recently, a novel non-structural protein was identified in the genus Parvovirus, termed 
SAT, for small alternatively translated protein. The SAT protein is translated from a 
small open reading frame (ORF) located at the 5’ end of the VP2 ORF, highly 
conserved in the genome of all members of the Parvovirus genus. The SAT protein is a 
late non-structural protein, expressed from the VP2 mRNA. The role of the SAT protein 
remains elusive but its localization in the endoplasmic reticulum (ER) in porcine 
parvovirus suggests that SAT could mediate immune evasion by blocking major 
histocompatibility complex (MHC) type I processing or induce cell death pathways 
through ER stress as previously shown for other viral proteins localized in the ER 
(Zadori et al., 2005). 
1.3.3.2 Viral capsid proteins 
Parvoviral capsid proteins include VP1 (83 kDa), VP2 (64 kDa) and VP3 (60 kDa). 
While VP1 and VP2 constitute the majority of capsid proteins, both in empty and full 
capsid, VP3 is only found in DNA-containing capsids (Cotmore and Tattersall, 1987). 
Viral capsid proteins VP1 and VP2 are both endowed with unusual nuclear import 
signals and are translocated as oligomeres via nuclear pore complexes into the 
nucleus, where capsid assembly occurs (Lombardo et al., 2002). Besides its nuclear 
import signal, VP2 harbors also a nuclear export signal, required for the nuclear export 
of full particles (Maroto et al., 2004). While VP2 is sufficient for empty capsid assembly 
and virus binding to the host cell receptor, VP1 is required for a productive infection 
(Tullis et al., 1993). This is possibly owing to N-terminal VP1 phospholipase A2 (PLA2) 
activity, required for the transport of virions and/or viral DNA from the late endosomes to 
the nucleus (Zadori et al., 2001).  
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1.3.4. Parvoviral Life cycle 
Parvoviral infection begins with adsorption of the virus particle to specific cell surface 
receptors. Some cellular receptors of parvoviruses have been identified, including the 
erythrocyte P antigen globoside for B19 (Brown et al., 1993) and transferring receptors 
for the related canine (CPV) and feline (FPV) parvoviruses (Parker et al., 2001). The 
cellular receptors of MVM and H-1 remain unknown, but their sensitivity to 
neuraminidase and trypsin treatment favors N-acetyl neuraminic (sialyl) containing 
glycoproteins (Cotmore and Tattersall, 1987). Upon adsorption, parvoviruses are 
internalized by receptor-mediated endocytosis, most likely through clathrin-mediated 
endocytosis (Vihinen-Ranta et al., 2004), as shown for CPV (Suikkanen et al., 2002). 
The viral particles are then transported via several endosomal compartments, early 
toward late, to perinuclear compartments (Cotmore and Tattersall, 2007; Ros et al., 
2002). The endosomal acidification was shown to be essential for MVMp infection (Ros 
et al., 2002), inducing major rearrangements of the viral capsid necessary for nuclear 
entry in particular the externalization of the VP1 N-terminal sequence, and the cleavage 
of an exposed VP2 N-terminal sequence (Mani et al., 2006). The mechanisms implied in 
the transfer of viral DNA and/or viral particles from the endosomal compartments to the 
nucleus remain unclear but evidence suggests the implication of N-terminal VP1 PLA2 
activity (Zadori et al., 2001). In the nucleus, the viral single-stranded DNA is converted 
into a double-stranded monomeric replicative form, using the right-end palindromic 
hairpin as template to initiate DNA replication by the host cell polymerase (Berns, 1996). 
The conversion depends strictly on cellular factors transiently expressed during the S 
phase of the cell cycle such as cyclin A (Bashir et al., 2001). Thus, autonomous 
parvoviruses can only replicate in proliferating cells. Infection of resting cells leads to a 
latent infection, delayed until the host cells enter the S phase (Deleu et al., 1999). The 
monomeric replicative form is further amplified in multimeric intermediates and serves 
as template for the synthesis of viral mRNAs and progeny single-stranded DNA, which 
is then encapsidated in newly assembled capsids (Berns, 1996; Cotmore and Tattersall, 
1987). The viral life cycle ends in permissive cells with the release of progeny virions, 
usually associated with cell death. The parvoviral life cycle is schematically represented 
in Figure 1-3. 
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Figure 1-3: The parvoviral life cycle 
 
1.3.5. Oncosuppressive properties of rodent parvoviruses 
Originally isolated from tumor cells or tumor-bearing animals, rodent parvoviruses were 
first identified as potential cancerogen agents (Kilham and Olivier, 1959; Toolan et al., 
1962). On the contrary, they were later shown to prevent the formation of spontaneous, 
virally or chemically induced tumors in laboratory animals in vivo, a phenomenon known 
as oncosuppression (Dupressoir et al., 1989; Rommelaere and Cornelis, 1991; Toolan 
et al., 1982). In addition, antitumor effects of rodent parvoviruses could also be 
demonstrated both in established tumors or virus-infected tumor cells grafted in mice 
(Faisst et al., 1998; Haag et al., 2000). 
Tumor cells as well as in vitro transformed cells with oncogens or carcinogens were 
shown to sustain an increased viral DNA replication and gene expression, in 
comparison to their normal counterparts (Cornelis et al., 1988; Salome et al., 1990). The 
preferential replication of parvoviruses in transformed cells is referred to as oncotropism 
(Rommelaere and Cornelis, 1991). Cell transformation appears to provide beneficial 
environment for parvoviral replication. Indeed, it induces a dysregulation of the cell 
cycle, leading to proliferation but also to the activation of oncogenes, and was shown to 
stimulate all the steps of the virus life cycle depending on the cells. 
Conversion
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Rodent parvoviruses were also shown in vitro to preferentially kill transformed cells, 
compared to the normal parental cells (Rommelaere and Cornelis, 1991). This 
phenomenon is known as oncolysis and has been assigned, at least in part, to the 
cytotoxic NS1 protein (Caillet-Fauquet et al., 1990; Li and Rhode, 1990). 
1.3.6. Low pathogenicity of rodent parvoviruses 
The pathology of rodent parvoviruses in their natural host depends both on the virus 
strain and on the age of the animal. H-1 or MVMi infection of fetuses and neonates 
leads to acute, lethal diseases, while the infection of adult animals remains fully 
asymptomatic. Other rodent parvoviruses, like MVMp, or MPV-1 seem to be non 
pathogen in both neonates and adults (Ball-Goodrich et al., 1998; Jacoby et al., 1996; 
Siegl, 1984). 
In regards to the potential use of rodent parvoviruses as anti-cancer agents, their 
possible pathological effects in human are of importance. No correlation could be 
established between any human disease and serological evidence of prior infection with 
parvovirus H-1 (Siegl, 1984). In two limited phase I clinical trials, in vivo injections of H-1 
in few patients with advanced disseminated cancers lead to viremia followed by 
seroconversion, without causing any pathological side effects (Le Cesne et al., 1993; 
Toolan et al., 1965). Yet, there is a need to accumulate data concerning the safety of 
rodent parvoviruses for human therapy.  
1.3.7. Parvoviral vectors based on rodent parvoviruses 
As mentioned, the oncolytic, oncotropic, and oncosuppressive properties of rodent 
parvoviruses, together with their low pathogenicity make them attractive candidates for 
cancer therapy. However, their frequent isolation from tumors demonstrates that wild-
type (wt) parvoviruses are not always able to eradicate tumors. Therefore, in order to 
increase the antitumor properties of wt parvoviruses, recombinant parvoviruses were 
constructed so as to deliver transgenes in the tumors able to stimulate the immune 
system.  
 
Up to now, recombinant rodent parvoviral vectors have been engineered from the 
MVMp, H-1 and LuIII infectious clones. Two main types of constructs were used, 
namely complete coding replacement vectors and capsid replacement vectors. 
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In the first type, based on LuIIIV, all the viral coding regions between the telomeric 
origin of replication were removed and replaced by a transgene (Maxwell et al., 1993; 
Maxwell et al., 1996). These vectors allow high encoding capacity (up to 4 kb). They 
retain the cis-acting elements but lack viral non-structural proteins and are thus deficient 
for viral DNA replication.  
In contrast, capsid replacement vectors enable the expression of transgenes while 
maintaining the parvoviruses intrinsic properties and were thus used in this study. 
Based on MVMp and H-1, these vectors retain the expression of the non-structural 
proteins, under the control of the parvoviral early promoter P4, whereas the capsid 
genes, driven by the late promoter P38, have been replaced by a therapeutic transgene 
(Brandenburger et al., 1999; Kestler et al., 1999; Russell et al., 1992). These vectors 
were shown to retain the oncotropic properties of the wild-type viruses in vitro and 
represent therefore selective gene delivery vectors for cancer gene therapy (Dupont et 
al., 2000; Dupont et al., 1994; Russell et al., 1992). Furthermore, they retain the non-
coding terminal sequences. This, together with the expression of NS1, allows viral DNA 
replication and high levels of transgene expression through transactivation of the P38 
promoter (Kestler et al., 1999). Due to the deletion of the capsid genes, these vectors 
are no longer able to produce capsid proteins and hence, progeny virions. They are viral 
DNA-replication competent, since they retain the NS genes, but propagation deficient. 
 
Recombinant parvoviruses are produced by co-transfection of the recombinant 
parvoviral vector plasmid together with a helper plasmid, providing the parvoviral capsid 
proteins. One major problem encountered during the production was the contamination 
of recombinant virus stocks with replication-dependent viruses (RCV), produced by 
homologous recombination between the vector and helper constructs (Dupont et al., 
1994; Kestler et al., 1999; Russell et al., 1992). To reduce the probability of 
recombination, several strategies were developed including the decrease of homology 
between the two constructs (Dupont et al., 2001; Wrzesinski et al., 2003), pseudotyping 
(Wrzesinski et al., 2003), or the use of split helper constructs (Brown et al., 2002).  
 
The MVMp-based capsid replacement vectors used in this study are so-called chimeric 
recombinant vectors (see Figure 1-4). Taking advantage of the similarity between the 
MVM and H-1 genomes, viral sequences were exchanged up- and downstream of the 
transgenes between both viruses. This strategy resulted in a dramatic decrease of RCV 
contamination without affecting virus titers (Wrzesinski et al., 2003). 
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Another limitation of capsid replacement vectors is their low cloning capacity. Indeed, 
while removal of up to 800 bp in the 5’ VP sequence did not affect the virus yields, 
larger deletions lead to a dramatic reduction of the virus titers (Kestler et al., 1999). The 
choice of transgenes in parvoviral-based therapy is therefore restricted by their 
respective size. However, most immunostimulatory genes used for cancer gene therapy 
have a small size, compatible with the limited size of parvoviral vectors. Therapeutic 
transgenes used so far in H-1 and MVMp-derived vectors include genes encoding 
toxins, co-stimulatory factors, cytokines/chemokines and antigens from bacterial origin 
(reviewed in Cornelis et al., 2004b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-4: Schematic representation of pMVMp and recombinant parvoviruses 
In order to increase the antitumor properties of wt MVMp, recombinant parvoviral MVMp-based vectors 
were developed. Based on the wt pMVMp infectious clone, part of the VP-coding sequence were deleted 
(800 bp), producing the so-called control empty vector (pChi-MVMp/Δ800) and replaced by various 
transgenes (pChi-MVMp/Transgene). Recombinant viruses are produced by co-transfection of the 
recombinant parvoviral vector plasmid together with a helper plasmid (pMVMp Helper), providing the 
parvoviral capsid proteins in trans, driven by the human cytomegalovirus (CMV) promoter. To reduce the 
probability of homologous recombination between the vector and helper constructs, viral sequences were 
exchanged up- and downstream of the transgenes between the close related MVMp (blue) and H-1 (red) 
viruses, producing so-called chimeric recombinant vectors.  
MVM Origin H1 Origin
pMVMp
pChi-MVMp/Δ800
pMVMp Helper
NS1/NS2 VP1/VP2
P4 P38
Δ800NS1/NS2
P4 P38
P-CMV
VP1/VP2
pChi-MVMp/Transgene
NS1/NS2
P4 P38
Transgene
                                                                                                                INTRODUCTION 
                                                                                                                                                                              
17 
1.3.8. Antitumor effects of recombinant parvoviruses in vivo 
The anti-neoplastic effects of recombinant parvoviruses transducing various cytokines 
and chemokines as well as the co-stimulatory factor B7.1 were evaluated by monitoring 
the formation and growth of tumors after implantation of human or mouse tumor cells in 
recipient mice (see Table 1-1).  
 
Tumor cells 1 Virus  Transgene 2 Mice 3 Infection 4 Antitumor effect 5 Ref 6 
HeLa H-1 IL-2 nude ex vivo + 1 
HeLa H-1 MCP-1 nude ex vivo - 1 
HeLa H-1 MCP-3 nude ex vivo + 2 
K1735 MVMp IL-2 syn ex vivo + 3 
K1735 MVMp MCP-3 syn in vivo + 4 
B78/H-1 MVMp MCP-3 syn ex vivo / in vivo + 4 
H5V MVMp IP-10 syn in vivo + 5 
H5V MVMp IL-2 syn in vivo - 5 
EL4 MVMi B7.1 syn in vivo + 6 
 
Table 1-1: Antitumor effects of recombinant parvoviral vectors in vivo  
1: HeLa: human cervical carcinoma; K1735: mouse melanoma; B78/H-1: mouse melanoma; H5V: mouse 
endothelioma; EVL4: mouse thymoma. 
2: IL-2: interleukin-2; MCP-1 and MCP-3: monocyte chemotactic protein 1 and 3; IP-10: interferon-γ 
inducible protein 10; B7.1: costimulatory molecule B7.1. 
3: H-1-derived vectors were used against human tumor cells grafted in immunosuppressed (nude) mice, 
whereas MVMp-derived vectors were against mouse tumor cells injected in syngeneic (syn) mice. 
4: ex vivo: tumors cells infected prior to subcutaneous grafting; in vivo: established tumors treated with 
peritumoral injections of virus. 
5: Antitumor effects include longer life expectancy, prevention of tumor appearance, inhibition of tumor 
growth, and regression of established tumors. +: enhanced effect of the transgene-delivering vector 
compared to a control virus (wild-type, empty vector or vector carrying a reporter gene); -: no 
improvement of the antitumor effect with the transgene-delivering vector over a control virus.  
6: The numbers correspond to the following references: (1) Haag et al., 2000;(2) Wetzel et al., 2001; (3) 
El Bakkouri et al., 2005; (4) Wetzel et al., 2007; (5) Giese et al., 2002; (6) Palmer and Tattersall, 2000. 
(Adapted from Kerr et al., 2006) 
Altogether these studies show that H-1 and MVMp-based vectors transducing IL-2, 
monocyte chemotactic protein (MCP) -3, Interferon-γ inducible protein 10 (IP-10), and 
B7.1 induce significant antineoplastic effects in several mouse tumor models. 
Furthermore, these studies argue for the safety of parvoviral based-therapy as relatively 
low doses of parvoviral vectors were sufficient to achieve a therapeutic effect and no 
harmful side effects could be detected, even after repeated virus injections (Giese et al., 
2002; Lang et al., 2006; Wetzel et al., 2007). 
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The antitumor effects observed could be assigned largely to the virus-mediated 
transgene expression. Indeed, therapeutic vectors had greater antitumor effects than 
the respective control viruses including wild-type viruses, empty vectors or 
recombinants expressing a reporter gene (Giese et al., 2002; Haag et al., 2000; Wetzel 
et al., 2001; Wetzel et al., 2007). In these studies, parvoviral vectors were inoculated 
either to tumor cells prior to implantation (ex vivo) or to established tumors (in vivo). The 
antitumor effects of parvoviral vectors were generally lower in vivo than ex vivo (Wetzel 
et al., 2007). This can be ascribed to poor intratumoral virus spread, virus uptake by 
non-tumoral cells, and generation of neutralizing antibodies at later stages. 
1.3.9. Rationale for the use of rodent parvoviruses in glioma therapy 
The properties of parvoviruses outlined above and especially their oncotropic properties 
make them attractive candidates as antitumor agents in glioma therapy. Indeed, the 
adult brain is composed of post-mitotic neurons and low proliferative glial cells, and 
should therefore not be prone to parvoviral infection, as the parvoviral life cycle is strictly 
dependent on host cell proliferation. In accordance with this, rodent parvovirus 
replication was reported in fetal but not adult brain (Cotmore and Tattersall, 1987). 
In this context, several pre-clinical studies investigated the permissiveness of glioma 
cells for rodent parvoviruses H-1 and MVMp infection. The permissiveness for H-1 
infection was analyzed in established glioma cell lines of rat and human origin as well 
as in short-term and low-passage cultures of malignant brain tumors. H-1 was found to 
infect all the cells tested and to induce a dose-dependent killing (Herrero et al., 2004). 
MVMp was shown to infect and to efficiently kill in vitro mouse glioma cells but also 
several rat and human gliomas cells lines (Dupont et al., 2000; Wollmann et al., 2005). 
In the rat system, a MVMp-based vector carrying a reporter gene showed preferential 
transduction and killing in rat C6 glioma cells, whereas no killing and no or low levels of 
transgene expression could be detected in normal rat neurons and astrocytes 
respectively (Dupont et al., 2000). Similarly to rat astrocytes, normal mouse astrocytes 
were shown to sustain an abortive viral life cycle and to express limited amounts of viral 
proteins upon MVMp infection, whereas microglia did not (Abschuetz et al., 2006). 
Together, these data show that H-1 or MVMp are able to efficiently infect and kill most 
malignant glioma cells, without deleterious effects on normal brain cells in vitro. Thus, 
these preclinical studies suggest that glioma cells may represent a good target for 
rodent parvoviral-mediated gene therapy. 
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1.4. Candidate transgenes 
As described above, gliomas are highly vascularized tumors, known to grow in a very 
immunosuppressive environment. Thus, antiangiogenic and immunostimulatory 
cytokines represent attractive candidates as antitumor agent for glioma gene therapy. 
In this context, the antitumor effects of MVMp-based parvoviral vectors transducing 
such cytokines/chemokines were evaluated in a mouse glioblastoma model. 
1.4.1. Tumor necrosis Factor-α  
Tumor necrosis Factor-α (TNF-α) was first isolated from the serum of mice treated with 
bacterial endotoxin, and shown to cause hemorrhagic necrosis of mice tumors (Carswell 
et al., 1975). Since then, TNF-α was shown to be a multifunctional cytokine involved in 
apoptosis, cell survival, inflammation, and immunity. TNF-α is mainly produced by 
activated macrophages, natural killer (NK) cells, and T lymphocytes. TNF-α expression 
was also reported in a variety of other cell types, including, DCs, fibroblatsts, astrocytes, 
endothelial cells, smooth muscle cells, and tumor cells (Oppenheimer and Feldmann, 
2000).  
TNF-α is synthesized as a 26 kDa membrane-bound propeptide (pro-TNF), and is 
released upon cleavage of its pro-domain by the TNF-converting enzyme. In its soluble 
form, TNF-α is biologically active as a homotrimer of 17 kDa subunits (Bemelmans et 
al., 1996). 
TNF-α signals through two distinct cell receptors, referred to as TNFR-1 and TNFR-2. 
While TNFR-1 is expressed on all cell types, TNFR-2 expression is restricted to 
endothelial and immune cells (Aggarwal, 2003). The major difference between the two 
receptors is the presence of a death domain in TNFR-1, absent in TNFR-2. Through this 
domain, TNFR-1 is able to induce apoptotic cell death and belongs to the death 
receptor family (Ashkenazi and Dixit, 1998). Besides the induction of apoptosis, TNFR-1 
has also the ability to transduce cell survival signals. Both TNFR-1 survival and death 
pathways are well defined but their regulation remains elusive (Muppidi et al., 2004). 
TNFR-1 signaling activates multiple signal transduction pathways including Nuclear 
Factor kappa B (NF-κB) and Jun kinase (JNK) survival pathways as well as the 
apoptosis pathway. TNFR-2 was also shown to activate both NF-κB and JNK (Chen and 
Goeddel, 2002; Wajant et al., 2003). 
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TNF-α acts on many cells types and has a broad range of activities. TNF-α is above all 
a potent pro-inflammatory cytokine, inducing the release of inflammatory cytokines such 
as IL-6 or IL-8. It also induces the activation of many professional cells of the immune 
system including macrophages, lymphocytes, and NK cells (Waterston and Bower, 
2004). In addition, TNF-α is also reported to induce the maturation of DCs which in turn 
activate the adaptative immune response (Trevejo et al., 2001; Yanagawa et al., 2002). 
While TNF-α is involved in the clearance of viral, bacterial, fungal, or parasitic infection, 
it has also been shown to be involved in the pathogenesis of many human diseases, 
including autoimmunity, allergy, and septic shock (Oppenheimer and Feldmann, 2000). 
The role of TNF-α in cancer is controversial and both tumor promoting as well as 
antitumor activities are discussed. Indeed, TNF-α was shown to promote tumor 
formation, growth, invasion, and metastasis. On the other hand, TNF-α was shown to 
have antineoplastic effects such as induction of apoptosis, disruption of tumor 
vasculature, stimulation of antitumor immunity, and synergism with chemotherapeutic 
drugs (Balkwill, 2006; Mocellin and Nitti, 2008; Mocellin et al., 2005). It is worth 
mentioning that systemic administration of TNF-α in clinical trials resulted in minimal 
tumor response with severe toxicity (reviewed in Creagan et al., 1998; Lejeune et al., 
1998; Van Horssen et al., 2006). In contrast, local delivery of high concentration of TNF-
α could be maintained safely, in particular for the treatment of melanoma (Lejeune et 
al., 1994; Lejeune et al., 2006; Manusama et al., 1996). 
1.4.2. Chemokines 
Chemokines (chemotactic cytokines) represent a large family of structurally and 
functionally related small (8-15 kDa) proteins that induce directional cellular migration. 
Chemokines establish concentration gradients along which responding cells migrate, 
thus promoting the accumulation of cells at the source of chemokine production. 
Chemokines and their receptors have been involved in development, homeostasis, and 
angiogenesis but also in autoimmune and infectious diseases, as well as tumor growth 
and metastasis (Horuk, 1998; Rossi and Zlotnik, 2000). 
Until now, the chemokine superfamily consists of approximately fifty members (Laing 
and Secombes, 2004; Zlotnik et al., 2006) and twenty receptors (Zlotnik and Yoshie, 
2000).  Chemokines are structurally subdivided into four subfamilies, CXC (α), CC (β), 
CX3C (δ) and C (γ), according to the position of two highly conserved N-terminal 
cysteine residues (Murphy, 2002; Zlotnik et al., 2006). Functionally, chemokines are 
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divided into homeostatic and inflammatory proteins. Homeostatic chemokines are 
constitutively expressed, and generally involved in the development and homeostasis of 
the hematopoietic and immune systems as well as in immune surveillance. In contrast, 
inflammatory chemokines are inducible, produced only in response to physiological 
stress including inflammation or infection, and induce leukocyte recruitment to the 
injured or infected site (Luster, 1998; Zlotnik and Yoshie, 2000). The CXC subfamily is 
further functionally divided in ELR+ and ELR- chemokines, depending on the presence 
or absence of the ELR (glutamic acid - leucine - arginine) motif preceding the CXC 
domain. Whereas ELR+ chemokines are strong angiogenic factors, able to simulate 
endothelial cell chemotaxis, ELR- are potent angiostatic factors (Strieter et al., 1995). 
Chemokines signal through G-protein coupled, seven transmembrane receptors, which 
are divided into four subfamilies, CXCR, CCR, CX3CR and XCR, based on their 
chemokine subclass specificity (Murphy, 2002). Most receptors can respond to several 
chemokines and similarly most chemokines can bind to more than one receptor, 
although these interactions are typically class restricted (Rossi and Zlotnik, 2000). 
Upon signaling, chemokines receptors induce inhibition of adenylcyclase and activation 
of phospholipase C, leading to release of intracellular calcium. Downstream of the G 
proteins, several signal transduction molecules were shown to be activated by 
chemokines including GTPases like Rho, Rac and Cdc42, or pathways of major kinases 
like mitogen-activated protein kinase (MAPK) and phosphatidyl inositol-3 kinase (PI3K) 
(reviewed in Balkwill, 1998; Thelen, 2001). After signaling, chemokine receptors are 
usually internalized and cells become thus refractory to further stimulation with the 
same or other ligands. 
1.4.3. Interferon-γ inducible protein 10  
Interferon-γ (IFN-γ) inducible protein 10, commonly designated as IP-10 or CXCL10 is a 
10 kDa protein, member of the ELR- CXC chemokine subfamily. IP-10 binds to a unique 
chemokine receptor, CXCR3, shared with two other ELR- CXC ligands, namely 
monokine induced by IFN-γ (Mig or CXCL9) and IFN-inducible T-cell α-chemoattractant 
(I-TAC or CXCL11) (Cole et al., 1998; Loetscher et al., 1996). 
Human IP-10 was originally isolated from U937 monocytic leukemia cells as an 
interferon-γ inducible mRNA (Luster et al., 1985). Later, IP-10 was found to be 
synergistically induced by IFN-γ and TNF-α in several cells types (Majumder et al., 
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1996), but also slightly by TNF-α alone (Sheng et al., 2005) or lipopolysaccharide (LPS) 
(Ohomori and Hamilton, 1992). 
IP-10 has multiple biological functions including T cell development, recruitment of 
immune cells, adhesion of T cells to endothelial cells, and inhibition of angiogenesis. 
IP-10 is a potent chemoattractant for NK cells (Taub et al., 1995), NKT cells (Kim et al., 
2002), plasmoid dendritic cells (Penna et al., 2001), monocytes and stimulated T cells 
(Loetscher et al., 1996; Taub et al., 1993). Both the activation status and the phenotype 
of T cells were shown to be determinant for IP-10 chemotaxis. Indeed, IP-10 promotes 
the migration of stimulated but not of naïve T cells (Taub et al., 1993). Furthermore,    
IP-10 attracts specifically activated Th1 but not Th2 lymphocytes (Bonecchi et al., 1998; 
Sallusto et al., 1998). In agreement with this, IP-10 has been shown to be involved in 
several Th1-type inflammatory diseases, such as multiple sclerosis (Salmaggi et al., 
2002) or experimental autoimmune encephalomyelitis (EAE) (Ransohoff et al., 1993). In 
addition to the recruitment of T cells, IP-10 also promotes the adhesion of activated T 
cells to endothelial cells, and thus seems to play a role in the entry of T cells to sites of 
tissue inflammation (Taub et al., 1993). IP-10 is a highly inducible gene but it is also 
constitutively expressed in some organs including naïve lymphoid organs, suggesting a 
role for IP-10 in T cell development (Gattass et al., 1994). Besides its function as 
chemoattractant, IP-10, as ELR- chemokine, has been shown to be a potent inhibitor of 
angiogenesis in vitro (Angiolillo et al., 1995; Strieter et al., 1995) and in vivo (Sgadari et 
al., 1996). This seems to be mediated by direct effects on endothelial cells through 
inhibition of endothelial cell migration (Belperio et al., 2000; Strieter et al., 1995), 
proliferation (Angiolillo et al., 1995; Feldman et al., 2006; Luster et al., 1995; Strieter et 
al., 1995), and differentiation (Angiolillo et al., 1995). In addition, IP-10 was also recently 
shown to induce endothelial cell apoptosis (Feldman et al., 2006).  
Owing to both its angiostatic and immunostimulatory properties, IP-10 represents an 
attractive candidate for cancer therapy. Indeed, IP-10 demonstrated strong antitumor 
effects in several mouse tumor models, used either alone (Feldman et al., 2002; Giese 
et al., 2002; Sun et al., 2005) or in combination with other cytokines, such as MIG 
(Tominaga et al., 2007), or IL-12 (Keyser et al., 2004; Narvaiza et al., 2000). The 
antitumor effects of IP-10 were shown to be mediated by both its immunostimulatory 
(Luster and Leder, 1993) and angiostatic properties (Arenberg et al., 1996; Sgadari et 
al., 1996). 
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1.4.4. Monocyte chemotactic protein-2 and -3  
Monocyte chemotactic protein-2 and -3 (MCP-2, MCP-3), also known as CCL8 and 
CCL7, are inflammatory chemokines belonging to the CC chemokine family (Van 
Damme et al., 1992). MCP-2 and -3 are produced by various cell types, including tissue 
cells, leukocytes, and tumor cells. Their expression is induced by pro-inflammatory 
cytokines such as IL-1, TNF-α, and IFN-γ, but also by exogenous stimuli like LPS, 
bacteria, and viruses (reviewed in Van Coillie et al., 1999; Zlotnik et al., 2006). Both 
chemokines bind multiple CCR receptors including CCR1, CCR2, CCR3 and CCR5 
(Fioretti et al., 1998). Owing to their multiple receptors, they have a broad range of 
target cells, including most leukocyte cell types. Indeed, they were shown to be 
chemotactic in vitro for monocyte/macrophages, basophils, neutrophils, eosinophils, 
T lymphocytes, NK cells, and DCs. Besides leukocyte chemotaxis, MCP-2 and -3 were 
reported to induce the release of specific enzymes in monocytes and T cells, allowing 
these cells to digest extracellular matrix components and thus to migrate into tissues. 
They were also reported to induce histamine release in basophils and granzyme A 
release from T and NK cells (reviewed in Menten et al., 2001; Van Coillie et al., 1999). 
The broad range of actions of MCP-2 and -3 and especially their chemotaxis for NK 
cells, T cells and DCs, known to play a critical role in antitumor immunity, make them 
attractive candidates as antitumor agents. MCP-3 was shown to be a potent antitumor 
agent in several mouse tumor models, including mouse mastocytoma (Fioretti et al., 
1998), human carcinoma HeLa (Wetzel et al., 2001), and mouse melanomas B78/H-1 
and K1735 (Wetzel et al., 2007).  
 
1.5. Aim of the study 
Recombinant parvoviral vectors encoding TNF-α and IP-10 were recently shown in our 
laboratory to exert antitumor effects on mouse GL261 glioma implanted subcutaneously 
(Enderlin et al., 2008). In this context, the first aim of this study was to investigate the 
mechanisms sustaining tumor inhibition by TNF-α- and IP-10-expressing parvoviral 
vectors in the GL261 subcutaneous tumor model. The second aim of this work was to 
implement the intracranial GL261 tumor model in our laboratory, which was not 
established at the time this study was started, and to analyze the antitumor effects of 
parvoviral vectors transducing TNF-α, IP-10, compared to MCP-2 and MCP-3 on GL261 
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implanted intracranially in syngeneic C57BL/6 mice. The mechanisms sustaining tumor 
inhibition subcutaneously as well as intracranially were to be investigated by 
immunohistochemistry on tumor samples and included the analysis of the cellular 
immune infiltration, intratumoral cell proliferation and apoptosis as well as 
microvascularization.  
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2. MATERIALS 
2.1. Animals 
Female, 5 to 7 weeks old, C57BL/6 mice were purchased from Charles River WIGA. 
 
2.2. Mammalian cells lines  
Name Species Description Reference 
293T Human Adenovirus-transformed human embryonic kidney cells expressing SV40 large T antigen Graham et al., 1977  
A9 Mouse Fibroblastic cells Littlefield, 1964 
GL261 Mouse 3-methylcholanthrene induced astrocytoma cells Seligman and Shear, 1939 
MLEC-
PAI/Luc Mouse 
Mink lung epithelial cells transfected with 
luciferase under a plasminogen activator 
inhibitor-1 promoter 
Abe et al., 1994 
 
 
2.3. Bacteria strains 
Name Resistance Origin Reference 
E. Coli SURE Tetracyclin + Kanamycin Stratagene Greener, 1990 
E. Coli JM 109 - Stratagene Yanisch-Perron et al., 1985 
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2.4. Plasmids 
Name Description Size (bp) Resistance Origin 
 pChi-MVMp/∆800 Infectious MVMp DNA clone bearing an 800 bp deletion in VP genes 
6469 
- Ampicillin 
Wrzesinski 
et al., 2003 
 pChi-MVMp/MCP-2 Infectious MVMp DNA clone expressing human MCP-2 
6855 
440 Ampicillin 
 T.Kayser, 
unpublished 
 pChi-MVMp/MCP-3 Infectious MVMp DNA clone    expressing human MCP-3 
6987 
434 Ampicillin 
Wetzel et al., 
2007 
 pChi-MVMp/TNF-α Infectious MVMp DNA clone expressing mouse TNF-α 
7283 
700 Ampicillin 
Enderlin et 
al., 2008 
 pChi-MVMp/IP-10 Infectious MVMp DNA clone expressing human IP-10 
6984 
380 Ampicillin 
Enderlin et 
al., 2008 
 pCMV-VP<MVMp MVMp helper plasmid expressing VP  genes under a CMV promoter 7700 Ampicillin 
Wrzesinski   
et al., 2003 
 
2.5. Primers 
Transcript 
Primer sequence 5´→3´                  
sense/antisense 
Tannealing 
(°C) 
Cycles
Supplier 
Reference 
ACCACAGTCCATGCCATCAC mGAPDH 
TCCACCACCCTGTTGCTGTA 
60 25 Paulukat et al., 2001 
TGACCTCCACCAGCAGCTCAA mIFN-α 
GACCACCTCCCAGGCACAGG 
58 35 Maxim Biotech 
CATCAACTATAAGCAGCTCCA mIFN-β 
TTCAAGTGGAGAGCAGTTGAG 
56 35 Cervantes-Barragan et al., 2007 
TGAGCAGAGATGTCTGAATC mIP-10 
TCGCACCTCCACATAGCTTACAG 
58 25 Giese et al., 2002 
ACTTCTTCTGCTGCACAGCA MCS  
GGGTCAGTGTTAAAGATGTAGGTG 
58 30 self designed 
TGAATGGAAAAGATATCGGATGGAATAG NS1 
GCCTCCGTCTCTTGGTGG 
58 30 Giese et al., 2002 
TCAACGGGATCAGCCCCAAA mTGF-β1 
TGGTAGCCCTTGGGCTCGTG 
58 35 Maxim Biotech 
CCCCCGGAGGTGATTTCCAT mTGF-β2 
TGGGGTTTTGCAAGCGGAAG 
58 35 Maxim Biotech 
CACTGTGCGCGAGTGGCTGT mTGF-β3 
TCCTCCAGGTTGCGGAAGCA 
58 35 Maxim Biotech 
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2.6. Antibiotics 
 
2.7. Antibodies 
2.7.1. Primary antibodies 
Antigen Host Isotype Clonality Dilution Application Supplier / Reference 
33D1 Rat IgG Monoclonal 1:200 IHC BD Pharmingen 
CD4 Rat IgG Monoclonal 1:200 IHC Abcam 
CD8 Rat IgG Monoclonal 1:200 IHC Abcam 
CD31 Rat IgG Monoclonal 1:200 IHC BD Pharmingen 
CD68 Rat IgG Monoclonal 1:500 IHC AbD Serotec 
Ki67 Rabbit IgG Polyclonal 1:500 IHC Abcam 
NKG2D Rat IgG Monoclonal 1:100 IHC R&D Systems 
2.7.2. Secondary antibodies 
Specificity Host Conjugate Dilution Application Supplier Reference 
Rabbit IgG Donkey Biotin 1:100 IHC Amersham Biosciences 
Rat IgG Goat Biotin 1:100 IHC Amersham Biosciences 
Antibiotic Working dilution Stock concentration Supplier 
Ampicillin 75 ng/ml 75 μg/ml Roche Applied Science 
Chloramphenicol 136 µg/ml 34 mg/ml, in 75% EtOH Roche Applied Science 
Geneticin 250 µg/ml 50 mg/ml Gibco-Invitrogen 
Kanamycin  12.5 ng/ml 25 μg/ml Roche Applied Science 
Penicillin 100 U/ml 10,000 U/ml Gibco-Invitrogen 
Streptomycin 100 µg/ml 10,000 µg/ml Gibco-Invitrogen 
Tetracyclin 12.5 ng/ml 12.5 μg/ml, in 75% EtOH Sigma 
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2.8. Cytokines and growth factors 
Product name Supplier 
Recombinant human IP-10  R&D systems 
Recombinant human TGF-β1 PeproTech  
 
2.9. Enzymes 
Product name  Supplier 
M-MLV reverse transcriptase Promega  
Rnasin ribonuclase inhibitor Promega  
RQ1 Rnase-Free Dnase I Promega  
Taq DNA polymerase Invitrogen  
Restriction endonucleases NEB, Roche, Fermentas 
Streptavidin-horseradish peroxidase complex Amersham Biosciences 
 
2.10. Kits 
Name used in the text Product name Supplier 
DNA labeling system Megaprime DNA Labeling systems Amersham Biosciences 
Gel Extraction kit QIAQuick Gel Extraction kit Qiagen  
Luciferase assay system Luciferase assay system Promega  
Mouse IFN-α ELISA Mouse IFN-α ELISA kit PBL Biomedical Laboratories 
Mouse IP-10 ELISA  Quantikine Mouse CXCL10/IP-10 R&D Systems  
Mouse TNF-α ELISA BD optEIA Mouse TNF-α ELISA set BD Biosciences  
Plasmid mega kit Qiagen Plasmid mega kit Qiagen  
TUNEL assay kit Apoptag Qbiogene 
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2.11. Reagents    
Name used in the text Product name Supplier 
Agarose Agarose NA  Pharmacia Biotech  
Antiseptic cream Bepanthen Bayer 
BSA BSA Fraction V Roche  
Casy blue Casy blue Schärfe System  
Casy ton Casy ton Schärfe System  
DAB DAB substrate Roche 
DMSO DMSO Hybri Max Sigma  
Dnase/Rnase-free water UltraPURE water DNAse/RNAse Free Gibco-Invitrogen  
dNTPs Mix dNTPs Mix (PCR grade) Invitrogen  
DPBS  calcium- and magnesium-free DPBS  Gibco-Invitrogen  
Guanidium thiocyanate / 
phenol solution TRIzol Invitrogen  
HBSS  HBSS  -CaCl2 and –MgCl2 Gibco-Invitrogen  
Herring sperm DNA Herring sperm DNA Promega  
Histogreen Histoprime Linaris 
Hydrogen peroxyde Hydrogen peroxyde Roth 
Iodixanol OptiPrep Axis-Shield 
Isopetane Isopentane Roth 
Ketamin Ketavet (100 mg/ml) Pfizer  
Mounting medium Histofluid Marienfeld 
NaCl 0.9%  0.9% NaCl solution   Braun  
OCT Compound Tissue-Tek Sakura Finetek  
Oligo (dT) primer Oligo (dT)18 primer Fermentas  
Paraformaldehyde Paraformaldehyde Roth 
Rotihistol Rotihistol Roth 
Trypan blue  Trypan blue solution Fluka  
Trypsin 0.25% 0.25% Trypsin-EDTA  Gibco-Invitrogen  
Xylazin Rompun 2%   Bayer  
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2.12. DNA ladders 
Name used in the text Product name Supplier 
2 Log DNA ladder NEB  
DNA ladder 
100 bp DNA ladder NEB  
 
2.13. Chemicals 
Acids, bases, as well as organic and inorganic solutions were purchased in analytical 
grades from Applichem, Becton Dickinson, Bio-Rad, Calbiochem, Fluka, Gerbu, Baker, 
Merk, Pharmacia Biotech, Riedel-de Haen, Roth, and Sigma. 
Radiochemicals used for the labeling of DNA probes (32P-dCTP) were obtained from 
Amersham Pharmacia. 
2.14. Consumables 
Standard plasticware for cell culture and molecular biology was purchased from 
Greiner, Nunc, Satstedt, Costar, Millipore, BD Falcon, and Eppendorf. 
 
Name used in the text Product name Supplier 
Absorbent swabs Sugi absorbent swabs Kettenbach  
Centrifugal buffer exchange columns Zeba Desalt Spin Column Pierce-Therma Scientific 
Cryomolds Cryomold 10x10x5 mm Sakura 
33 gauge beveled needle NanoFil 33 gauge beveled  WPI  
Nitrocellulose membrane filters NC45 Schleicher & Schuell 
Non absorbable nylon thread Daclon DS 12mm EP 0.7  SMI 
1 ml fine dosage syringe Omnican-F 1ml  B/Braun  
10 µl syringe 10µl NanoFil   WPI  
Polyallomer centrifuge tube Polyallomer Quick-seal Beckman Instruments 
Matrix tubes Lysing Matrix D Qbiogene 
Superfrost microscope slide Superfrost Plus Menzel 
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2.15. Equipment  
Name used in the text Product name Supplier 
Cell counter CASY Cell Counter & Analysis System  Schärfe System  
Cell disrupter Fast-Prep Qbiogene 
Centrifuges:   
     High speed HERMLE ZK380; Megafuge 1.0R Hermle; Heraeus  
     Super speed Sorvall RC 5C Super Speed  Thermo Scientific  
     Ultra speed Optima LE-80K Beckman Coulter  
     Table MiniSpin Eppendorf  
Centrifuge rotors:   
     Fixed angle  FiberLite F-10 Thermo Scientific  
     Fixed angle (ultra speed) 50.2 Ti Beckman Coulter  
     Swinging bucket Sorvall HB-6 Thermo Scientific  
     Swinging bucket Heraus 2706D Heraus  
Clinical 1.5 T MR scanner Magnetom Vision  Siemens 
Heating pad Solac CT8630 Solac  
Horizontal electrophoresis system Easy Cast electrophoresis system Peqlab 
Luminometer  Fluoroskan Ascent FL  Thermo Labsystems   
Microinjection unit: UltraMicroPump II Microserynge Injector WPI  
 Micro4 Microsyringe Pump Controller WPI  
Microplate reader Multiscan EX   Thermo Labsystems  
Microscopes: leica DMIL Leica  
 Axio Imager Z1 Carl Zeiss 
Microtome HM 550 Microm 
Spectrophotometer Ultrospec 3100 pro Amersham Biosc.  
Stereotactic frame: Stoelting Lab Standard Stereotaxic WPI  
 Stoelting Mouse/Neonatal Rat Adapter  WPI  
Thermal cycler Mastercycler epGradientS Eppendorf  
UV-transilluminators: Image Master VDS (302 nm) Pharmacia Biotech  
 N90 (366 nm) Konrad Benda  
Water purification system Milli-Q Biocell A10 Millipore  
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2.16. Softwares 
Product name Supplier 
Adobe Photoshop Adobe Systems Inc 
Ascent Multiscan Thermo Labsystems  
Ascent Fluoroscan Thermo Labsystems  
AxioVision Rel. 4.7 Carl Zeiss 
Endnote X Thomson 
Image Master 1D Amersham Pharmacia Biotech  
Microsoft Office Microsoft 
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3. METHODS 
3.1. Microbiological methods 
3.1.1. Bacteria culture 
All bacteria were grown in Luria Bertani (LB) medium supplemented with the 
appropriate antibiotics at 37°C with vigorous shaking (200 rpm). The Escherichia Coli 
(E. Coli) strains used in this study as well as the antibiotics applied for the selection of 
plasmid containing bacteria are listed below. 
 
Strain Use Selective antibiotics 
E. Coli SURE Propagation of infectious recombinant DNA clones Tet + Kan + Amp 
E. Coli JM 109 Propagation of MVM helper vector Amp 
 
Media and additives for bacteria culture were purchased from Fluka, Gibco-Invitrogen, 
PAA Laboratories, and Sigma. 
 
LB-medium: 1% (w/v) Bacto-tryptone  
 0.5% (w/v) Yeast extract 
 0.5% (w/v) NaCl  
 pH 7.0  
   
3.1.2. Preparation of bacteria for plasmid isolation 
For amplifying plasmid DNA, 20 ml LB-medium supplemented with the appropriate 
selective antibiotics were inoculated with transformed E. Coli SURE or E. Coli JM109 
bacteria containing the desired plasmid. After incubation at 37°C with vigorous shaking 
(200 rpm) for 8 h, 5 ml of the starter culture were transferred to 250 ml LB-medium with 
the appropriate antibiotics. The culture was incubated at 37°C for 12-16 h until bacteria 
growth reached the end of the logarithmic growth phase. In the case of E. Coli SURE 
bacteria, the culture was further incubated for 5 h at 37°C in the presence of 
chloramphenicol to amplify plasmid replication. The bacterial cells were harvested by 
centrifugation at 5000 rpm for 10 min at 4°C (fixed angle rotor, super speed centrifuge) 
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and all traces of supernatant were removed. The cell pellet was further processed to 
isolate plasmid DNA or stored at -20°C. 
3.1.3. Long-term storage of bacteria 
For cryopreservation of bacteria, 1 ml of late logarithmic phase growing bacteria was 
removed from the culture before addition of chloramphenicol, mixed with 0.5 ml 50% 
glycerol, freezed in liquid nitrogen, and stored at -80°C.  
 
3.2. Molecular biological methods 
3.2.1. Plasmid DNA isolation and purification 
Plasmid DNA isolation and purification from 2 x 250 ml bacteria culture was performed 
using a plasmid purification kit according to the manufacturer’s instructions. Briefly, 
bacteria were lyzed under alkaline conditions and the plasmid DNA was bound to an 
anion exchange resin under low salt conditions. RNA, proteins and low molecular 
weight impurities were removed by a medium salt wash. Plasmid DNA was eluted in a 
high salt buffer and precipitated with isopropanol. Purified DNA was dissolved in Tris-
EDTA (TE) buffer, quantified by spectrophotometry at 260 nm, and analyzed by 
restriction digestion followed by agarose gel electrophoresis. Plasmid DNA was further 
processed for calcium phosphate transfection or stored at -20°C. 
 
TE buffer: 10 mM Tris-HCl, pH 8.0  
 1 mM EDTA, pH 8.0 
  
3.2.2. DNA quantification and quality assessment 
The DNA concentration was determined by measuring the absorbance at 260 nm with a 
spectrophotometer. An absorbance of 1 unit at 260 nm corresponds to 50 µg/ml dsDNA. 
The purity of DNA can be estimated by the ratio of the absorbance values at 260 nm 
and 280 nm (A260/A280). Only pure plasmid preparations with a ratio of A260/A280 
between 1.8 and 2.0 were subjected to transfection of mammalian cells. Alternatively, 
the concentration of a DNA fragment was estimated by gel electrophoresis by 
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comparing the intensity of the isolated band with a molecular weight marker of known 
concentration. 
3.2.3. Restriction enzyme digestion of DNA 
Restriction analysis was used for the characterization, identification, and isolation of 
DNA molecules. The treatment of plasmid DNA with restriction endonucleases 
produces, due to their sequence specificity, a series of precisely defined fragments 
which are separated according to their size by gel electrophoresis.  
Restriction enzyme digestions were performed in a final volume of 20 μl according to 
the enzyme manufacturer’s instructions, using 1 µg of plasmid DNA. Incubation periods 
ranged from 1 h to 2 h at 37°C depending on the enzyme used. Analysis of the 
fragmented plasmid DNA was done by agarose gel electrophoresis. 
3.2.4. Agarose Gel electrophoresis 
Separation of nucleic acids according to size was conducted for analytical as well as 
preparative purposes by agarose gel electrophoresis. Agarose concentrations varied 
between 1 and 2 % in Tris-Acetate-EDTA (TAE) buffer, depending on the expected size 
of the fragments. Ethidium bromide was added to the gel at a final concentration of 
1 μg/ml to allow visualization of the nucleic acids under UV-light. The samples were 
supplemented with 10x DNA loading buffer and loaded in parallel to DNA molecular 
weight markers for product size and concentration estimation. The gels were run in an 
horizontal electrophoresis system at 5-10 V/cm in 1x TAE buffer until sufficient 
separation of the fragments. The gel was visualized in a UV transilluminator (302 nm), 
and documentation was done by photography of the visualized bands using the Image 
Master 1D software. 
 
TAE buffer: 40 mM Tris-Acetat, pH 7.8 
 1 mM EDTA 
 pH 8.0 
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3.2.5. DNA gel extraction  
The DNA fragment to be purified was run in an agarose gel, visualized under UV light at 
a wavelength of 366 nm (UV transilluminator) to avoid DNA damage, and was cut out 
from the gel using a scalpel. Isolation and purification of the fragment was performed 
with the gel extraction kit, according to the manufacturer’s instructions. The purified 
DNA fragment was dissolved in TE buffer and stored at -20°C. Qualitative and 
quantitative analysis was carried out by agarose gel electrophoresis.  
3.2.6. Total RNA isolation from eukaryotic cells 
Total RNA was isolated from cell monolayers by guanidium thiocyanate extraction and 
purified by phenol/chloroform extraction according to the method described by 
Chomczynski and Sacchi, 1987. Monolayer cells were washed once with PBS and lyzed 
with a cell scraper using 1 ml of guanidium thiocyanate/phenol solution (TRIzol) per 
10 cm plate. The cell lysates were transferred into matrix tubes, homogenized with rapid 
and vertical angular motion in a cell disrupter (time: 3x 20 s, speed: 5) at RT and 
transferred to eppendorf tubes. Addition of chloroform (0.2 ml per ml of TRIzol) and 
incubation for 3 min at RT, followed by centrifugation (15 min, 13000 rpm, 4°C, table 
centrifuge), separated the solution in an aqueous phase, containing RNA, and an 
organic phase, containing protein. The upper aqueous phase was transferred to a new 
tube and mixed with equal volume of isopropanol. Samples were then incubated for 10 
min at RT, centrifuged (10 min, 11000 rpm, 4°C, table centrifuge) and the supernatant 
discarded. The RNA pellet was washed once with 75% ethanol, centrifuged again, air-
dried and dissolved in 300 μl Dnase/Rnase-free water. Total RNA was stored at -80ºC.  
3.2.7. Total RNA quantification and quality assessment 
The RNA concentration was determined by measuring the absorbance at 260 nm with a 
spectrophotometer. An absorbance of 1 unit at 260 nm corresponds to 40 µg/ml ssRNA. 
The purity of RNA can be estimated by the ratio of the absorbance values at 260 nm 
and 280 nm (A260/A280), with pure RNA having a A260/A280 ratio of 1.9 -2.1. 
The integrity of total RNA was verified by agarose gel electrophoresis in the presence of 
ethidium bromide. For this, 1µg RNA was run on a 2% agarose gel. The 18S and 28S 
ribosomal RNA from eukaryotic source should appear as sharp bands. Pure RNA was 
further used for reverse transcriptase polymerase chain reaction (RT-PCR).  
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3.2.8. Reverse transcription-polymerase chain reaction (RT-PCR)  
This method is a two steps process allowing the amplification of a defined piece of RNA. 
In the first step, called ‘first strand cDNA synthesis’, complementary DNA (cDNA) is 
made from a messenger RNA template by a RNA-dependent DNA polymerase reverse 
transcriptase through the process of reverse transcription (RT).  
The second step consists in the amplification of the resulting cDNA through polymerase 
chain reaction (PCR). This method allows specific amplification of defined regions of a 
DNA molecule in vitro through enzymatic replication by a DNA-dependent DNA 
polymerase. 
3.2.8.1 Deoxyribonuclease treatment and secondary structures removal 
Prior to RT-PCR, 1 μg of total RNA was treated with 1 U Rnase free 
Deoxyribonuclease I (DNAse I) according to the manufacture’s instructions in order to 
eliminate contaminating DNA. 
RNA secondary structures were denatured by incubation at 70°C for 5 min, followed by 
direct chilling on ice for 5 min to prevent their reformation. 
3.2.8.2 First strand cDNA synthesis from total RNA  
Total polyA RNA was reverse transcribed by the Moloney Murine Leukaemia Virus 
Reverse Transcriptase, RNAse H Minus Point Mutant (M-MLV RT (H-)), a RNA-
dependent DNA polymerase, using oligo(dT) primers. 
The reverse transcription was performed using a thermal cycler and the reaction was 
set up on ice in a final volume of 25 µl as follows: 
 
Component          Final quantity 
- DNAse-treated RNA   1 µg 
- M-MLV RT (H-)   200 U 
- Oligo(dT) primers   0.5 µg  
- dNTPs mix    0.5 mM each 
- Rnasin (Rnase Inhibitor)  20 U 
           
The reaction was mixed gently, briefly centrifuged, and incubated at 40°C for 1 h. The 
reverse transcriptase was subsequently inactivated by incubating at 90°C for 5 min. The 
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cDNA was diluted 1:8 using RNAse/DNAse free water and further used for PCR 
amplification or stored at -20°C.  
The cDNA synthesis was verified by amplification of the housekeeping gene 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) via PCR. 
3.2.8.3 Polymerase chain reaction (PCR) amplification of cDNA 
The reverse transcribed cDNA was used as template to amplify target sequences by 
PCR using specific primer pairs, self-designed, or commercially purchased. For 
commercial primers, the PCR reaction was performed according to the manufacturer’s 
instructions. PCR reactions with self-designed primers were set up on ice in a total 
volume of 25 or 50 µl as follows:  
 
Component           Final quantity 
- cDNA template   5 / 10 µl 
- Taq DNA Polymerase  2 U 
- Forward primer    0.5 µM  
- Reverse primer   0.5 µM 
- dNTPs mix    0.2 mM each 
- MgCl2     1.5 mM  
 
The samples were mixed, briefly centrifuged and the PCR was performed in a thermal 
cycler. The PCR program was adapted to the primer pair, using the following protocol: 
 
Step             Temperature  Time 
- Initial denaturation   94°C  3 min 
- Denaturation    94°C  30 s 
- Annealing    58-60°C 30 s     25-35 cycles 
- Extension    72°C  30 s   
- Final extension   72°C  10 min  
- Storage    4°C   hold 
 
The primers, as well as their specific PCR conditions (annealing temperature, number of 
cycles) are listed in section 2.5. The amplified PCR products were analyzed in terms of 
size and quantity by agarose gel electrophoresis and stored at -20°C. 
When semi-quantitative PCR was performed, the quantity of cDNA templates was 
adjusted according to their housekeeping gene signal intensity. 
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3.2.9. Preparation of a NS-specific radioactive labeled probe for virus titration  
The replication titer of purified viruses was determined by hybridization with a NS-
specific radiolabeled DNA probe to detect the viral DNA amplified within infected cells 
(see section 3.4.3.2). The probe was prepared according to Wrzesinski et al., 2003. 
The NS-specific DNA probe was generated by double restriction digestion of 50 µg 
pMVMp/Δ800 plasmid with EcoRV and EcoRI in a final volume of 50 µl, generating two 
fragments of 703 and 5716 bp, which were separated in a 1% preparative agarose gel. 
The 703 bp NS-specific DNA fragment was purified by agarose gel extraction and its 
concentration was estimated by comparison with a DNA standard. The DNA probe was 
stored at – 20°C before further processing for radioactive labeling. 
The NS-specific DNA fragment was radiolabeled using a DNA labeling system with   
32P-dCTP according to the manufacturer’s instructions, and the reaction was terminated 
by addition of 150 µl TE buffer. The radiolabeled probe was subsequently purified from 
unincorporated radiolabeled dNTPs by gel filtration through a Sephadex G50 column. 
For this, the probe was carefully pipetted onto the column matrix and centrifuged at 
2000 rpm for 10 min at RT (high speed centrifuge). The radioactivity of the purified 
probe was measured in a radioisotope counter using 2 µl of probe. The activity ranged 
typically between 30000 and 50000 CPM/µl. The labeled probe was subsequently 
denatured at 100°C for 10 min (heat block) and chilled on ice for 5 min before being 
transferred into the hybridization solution. Alternatively, the probe was frozen at -20°C 
before denaturation for short-term storage.  
 
3.3. Cell biological methods 
3.3.1. Maintenance of mammalian cell lines 
The given cell lines were maintained in monolayer cultures in defined medium with the 
adequate supplements under standard conditions (37°C, 5% CO2, 90% humidity). Sub-
confluent cells were splitted 1:5 - 1:20, depending on the cellular growth, usually twice a 
week. For this, the medium was removed, the cells were detached with 0.25% trypsin, 
and resuspended in fresh complete medium. Mammalian cells were generally 
centrifuged at 1000 rpm for 10 min at RT (high speed centrifuge) or alternatively at 1500 
rpm for 10 min at RT (table centrifuge). 
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The different cell lines used in this study as well as their respective media are indicated 
in the table below.  
 
Cell line Use Media 
293T Production of recombinant viruses by co-transfection DMEMc 
A9 Production of wt MVMp Titration of wt and recombinant MVM MEMc 
GL261 Glioma tumor model  DMEMc 
MLEC-PAI/Luc TGF-β luciferase bio-assay DMEMc + geneticin 
 
 
Media and additives for cell culture were purchased from: Fluka, Gibco-Invitrogen, PAA 
Laboratories, and Sigma. 
 
DMEM complete: 10% FBS  MEM complete: 5% FBS 
(DMEMc) 100 U/ml Penicillin  (MEMc) 100 U/ml Penicillin 
 100 µg/ml Streptomycin   100 µg/ml Streptomycin
 2 mM Glutamine   2 mM Glutamine 
 in DMEM   in MEM 
     
DMEMc + geneticin: 250 µl/ml  G418    
 in DMEMc    
     
3.3.2. Long term storage of mammalian cell lines 
For cryopreservation, cells were trypsinised, collected in 15 ml tubes, pelleted by 
centrifugation, and resuspended at the desired density in freezing medium. The cell 
suspensions were aliquoted into cryovials, gradually frozen to -80°C overnight in a cell 
freezing box, and then transferred to a cryogenic refrigerator for long term storage in 
liquid nitrogen. 
 
Freezing medium: 5% DMSO 
 5% Glycerol 
 in DMEMc or MEMc 
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3.3.3. Thawing of mammalian cell lines 
The cryo-preserved cells were quickly thawed in a water bath at 37°C and the cell 
suspension was added to pre-warmed medium containing all supplements. The cells 
were incubated overnight under standard conditions and the next day, fresh medium 
was provided.   
3.3.4. Cell number and viability determination 
3.3.4.1 Manual counting: trypan blue exclusion 
This assay is based on the principle that living cells possess intact cell membranes that 
exclude certain dyes, such as trypan blue, eosin, or propidium, whereas dead cells do 
not and therefore take up the dyes. The cell suspension is simply mixed with dye and 
then visually examined to assess whether cells take up or exclude the dye. 
An aliquot of cells was diluted in trypan blue solution, loaded onto a haemocytometer, 
and counted under a light microscope. For statistical significance, a minimum of 100 
cells per large square were counted. 
The cell concentration, total amount of viable cells, and the percentage of viability of a 
cell suspension were calculated as follows: 
 
 
 
 
 
 
The factor 104 compensates for the volume of the counting chamber to obtain the 
amount of cells present per ml of cell suspension as the volume over the central 
counting area is 0.1 µl.  
3.3.4.2 Automated counting:  CASY cell counter and analyzer system 
Automated cell counting was performed with a CASY cell counter and analyzer system. 
The CASY technology combines an established particle measurement technique with 
an additional pulse area analysis. For measurement of cell number or viability, the cell 
suspension is diluted in a weak electrolyte (CASY ton) and drawn through a capillary 
with a constant flow velocity. A low voltage field is applied to the capillary by two 
Cell concentration (cells/ml) = average of viable cells per square x dilution factor x 104
Total number of cells = cell concentration x volume of original cell suspension 
x100
cells of number total
cells viable of number  (%) viability  Cell  =
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platinum electrodes, resulting in a defined electrical resistance. During their passage, 
the cells displace a quantity of electrolyte corresponding to their volume and intact cells, 
considered as isolators, increase the resistance. These electric changes are 
proportional to the cell volume and can be used as a scale for living cells.  
Depending on the cell amount, about 50 - 200 µl of cell suspension were diluted in 
10 ml of CASY ton and gently mixed by inverting the solution. 400 µl of diluted cell 
suspension were then measured in triplets, and the number of viable and total cells as 
well as the viability were determined. Discrimination between vital and dead cells or cell 
debris was carried out by cell-type-dependent cursor setting as determined with the 
CASY blue solution. 
 
3.4. Virological methods 
3.4.1. Virus production 
3.4.1.1 Production of wild-type parvovirus  
Wild type MVMp was produced by infection of mouse A9 cells with a master stock of 
virus, and virions were extracted from the cells by freeze-thaw cycles in Viral Tris-EDTA 
(VTE) buffer as described by Kestler et al., 1999. The EDTA present in VTE complexes 
the calcium ions needed for the binding to the receptor and therefore leads to the 
release of the virus from the cell membrane. In addition, freeze-thaw cycles help 
destroying the cells. For large scale production, 21 x 10 cm cell culture dishes were 
seeded with A9 cells and incubated overnight so that they reached 90 - 95% confluency 
before infection. The cells were infected at a multiplicity of infection (MOI) of 3 x 10-3 
plaque forming units/cell (PFU/cell), trypsinised 4 h post-infection and transferred to 
15 cm dishes. The cells were further incubated for 4 to 5 days, until the cytopathic 
effects were visible. A9 cells were then detached from the plate with a cell scraper and 
pooled together with their media into 50 ml tubes. Cells were pelleted by centrifugation 
at 2500 rpm for 10 min at RT (swinging bucket rotor, high speed centrifuge), washed 
with PBS, and centrifuged again. The cell pellets were then resuspended each in 5 ml 
VTE and lyzed by three subsequent freeze-thawing cycles (-20°C/RT). Cell debris were 
pelleted by centrifugation at 2500 rpm for 10 min at RT (swinging bucket rotor, high 
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speed centrifuge), whereas supernatants, containing recombinant viruses were 
collected in 50 ml tubes and stored at 4°C. Pelleted cells were resuspended again in 
5 ml VTE and viruses were extracted as described above. The supernatants were 
pooled to a final volume of 20 ml virus-containing crude extract, and further processed 
for purification or stored at 4°C. 
 
VTE buffer: 50 mM Tris-HCl, pH 8.7 
 0.5 mM EDTA, pH 8.0  
  
3.4.1.2 Production of recombinant MVM parvoviruses 
Recombinant viruses were produced in 293T cells by calcium phosphate co-transfection 
of parvoviral vector DNA and helper plasmid, as described by Haag et al., 2000; Kestler 
et al., 1999. On the day before transfection, 30 x 10 cm culture dishes were seeded with 
2 x 106 293T cells and incubated overnight so that they reached 90 - 95% confluency 
before the transfection. Per dish, 6 μg recombinant vector DNA and 12 μg of capsid 
protein-providing helper plasmid pBK-CMV/VP were suspended in a 250 mM CaCl2 
solution. In parallel, a separate tube containing an equal volume of HBSS 2x, pH 7.05 
was prepared. Following, the DNA/CaCl2 solution was added drop-wise to the HBSS 
solution under delicate mixing. The mixture was allowed to precipitate for 15 - 20 min 
and then spread equally onto the 293T cells. Three days post-transfection, virions were 
extracted from the cells as described for wild-type MVMp and further processed for 
purification or stored at 4°C.  
 
HBSS, 2x: 280 mM NaCl 
 50 mM HEPES 
 12 mM D-Glucose 
 10 mM KCl 
 1.5 mM Na2HPO4 
 pH 7.05 
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3.4.2. Purification and buffer exchange of virus stocks 
3.4.2.1 Virus purification through iodixanol density gradient centrifugation 
Virus purification was performed through an iodixanol discontinuous density gradient 
ultracentrifugation, adapted from Zolotukhin et al., 1999. The gradient is formed by 
under-layering and displacing the less dense cell lysate with solutions of increasing 
iodixanol concentration, buffered in PBS supplemented with 1 mM MgCl2 and 2.5 M KCl 
(PBS-MK). For each gradient, 20 ml of the virus-containing clarified lysate were 
transferred into a 40 ml polyallomer centrifuge tube using a Pasteur pipette. 
Successively, 7 ml of 15%, 5 ml of 25%, 4 ml of 40%, and 4 ml of 60% iodixanol 
solutions were under-layered. To prevent aggregation of virus particles with proteins 
from the cell lysates, NaCl was added to the 15% iodixanol solution to a final 
concentration of 1 M. In addition, phenol red was added to the upper 25% and lower 
60% density steps to a final concentration of 0.01 µg/ml to distinguish the different 
phases. Tubes were sealed and ultra-centrifuged at 50000 rpm for 2.5 h at 10°C (fixed 
angle rotor). The centrifuge tube was then ventilated with a syringe needle at the top 
and the 40% layer, containing full virus particles, was recovered under sterile conditions 
by inserting a syringe needle below the 60% to 40% density interphase and collecting a 
total of about 4 ml. The purified viral suspension was stored at 4°C. 
 
PBS: 136.9 mM NaCl  PBS-MK: 2.5 mM KCl 
 2.7 mM KCl   1 mM MgCl2 
 4.9 mM KH2PO4   in PBS 
 1.8 mM K2HPO4    
 pH 7.2 - 7.4    
     
3.4.2.2 Buffer exchange of virus suspensions 
For in vivo virus injection, a buffer exchange of the iodixanol virus suspension to 
Dulbecco PBS (DPBS) was performed using centrifugal buffer exchange columns, 
according to the manufacturer’s instructions. Viral suspensions in DPBS were short-
term stored at 4°C. 
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3.4.3. Virus titration 
3.4.3.1 Wild type infectious titer determination: Plaque assay 
This method, routinely performed to titrate replication competent viruses, was used to 
determine the infectious titer of wt MVMp as described by Cornelis et al., 1988. 
Briefly, 2.5 x 105 A9 cells per 6 cm culture dish were infected with serial dilutions (10-6 - 
10-10) of wt MVM. Dilutions were performed in duplicate and mock-infected cells were 
included as control. After aspiration of the inoculum, the cells were covered with 7 ml 
overlay medium 1 and incubated at 37°C in a CO2 incubator. 5 days post-infection, cells 
were stained with 3 ml of overlay medium 2, containing neutral red and incubated 
overnight at 37°C. The plates were dried and the plaques scored visually.  
Titers are expressed as plaque forming unit (PFU) per ml of virus suspension, and 
calculated as follows: 
 
 
 
Bacto-Agar, 1.7% 1.7% (w/v) Bacto-Agar  Overlay medium 1: 3/7 Bacto-Agar 1.7% 
 in LB-medium   4/7 MEMc 2x 
     
Neutral red solution: 0.33% (w/v) neutral red  Overlay medium 2: 2/32 neutral red sol. 
 pH 6.8 - 7.0   15/32 PBS 2x 
    15/32 Bacto-Agar 1.7% 
     
3.4.3.2 Recombinant and wt infectious titer determination: Hybridization assay 
This method, adapted for the titration of recombinant viruses, unable to produce 
progeny virions, measures the amplification of viral DNA within infected cells using a 
radioactive-labeled viral DNA probe as described by Kestler et al., 1999. 
2.5 x 105 A9 cells per 6 cm culture dish were infected with serial dilutions (10-4 - 10-7) of 
recombinant virus in supplement-free MEM. Dilutions were performed in duplicate and 
mock-infected cells were included as control. 48 h post-infection, the medium was 
aspirated and cells were washed with sterile PBS. Cells were transferred onto 
nitrocellulose filters by placing gently the filters on the cells and moistening them with 
100 μl PBS. Cells were lyzed and their DNA denatured by applying the filters to 
denaturation buffer for 8 min and subsequently neutralized in neutralization buffer for 
10 min. Fixation of the DNA was performed by backing filters for 2 h at 80°C. To avoid 
volume  inoculum x dilution
plaques of number average  (PFU/ml) Titer =
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unspecific binding of the radioactive probe, filters were pre-hybridized for at least 1 h at 
65°C in hybridization solution supplemented with 0.2 ng of heat-denaturated herring 
sperm DNA per ml hybridization solution. The denatured radioactive labeled DNA probe 
(see section 3.2.9) was added to the hybridization solution and hybridization was 
performed overnight at 65°C. The next day, the hybridization solution was discarded 
and membranes were washed twice in washing solution 1 for 45 min at 65°C and once 
in washing solution 2 for 15 min at 65°C. After air-drying, the membranes were exposed 
to X-ray films in an autoradiography cassette for 24 - 72h at -80°C in the presence of an 
amplifier screen and films were developed in a darkroom film processor. Each spot on 
the X-ray film represents viral DNA-replication within one cell. Alternatively, this method 
was also used for titration of wt MVM. In this case, the infection was stopped 28 h post-
infection in order to avoid secondary infections. 
Titers are expressed as replication unit (RU) per ml of virus suspension and calculated 
as follows: 
dilution
7.5 xspots  of number average  (RU/ml) Titer =  
inoculum)   µl400 
of (fraction   µl1000 
area) (filter cm7.2 
area) (dish cm 21.5  7.5 Factor 2
2
x=  
 
Denaturation buffer: 1.5 M NaCl  Neutralization buffer: 1.5 M NaCl 
 0.5 M NaOH   1 mM EDTA  
    0.5 M Tris-HCl  
    pH 7.0 
     
SSC, 20x: 3M NaCl  Hybridization solution: 3x SSC 
 300mM Tri-Na-Citrate   1% (w/v) SDS 
 pH 7.0   5 mM EDTA 
    10x Denhardt’s 
     
Denhardt´s, 100x: 2% (w/v) BSA  Washing solution 1: 3x SSC 
 2% (w/v) Ficoll 400   1% (w/v) SDS 
 2% (w/v) PVP    
   Washing solution 2: 0.3x SSC 
    1% (w/v) SDS 
     
3.4.4. Virus infection of adherent cells 
To infect mammalian cell lines, a defined ratio of infectious virus particles to cell is used, 
termed multiplicity of infection (MOI). Depending on the titration method, the MOI is 
expressed as PFU/cell (plaque assay) or RU/cell (hybridization assay).  
METHODS 
47 
On the day before infection, the cells were seeded at the appropriate density and 
incubated overnight in a 37°C incubator. The culture medium was aspirated and 0.1 ml 
(24 well plate), 0.4 ml (6 cm dish), or 1 ml (10 cm dish) of virus inoculum was applied 
onto the cell monolayer. Virus dilutions with the appropriate MOI were prepared in 
supplement-free MEM or DMEM, depending on the cell type. Virus stocks were diluted 
at least 1:3 in media to avoid high concentrations of iodixanol which could affect the 
infection efficiency. As negative control (mock infection), virus free buffer was used as 
inoculum. Cells were incubated under standard conditions for 1 h and the dishes were 
gently rocked every 10 min to allow the inoculum to spread evenly over the whole dish. 
Finally, the inoculum was replaced by complete fresh medium and cells were further 
incubated at 37°C.  
3.4.5. Assessment of progeny virion production by virus production assay 
2 x 105 GL261 or A9 cells were seeded in 6 cm plates and infected at a MOI of 0.1 or 1 
PFU/cell. 7 days post-infection, cells were scraped in their culture medium, transferred 
into 15 ml tubes, and pelleted by centrifugation at 2500 rpm for 10 min at RT (swinging 
bucket rotor, high speed centrifuge). The supernatant was collected in a new tube and 
stored at -20°C until further processing. The cell pellet was resuspended in 1 ml VTE 
and viruses were extracted from the cell pellet as described above (see section 3.4.1.1), 
performing five freeze-thaw cycles. Titration of progeny virions present in the cell pellets 
and supernatants respectively was performed by plaque assay (see section 3.4.3.1). 
 
3.5. Biochemical methods 
3.5.1. Quantification of TGF-β in cell supernatants: PAI/L bioassay   
The amount of TGF-β present in cell supernatants was assayed using the plasminogen 
activator inhibitor-1 / luciferase (PAI/L) bioassay, as described by Abe et al., 1994 . This 
quantitative bioassay is based on the ability of TGF-β to induce PAI-1 expression, using 
mink lung epithelial cells (MLEC) stably transfected with a luciferase reporter gene 
under the control of a truncated PAI-1 promoter. Under these conditions, binding of 
TGF-β to the receptors of the PAI-1/Luc transfected MLEC (MLEC-PAI/Luc) results in a 
dose-dependent increase of luciferase activity.  
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Briefly, transfected MLEC cultures were plated in a 96 well plate at a density of 1.6 x 104 
cells per well in complete DMEM supplemented with geneticin and allowed to attach for 
3 h at 37°C in a 5% CO2 incubator. After being washed once with production media, 
MLEC cells were further incubated for 14 to 18 h with 100 µl of cell supernatants to be 
investigated, or recombinant human TGF-β1, serially diluted in production media       
(0 - 4 µg/ml), to generate a standard curve. Cells were then washed twice with PBS and 
lyzed using 20 µl of cell lysis buffer for 30 min at RT under gentle agitation. The cell 
lysates were freezed at -20°C for 3 h and 20 µl cell lysates were subsequently 
transferred to an opaque 96 well plate. The bioassay was measured in a luminometer 
following the injection of 100 μl/well luciferase substrate reagent, using a luciferase 
assay system according to the manufacturer’s instructions. Luciferase activity was 
reported as relative light units (RLU), converted into concentrations using the standard 
curve obtained with human recombinant TGF-β1 and normalized in cell number. 
Only the active form of TGF-β is detected with the MLEC-PAI/Luc bioassay. Therefore, 
to evaluate the amount of total (active and latent) TGF-β, half of the cell supernatants 
were transiently acidified with 1 N HCl for 5-10 min at RT, followed by neutralization with 
1 N NaOH prior addition to the MLEC cells.  
 
Production Media: 0.1% (w/v) BSA  Cell lysis buffer: 25 nM Tris-HCl pH 7.4 
 100 U/ml Penicillin   2 mM EDTA-NaOH pH 7.4
 100 µg/ml Streptomycin   10% Glycerol 
 2 mM Glutamine   1% NP40 
 in DMEM   2 mM DTT  
     
 
3.6. Immunological methods 
3.6.1. Cytokine quantification by enzyme-linked immunosorbent assays (ELISA) 
The expression of cytokines in vitro was measured by a quantitative sandwich enzyme 
immunoassay, ELISA, which specifically detects and quantitates the concentration of 
soluble cytokines. Briefly, a capture antibody, specific for the cytokine of interest, is pre-
coated onto a microplate and the plate is blocked to avoid non-specific binding. 
Standards, controls, and samples are distributed into the coated wells and the cytokine 
of interest is bound to the immobilized capture antibody. A detection antibody, 
horseradish peroxidase-linked specific for the cytokine is then added, followed by a 
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chromogenic substrate solution, which is acted upon by the bound enzyme to produce 
color. The reaction is stopped, and the levels of colored product are determined 
spectrophotometrically at 450 nm using a microplate reader. The intensity of this 
colored product is directly proportional to the amount of cytokine bound in the initial 
step. Cytokine concentrations are determined from the standard curve established from 
serial dilutions of a recombinant cytokine. 
The levels of cytokines released in cell culture supernatants were determined with 
commercially available ELISA kits according to manufacture’s instructions or with 
specific ELISA established by the laboratory of Prof. Dr. Jo Van Damme (Rega Institute, 
University of Leuven, Belgium) for hMCP-2, hMCP-3 and hIP-10. 
Cell supernatants were harvested at the indicated time post-infection (p.i.), and stored 
at -80°C until analysis. The cumulative and daily cytokine production were determined. 
For the measurement of daily cytokine production, the medium was removed, frozen 
and replaced with fresh medium every day.  
3.6.2. Immunohistochemistry 
Immunohistochemistry was done in collaboration with the laboratory of Prof. Dr. Ralf 
Kinscherf, in the Centre for Biomedicine and Medical Technology Mannheim (CBTM), 
Medical Faculty Mannheim, University of Mannheim.  
3.6.2.1 Immunohistochemical staining 
Cryosections (6 µm) were cut with a microtome, mounted on Superfrost microscope 
slides, fixed in acetone for 10 minutes at -20°C and air-dried for 30 min. 
The sections were fixed in 4% paraformaldehyde in PBS for 10 min, washed three times 
with PBS for 5 min and non-specific binding sites were blocked in 1% normal swine 
serum in PBS for 10 min. All subsequent washing steps were performed with PBS for 
5 min. The primary antibody (see section 2.7.1) diluted in PBS was applied on the tissue 
and incubated overnight at RT in a humidified chamber. The sections were then washed 
twice and the endogenous peroxidase activity was blocked with 3% hydrogen peroxide 
in PBS for 5 min at RT. The sections were then washed three times and the 
corresponding secondary biotinylated antibody (see section 2.7.2) was applied to the 
tissue and incubated at 37°C for 30 min. After being washed twice, the sections were 
incubated for 30 min at 37°C with streptavidin-horse radish peroxidase (HRP) complex 
diluted 1:100 in PBS. After washing three times, a chromogenic substrate solution was 
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added, either diamino-benzidine (DAB) or histogreen, staining in brown or green, 
respectively, and the reaction was stopped with PBS. The sections were counterstained 
with hematoxylin according to Mayer’s protocol for a few seconds and washed twice in 
water for 5 min. The sections were then dehydrated by successive incubations in 99% 
ethanol (twice) and rotihistol (three times, xylol replacement) and cover glasses were 
placed using mounting medium.  
Apoptosis measurement was performed by terminal deoxynucleotidyl transferase biotin-
dUTP nick end labeling (TUNEL) assay using a commercially available kit following the 
manufacturer’s instructions. This method allows detection of free 3’-OH termini present 
in the DNA of apoptotic cell by enzymatic labeling. 
 
PBS: 136.9 mM NaCl  Paraformaldehyde, 4%: 4% (w/v) paraformaldehyde
 2.7 mM KCl   in PBS 
 4.9 mM KH2PO4    
 1.8 mM K2HPO4    
 pH 7.2 - 7.4    
     
3.6.2.2 Morphometric analyses 
Cryosections were photographed using an Axio Imager Z1 microscope equipped with 
the AxioVision Rel 4.7 imaging software and digitalized images were processed with the 
same software to measure labeled nucleus, cells, or surfaces. 
For the intracranial model, the whole tumor was photographed and analyzed, whereas 
for the subcutaneous model, 10 regions of interest per tumor were photographed and 
analyzed.  
 
3.7. Animal experiments 
3.7.1. Mouse handling 
Animals were kept under specific pathogen-free conditions within the central animal 
facility at the German Cancer Research Center of Heidelberg. Mice were housed five 
per cage within a flexible film isolator. The temperature was maintained at 21 - 24°C 
and the relative humidity at 40 - 60%. All animals were housed under the same 
conditions with food and water ad libitum, with a 12 h regime light schedule. Animal 
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experimentation was performed in compliance with institutional, governmental, and EU 
guidelines, and in accordance with recommendations for proper care and use of 
laboratory animals. All mice used in experiments were females between 7 and 9 weeks 
of age. Individual animals were identified using ear punches. Animals were sacrificed by 
cervical dislocation or CO2 inhalation. 
3.7.2. Subcutaneous GL261 tumor model  
3.7.2.1 Preparation of virus for injection in established subcutaneous tumors 
Prior to injection in established tumors, the virus stock was diluted to desired 
concentration of viral particles in DPBS, or buffer exchanged to DPBS when the ratio 
iodixanol:DPBS was higher than 1:3 to avoid iodixanol- or phenol red-mediated side 
effects. Virus in DPBS was kept on ice until the injection or alternatively stored for short 
time at 4°C.  
3.7.2.2  Subcutaneous inoculation of GL261 
Subcutaneous tumors were established by injection of GL261 cell suspension into the 
mice right posterior flank. To transfer the tumor, the flank of the carrier was shaved and 
1 x 106 cells GL261 cells were injected subcutaneously in 100µl of DPBS with a 1 ml 
fine dosage syringe. 
3.7.2.3 Virus injection in established subcutaneous tumors 
100 μl of virus suspension was applied peritumorally to avoid mechanical damage of the 
tumor. 
3.7.2.4 Subcutaneous tumor growth monitoring 
After subcutaneous tumor inoculation, the tumor growth was monitored every 2 to 3 
days by measuring its dimensions using an electronic digital caliper. The tumor volume 
(V) was calculated using the formula for an ellipsoid, V(mm3)=(π/6) L x W x H, where L 
is the length and W the width and H the height of the tumor.  
Animals were sacrificed when the tumor volume reached 4 cm3, one dimension 
exceeded 2 cm, or in case of necrosis.   
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3.7.2.5 Tumor embedding for immunohistochemistry 
Mice were sacrificed at the indicated time by cervical dislocation and the subcutaneous 
tumors were resected. The tumor samples were placed in cryomolds and embedded in 
OCT compound for cryo-sectioning. The cryomolds were then snap frozen in liquid 
nitrogen-cooled isopentane and stored at -80°C. 
3.7.3. Intracranial GL261 tumor model 
3.7.3.1 Preparation of in vitro infected cells for intracranial injection 
Three hours post-infection, virus-infected tumor cells were trypsinized, collected by 
centrifugation, and washed twice with calcium- and magnesium-free DPBS. The cells 
were then counted, resuspended in DPBS at a concentration of 2.5 x 104 cells/µl, and 
kept on ice until the injection.  
3.7.3.2 Intracranial inoculation of GL261 
Intracranial implantation of 1 x 105 in vitro infected GL261 cells was performed 
stereotactically in the left striatum. 
Female 7 to 9 weeks old C57BL/6 mice were anesthetized by intraperitoneal injection of 
a mixture of ketamin (0.1 mg/g body weight) and xylazin (0.02 mg/g body weight) in 
0.9% NaCl. The eyes of the mice were carefully covered with an antiseptic cream to 
avoid cornea drying. The head of the mouse was fixed in a stereotactic frame fitted with 
a mouse adaptor. A 1 cm midline scalp incision was made to expose the surface of the 
skull and a small hole was made into the left side of the skull with a 25 gauge needle at 
the defined location of the caudate/putamen, in the striatum, 2.5 mm lateral to the 
sagittal suture at the level of the bregma. The cortical surface was carefully cleared of 
any traces of blood using absorbent swabs. Tumor cells were delivered using a 10 µl 
syringe with a 33 gauge needle inserted into an automated microinjection unit. The 
syringe was inserted to a depth of 3.5 mm and retracted to a depth of 3 mm below the 
surface of the skull to create an injection canal. 1 x 105 GL261 cells suspended in 4 µl of 
phosphate buffer (DPBS) were stereotactically injected with an injection rate of 
250 nl/min. Following injection, the needle was left in place for an additional 5 min and 
then slowly withdrawn to minimize any back-flow through the insertion canal. The skin 
was sutured with non absorbable nylon thread and the mice were placed on a heating 
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pad until recovery from anesthesia. Animals were monitored daily after treatment and 
sacrificed at the indicated time. 
3.7.3.3 Intracranial tumor growth monitoring by MRI 
Magnetic resonance imaging (MRI) provides high soft tissue contrast and high spatial 
resolution. Due to MRI as a non invasive in vivo imaging modality individual animals can 
be examined at various time points during longitudinal animal studies with little or no 
effect on measured animals.  
After intracranial tumor inoculation, tumor growth was monitored weekly by MRI. To 
avoid movements during MRI measurements, mice were immobilized by inhalation 
anesthesia applied by a nose cone (1.5% isoflurane in oxygen). MRI measurements 
were performed using a 1.5 tesla whole-body MR-scanner (see Figure 3-1 B) in 
combination with a custom-made radio-frequency coil for excitation and signal reception 
(see Figure 3-1 A). Morphologic MR-imaging was carried out using a transversal T2-
weighted turbo-spin echo sequence (repetition time, TR = 1,510 ms, echo time, TE = 
59 ms, field of view, FOV = 50  x 50 mm2, matrix 128,  slice thickness = 1.0 mm).  
Regions of interest were drawn by hand around tumor borders on every acquired two-
dimensional (2D) slice, and the tumor surface was determined on the MR scan with the 
biggest tumor diameter (see Figure 3-1 C). 
Morphologic MRI was done in collaboration with the division of Medical Physics in 
Radiology of the DKFZ (Prof. Dr. Dr. Semmler) by M. Batel and Dr. M. Jugold.  
 
 
 
 
 
 
 
 
 
Figure 3-1: Magnetic resonance imaging of mouse glioma 
Mice to be imaged were anesthetized and placed in a custom-made animal coil (A). Magnetic resonance 
imaging was performed on a clinical 1.5 T MR scanner (B), using a Turbo Spin Echo Sequence. 
Transversal sections of the brain (C) were obtained on which the tumor size was estimated. 
 
 
 
A B  C 
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3.7.3.4 Tumor embedding for immunohistochemistry 
Mice were sacrificed at the indicated time by CO2 inhalation. The brains were dissected 
and divided at the injection site into two coronal pieces. Tumor samples were placed in 
cryomolds and embedded in OCT compound for cryo-sectioning. The cryomolds were 
then snap frozen in liquid nitrogen-cooled isopentane and stored at -80°C.  
3.7.3.5 Survival follow-up 
Survival curves were constructed using the Kaplan and Meier survival rate analysis 
(Kaplan and Meier, 1958). For this, the percentage of surviving mice in the different 
groups of animals was recorded daily after glioma implantation. Moribund animals were 
euthanized and their death recorded as occurring on the following day. The median 
survival, representing the time at which half the subjects have died, was estimated for 
each group. In the cases where the survival curve was horizontal at 50% survival, the 
median survival time was calculated as the average of the two time points at which the 
survival curve equals 50 %. 
 
3.8. Statistics 
Statistical analyses for the intracranial tumor growth and animal survival were 
performed in collaboration with Dr. Lutz Edler (department of Biostatistics, DKFZ) using 
the nonparametric Wilkinson Rank Sum and Koziol tests (Koziol et al., 1981). 
All other statistical analyses were performed using the Student t test.  
P values < 0.05 were considered statistically significant. 
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4. RESULTS 
Gliomas are highly vascularized solid tumors, known to induce an immunosuppressive 
environment. In this context, our laboratory has recently investigated the antitumor 
effects of parvoviral vectors delivering TNF-α and IP-10, cytokines known to have both 
immunostimulatory and antiangiogenic properties, in a syngeneic subcutaneous glioma 
tumor model. The growth of mouse glioma GL261 cells infected in vitro with TNF-α- or 
IP-10-transducing parvoviruses, grafted subcutaneously in C57BL/6 mice, was 
significantly delayed compared to buffer-treated cells or to cells infected with the vector 
devoid of transgene (Chi-MVMp/Δ800). A complete tumor regression was observed 
when GL261 cells were coinfected with both TNF-α- or IP-10-encoding parvoviruses. 
The treatment of established tumors with repeated peritumoral injection of cytokine-
encoding parvoviruses also inhibited tumor growth compared to tumors treated with  
Chi-MVMp/Δ800, MVMp wt, or buffer-treated tumors, but to a lesser extend than in the 
in vitro setting. In vivo, the antitumor effects of TNF-α- and IP-10- transducing vectors or 
the combination of both were comparable.  
This work was initiated by Enderlin M. (Enderlin, 2004) and was completed during the 
present work, leading to a publication in which I contributed as second author (Enderlin 
et al., 2008). 
In this thesis, the mechanisms sustaining GL261 subcutaneous tumor inhibition were 
investigated. Next, the analysis of the antitumor effects of these parvoviral vectors was 
extended to GL261 implanted intracranially in syngeneic mice.  
 
Monocyte chemotactic proteins MCP-2 and MCP-3 are known to be potent 
immunoactive cytokines, recruiting a broad range of leukocytes. Parvoviral vectors 
delivering MCP-3 were previously demonstrated to inhibit the tumor growth of human 
Hela grafted in nude mice (Wetzel et al., 2001) and mouse melanoma implanted 
subcutaneously in syngeneic mice (Wetzel et al., 2007). This prompted us to investigate 
the antitumor effects of parvoviruses delivering these chemokines in the GL261 glioma 
tumor model.  
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4.1. Production of wt and recombinant MVM parvoviruses 
Wild-type (wt) MVMp was produced by infection of mouse A9 cells, the reference 
producer cell line, with a master-stock of virus available in the laboratory. Recombinant 
MVMp-derived viruses Chi-MVMp/Δ800, Chi-MVMp/TNF-α, Chi-MVMp/IP-10,           
Chi-MVMp/MCP-2, and Chi-MVMp/MCP-3 were produced in 293T cells by                  
co-transfection of the corresponding recombinant MVMp DNA clones with a helper 
plasmid, providing the parvoviral capsid proteins in trans. 
The virus stocks were purified by iodixanol gradient ultracentrifugation and titrated either 
by infected cell hybridization assay (recombinant and MVMp wt viruses), or by plaque 
assay on A9 cells (MVMp wt). The infectious titers of wt virus determined by infected 
cell hybridization (4 x 109 RU/ml) and plaque assay (3 x 109 PFU/ml) were comparable 
and typically higher than the ones of recombinant viruses which ranged between 9 x 106 
and 10 x 107 RU/ml. This difference can be assigned to the capacity of wt MVMp to 
produce progeny virions through secondary infections during the production procedure, 
whereas recombinant viruses are replication defective. 
4.2. Characterization of GL261 infected with wt MVMp and MVMp-
based vectors in vitro 
The recombinant parvoviruses used in this study are so-called capsid replacement 
vectors. While they retain the expression of parvoviral non-structural proteins (NS1 and 
NS2) under the control of the P4 promoter, the viral capsid proteins genes, driven by the 
P38 promoter, have been replaced by cDNA encoding cytokines or chemokines.  
Mouse glioma GL261 cells infected in vitro with recombinant parvoviruses were 
analyzed for the expression of the transgenes. Next, the effects of both wt and 
recombinant MVMp infection on GL261 cellular growth were analyzed.    
Recombinant viruses encoding TNF-α and IP-10 strongly inhibited the growth of GL261 
mouse glioma cells grafted subcutaneously in C57BL/6 mice, especially when used in 
combination (Enderlin et al., 2008). Therefore, in addition to the effects of parvoviral 
infection using single vectors, the effects of the coinfection of these both viruses were 
also investigated in the following experiments. 
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4.2.1. Transgene expression in GL261 after infection with parvoviral vectors 
High and transient expression of transgenes is a prerequisite in cytokine-mediated 
cancer gene therapy. Indeed, sustained expression of a cytokine could lead to chronic 
inflammation or autoimmunity and hence induce severe adverse reactions. 
We first verified the expression of transgenes in infected GL261 at the mRNA level, 
together with the expression of MVMp non-structural protein NS1. Indeed, NS1, 
retained in parvoviral capsid replacement vectors, is involved in the amplification of the 
viral genome and transactivates the parvoviral P38 promoter, driving the expression of 
the transgene (Kestler et al., 1999). For this, 2 x 105 GL261 cells were infected with        
Chi-MVMp/TNF-α, Chi-MVMp/IP-10, Chi-MVMp/MCP-2, and Chi-MVMp/MCP-3 at an 
MOI of 3 RU per cell. GL261 cells infected with Chi-MVMp/Δ800, or MVMp wt at an MOI 
of 3 RU per cell, or buffer-treated (mock) served as controls. Total RNA was isolated 
24 h post-infection, reverse-transcribed, and amplified by PCR using specific primers 
flanking the transgene in MVMp-derived vectors and for the MVMp non-structural 
protein NS1. Figure 4-1 shows the result of one representative experiment out of two. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-1: Expression of transgenes and NS1 by GL261 after infection with MVMp-
derived vectors 
2 x 105 GL261 cells were infected with Chi-MVMp/TNF-α, Chi-MVMp/IP-10, Chi-MVMp/MCP-2, and       
Chi-MVMp/MCP-3 (MOI = 3 RU/cell). Cells infected with Chi-MVMp/Δ800, MVMp wt (MOI = 3 RU/cell), or 
buffer-treated (mock) served as controls. Total RNA was isolated 24 h post-infection, reverse-transcribed, 
and amplified by PCR using specific primers for the multiple cloning site of MVMp-derived vectors and 
MVMp non-structural protein NS1. GADPH was used as loading control and a RT-PCR with all reagents 
except RNA (-RNA) was included as negative control. 
The expression of the transgenes and their relative size was verified at the mRNA level 
by amplification of the region comprised in the multiple cloning site of MVMp-based 
vectors. Furthermore, the levels of NS1 mRNA in GL261 cells were similar in all infected 
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cells, showing similar efficiency of infection by the different vectors. The expression of 
GAPDH was used as control for sample loading, and as expected no amplification 
products were obtained when RNA was omitted from the reaction. 
 
In order to evaluate the levels of cytokines secreted in the culture medium by GL261 
cells upon infection with recombinant MVMp viruses, 2 x 105 GL261 cells were infected 
with Chi-MVMp/TNF-α, Chi-MVMp/IP-10, Chi-MVMp/MCP-2, or Chi-MVMp/MCP-3 at an 
MOI of 3 RU per cell, and the amounts of cytokines released in the culture medium 
were measured by ELISA at day 1 to 4 post-infection. As controls, 2 x 105 GL261 cells 
were also infected with Chi-MVMp/Δ800 or MVMp wt at an MOI of 3 RU per cell or 
buffer-treated. Figure 4-2 shows the cumulative and daily production of secreted 
cytokines determined in one representative experiment. 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-2: Levels of mTNF-α, hIP-10, hMCP-2, and hMCP-3 in GL261 supernatants after 
infection with MVM-based vectors  
2 x 105 GL261 cells were infected with Chi-MVMp/TNF-α (A), Chi-MVMp/IP-10 (B), Chi-MVMp/MCP-2 
(C), or Chi-MVMp/MCP-3 (D) (MOI = 3 RU/cell). GL261 cells infected with Chi-MVMp/Δ800, MVMp wt 
(MOI = 3 RU/cell) or buffer-treated (mock) served as controls. Cell supernatants were harvested either 
daily (blue bars) or after 1 to 4 days for the accumulated (violet bars) cytokine secretion. The levels of 
cytokines released in the culture medium were measured by ELISA and expressed as nanograms per 
2 x 105 initially infected cells. All cytokine determinations were carried out at least in duplicates. The 
cytokines content in cell supernatants from Chi-MVMp/Δ800-, MVMp wt-, or mock-infected cells were 
lower than 8 ng per 2 x 105 GL261 cells. 
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The daily release of cytokines delivered by parvoviral vectors increased from day 1 
post-infection, peaked at day 2, and decreased thereafter, as previously observed in 
HeLa cells for hH-1/MCP-1 (Haag et al., 2000) or hH-1/MCP-3 (Wetzel et al., 2001). 
The peak production of cytokine at day 2 post-infection was observed for all vectors, 
ranging between 175 (MCP-2) and 276 (IP-10) ng per 2 x 105 initially infected GL261 
cells. Transgenes accumulated in large amounts ranging from 350 ng (MCP-2) up to 
750 ng (IP-10) of cytokines per 2 x 105 cells. The accumulation of cytokines in the cell 
culture medium increased and reached a plateau 4 or 5 days post-infection (data not 
shown), suggesting that all cytokines were stable for at least 5 days in the cell culture 
medium. As expected, human MCP-2, MCP-3, and IP-10 were undetectable in the 
supernatants of mouse GL261 cells infected with Chi-MVMp/Δ800-, MVMp wt- or mock-
infected cells showing the specificity of the ELISAs for human chemokines. No mouse 
TNF-α secretion could be detected in the same settings indicating that GL261 cells did 
not constitutively express mTNF-α and that its expression was not induced after 
infection with these parvoviral vectors.  
Taken together, these results show that parvoviral-mediated gene expression in GL261 
fulfills the conditions for gene therapy as mTNF-α, hIP-10, hMCP-2, and hMCP-3 are 
transiently secreted in high amounts into the culture medium of GL261 cells infected 
with the respective vector. The cytokine yields obtained in GL261 cells with recombinant 
parvoviruses were much higher than those obtained with retroviral or adenoviral 
vectors, transducing respectively MCP-1 (Herrlinger et al., 2004) and TNF-α (Ehtesham 
et al., 2002), where the production was limited to pg levels.  
4.2.2. Effects of wt and recombinant MVMp infection on GL261 cellular growth 
In order to investigate the effects of the parvoviral infection and the transduced genes 
on GL261 cells, the growth of in vitro infected GL261 cells was monitored over 4 days. 
2 x 105 GL261 cells were infected with MVMp wt, Chi-MVMp/TNF-α, Chi-MVMp/IP-10, 
Chi-MVMp/MCP-2, Chi-MVMp/MCP-3, or Chi-MVMp/Δ800 at an MOI of 3 RU per cell or 
buffer-treated (mock). For the coinfection with Chi-MVMp/TNF-α and Chi-MVMp/IP-10, 
an MOI of 1.5 RU per cell was used for each vector. The number of viable cells was 
determined from day 1 to 4 post-infection by the trypan blue dye exclusion method. 
Figure 4-3 shows the result of one representative experiment out of three. 
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Figure 4-3: Cellular growth of GL261 after infection with MVMp or MVMp based vectors  
2 x 105 GL261 cells were infected with MVMp-based vectors and wt (MOI = 3RU/cell), coinfected with    
Chi-MVMp/TNF-α and Chi-MVMp/IP-10 (MOI = 1.5 RU/cell for each vector) or buffer-treated (mock). The 
number of viable cells was determined at the indicated times by the trypan blue dye exclusion method. 
Buffer-treated (mock) GL261 cells grew fast, with a generation time of about 24 h. The 
infection with Chi-MVMp/Δ800 had only a marginal effect on the cellular growth. In 
contrast, infection with Chi-MVMp/IP-10, Chi-MVMp/MCP-2, and Chi-MVMp/MCP-3 
displayed cytostatic effects on GL261 cells, as shown by a limited increase in the cell 
number. Infection of GL261 cells with MVMp wt, Chi-MVMp/TNF-α alone, or coinfection 
with Chi-MVMp/IP-10 had comparable cytotoxic effects, as shown by the drop in the 
number of living cells from day 3 post-infection. This suggests a toxicity of the 
accumulated transgene products in GL261 cells, especially of TNF-α. The effects 
observed with wt MVMp, TNF-α-, and IP-10-encoding viruses are consistent with the 
results previously obtained in the laboratory (Enderlin, 2004). Indeed, GL261 glioma 
cells were shown to be very sensitive to TNF-α in vitro, either recombinant or parvoviral-
transduced and thus an autocrine cytotoxic effect of TNF-α, accumulated in the cell 
culture medium, is very likely. The cytotoxic effect of wt MVMp can be assigned to the 
ability of GL261 cells to produce progeny virions and to induce secondary infections, as 
shown in Figure 4-4.  
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4.2.3. Production of progeny virions by MVMp-infected GL261 
Since MVMp exerted a high cytotoxicity on GL261 cells in vitro, we investigated whether 
GL261 cells were able to produce progeny virions upon MVMp infection. To this end, 
2 x 105 GL261 cells were infected with MVMp wt at an MOI of 0.1 PFU per cell and the 
production of virions was compared to the production of the reference A9 cells. 7 days 
post-infection, the medium of infected cells was harvested and viruses were extracted 
from the cell lysates by freeze-thaw cycles. The titration of progeny virions released in 
the medium and intracellular was performed by plaque assay.  
 
 
 
 
 
 
 
 
 
 
 
Figure 4-4: Production of progeny viruses by GL261 and A9 cells after MVMp infection 
2 x 105 cells GL261 or A9 cells were infected with MVMp at a MOI of 0.1 PFU/cell and lyzed 7 days post-
infection. The production of progeny viruses was then determined by plaque assay on reference A9 cells. 
The input represents the quantity of virus used initially to infect the cells and the output corresponds to 
the total amount of virus produced. 
As shown in Figure 4-4, GL261 cells produced high amounts of progeny virions. Indeed, 
the amount of neosynthetized viruses (4.7 x 108 PFU) was much higher than the 
amount of inoculum used initially to infect the cells (5 x 104 PFU), and only slightly lower 
than with the producer A9 cell line (2.4 x 109 PFU).  
The production of progeny virions is of importance as it could contribute to increased 
killing of MVMp wt through successive rounds of infection, in contrast to MVMp-based 
vectors which are replication defective. Although MVMp wt was indeed shown to 
mediate high cytotoxicity on GL261 cells in vitro, it had similar effects as the 
recombinant parvovirus devoid of transgene when injected in established GL261 tumors 
(Enderlin et al., 2008), indicating that the cytotoxicity of MVMp wt is hampered in vivo. 
This could be due to the dilution in vivo of factors inducing cytotoxicity in vitro and/or to 
parvovirus entry in non tumoral cells in vivo and hence loss of infectious viruses. 
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4.3. Analysis of the mechanisms sustaining tumor inhibition by     
TNF-α- and IP-10-expressing parvoviral vectors in the GL261 
subcutaneous model 
 
The antitumor effects of recombinant parvoviral vectors encoding TNF-α and IP-10 on 
mouse GL261 glioma implanted subcutaneously were recently investigated in our 
laboratory. The growth of GL261 infected in vitro with TNF-α- or IP-10-transducing 
parvoviruses, grafted subcutaneously in C57BL/6 mice, was significantly delayed 
compared to buffer-treated cells or to cells infected with the empty vector                  
Chi-MVMp/Δ800. Complete tumor regression was observed when GL261 cells were 
coinfected with both TNF-α- and IP-10-transducing parvoviruses, suggesting a 
synergistic antitumor effect of these cytokines. In contrast, the treatment of established 
tumors with repeated peritumoral injections of cytokine-encoding parvoviruses viruses 
inhibited the tumor growth compared to wt MVMp-, Chi-MVMp/Δ800-, and PBS-treated 
tumors, but the effects were similar whether TNF-α, IP-10, or both cytokine-transducing 
vectors were used (Enderlin et al., 2008).  
In this thesis, I investigated the mechanisms sustaining tumor inhibition by TNF-α- and 
IP-10-expressing parvoviral vectors in the GL261 subcutaneous tumor model. The 
synergy between TNF-α and IP-10, observed when parvovirus-infected GL261 glioma 
cells were implanted subcutaneously, was analyzed in vitro.  
Next, the infiltration of leukocytes as well as proliferation and apoptosis of intratumoral 
cells were investigated by immunohistochemistry after peritumoral injections of 
recombinant parvoviruses in established tumors. 
4.3.1. Analysis of the synergistic antitumor effects of TNF-α and IP-10 
4.3.1.1 Increased mIP-10 RNA expression and protein secretion in GL261 cells 
infected with Chi-MVMp/TNF-α  
The subcutaneous growth of GL261 cells in vitro coinfected with both TNF-α- and 
IP10-expressing viruses grafted subcutaneously in mice was strongly impaired, in 
contrast to GL261 cells infected with each of the virus independently, showing 
synergistic antitumor effects of TNF-α and IP-10 in this system (Enderlin et al., 2008).  
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TNF-α was reported to induce, in synergy with IFN-γ, the production of IP-10 in various 
cell types, such as keratinocytes, fibroblasts (Majumder et al., 1996), or astrocytes 
(Salmaggi et al., 2002). TNF-α alone was also shown to induce IP-10 expression, for 
instance in human neural precursors cells (Sheng et al., 2005), normal astrocytes 
(Salmaggi et al., 2002), and astrocytomas (Majumder et al., 1998).  
To investigate whether TNF-α-encoding virus was able to induce murine IP-10 (mIP-10) 
expression in the GL261 model, the levels of mIP-10 transcripts were analyzed in 
infected GL261 cells. To this end, 2 x 105 GL261 cells were infected with                   
Chi-MVMp/TNF-α at an MOI of 3 RU per cell, or coinfected with Chi-MVMp/TNF-α and 
Chi-MVMp/IP-10 at an MOI of 1.5 RU per cell for each virus. MVMp wt-,                   
Chi-MVMp/Δ800-, and Chi-MVMp/IP-10-infected cells at an MOI of 3 RU per cell as well 
as buffer-treated (mock) were used as controls. Total RNA was isolated 24 h and 48 h 
post-infection, reverse transcribed using primers specific for mouse IP-10, and the PCR 
products were analyzed on agarose gel electrophoresis. Figure 4-5 shows the results 
obtained after 24 h post-infection. Similar results were obtained 48 h post-infection.  
 
 
 
 
 
 
 
 
 
Figure 4-5: Increased mIP-10 mRNA levels after infection of GL261 cells with                 
Chi-MVMp/TNF-α  
2 x 105 GL261 cells were infected with Chi-MVMp/TNF-α (MOI = 3 RU/cell), or coinfected with             
Chi-MVMp/TNF-α and Chi-MVMp/IP-10 (MOI = 1.5 RU/cell for each vector). MVMp wt-, Chi-MVMp/IP-10- 
and Chi-MVMp/Δ800-infected cells (MOI = 3 RU/cell) as well as buffer-treated cells (mock) were used as 
controls. Total RNA was isolated 24 h post-infection and reverse transcription-PCR analysis was 
performed for the expression of mIP-10. GADPH was used as loading control and a RT-PCR with all 
reagents except RNA (-RNA) was included as negative control. 
Similar mIP-10 mRNA expression levels were observed after infection with MVMp,                
Chi-MVMp/Δ800, and Chi-MVMp/IP-10, compared to buffer-treated GL261 infected 
cells. Thus, some mIP-10 expression is constitutive in GL261 cells and it is not 
increased upon parvoviral infection. In contrast, infection of GL261 cells with                  
Chi-MVMp/TNF-α or coinfection with Chi-MVMp/TNF-α and Chi-MVMp/IP-10 resulted in 
a significant increase of mIP-10 mRNA levels.  
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The induction of mIP-10 expression in GL261 cells by TNF-α-transducing parvovirus 
was verified at the protein level. To this end, 2 x 105 GL261 cells were infected with     
Chi-MVMp/TNF-α at an MOI of 3 RU per cell, or coinfected with Chi-MVMp/TNF-α and 
Chi-MVMp/IP-10 at an MOI of 1.5 RU per cell for each virus. Chi-MVMp/Δ800-,             
and Chi-MVMp/IP-10-infected cells at an MOI of 3 RU per cell as well as buffer-treated 
(mock) were used as control. The secretion of mIP-10 in the culture medium was 
measured 24 and 48 h post-infection by ELISA. The results are illustrated in Figure 4-6. 
 
 
 
 
  
 
 
 
 
 
 
 
 
Figure 4-6: Increased mIP-10 secretion in GL261 cells after infection with Chi-MVM/TNF-α 
2 x 105 GL261 cells were infected with Chi-MVMp/TNF-α (MOI = 3 RU/cell), or coinfected with             
Chi-MVMp/TNF-α and Chi-MVMp/IP-10 (MOI = 1.5 RU/cell for each vector). Chi-MVMp/IP-10- and      
Chi-MVMp/Δ800-infected cells (MOI = 3 RU/cell) as well as buffer-treated cells (mock) were used as 
controls. Cell supernatants were harvested after 24 and 48 h and the levels of mIP-10 accumulated in the 
culture medium were measured by ELISA. Results are expressed as nanograms per 2 x 105 initially 
infected cells and shown as mean of triplicates from one representative experiment. Error bars represent 
the standard deviation. Statistical analysis was performed using Student’s t test (*=p<0.01 versus mock). 
As shown in Figure 4-6, the infection of GL261 cells with Chi-MVMp/Δ800 and             
Chi-MVMp/IP-10 resulted in mIP-10 protein levels comparable to the constitutive 
secretion from mock-infected GL261 cells. In contrast, statistically significant increased 
levels of mIP-10 were detected in the supernatants of GL261 cells infected with         
Chi-MVMp/TNF-α, alone or coinfected with Chi-MVMp/IP-10 compared to mock-infected 
cells at 24 and 48h post-infection (p<0.01). The difference between GL261 cells 
infected with Chi-MVMp/TNF-α alone or in combination with Chi-MVMp/IP-10 was not 
statistically significant. The increase of mIP-10 secretion by TNF-α delivering viruses 
was about 4 times higher than the constitutive levels secreted 48 h post-infection. 
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These results, together with the data obtained by RT-PCR, show that the infection of 
GL261 glioma cells with TNF-α-transducing parvovirus significantly increases both   
mIP-10 mRNA expression and protein secretion in GL261 cells in vitro. The levels of 
mIP-10 produced after 48 h (30 ng per 2 x 105 cells) represent up to 20 % of the levels 
produced after infection with Chi-MVMp-hIP-10 under the same conditions (200 ng). 
The expression of mouse IP-10 induced by Chi-MVMp/TNF-α combined with the 
expression of human IP-10 induced by Chi-MVMp/IP-10 may thus result in IP-10 
amounts above a critical threshold. This could account for the synergistic antitumor 
effects of Chi-MVMp/TNF-α and Chi-MVMp/IP-10 observed in the GL261 subcutaneous 
tumor model. Indeed, TNF-α, and IP-10 may synergize to induce the production of one 
or more factors which, in turn, would also participate in the antitumor response. 
 
4.3.1.2 Production of interferons in parvovirus-infected GL261 cells 
As mentioned above, TNF-α was reported to induce the production of IP-10, usually in 
synergy with IFN-γ in various cell lines, but also more rarely in synergy with IFN-α or -β 
(Buttmann et al., 2007; Kato et al., 2003; Matikainen et al., 2000; Petry et al., 2006). 
Whereas IFN-γ is exclusively produced by lymphocytes, IFN-α, and -β, known as viral 
IFNs, can also be produced by most types of virally infected cells (Pestka et al., 2004). 
In this context, we investigated at the mRNA level, whether parvoviral infection of 
GL261 cells could induce the expression of IFN-α, and/or -β isoforms. For this, 2 x 105 
GL261 cells were infected with the different parvoviral vectors at an MOI of 3 RU per 
cell, coinfected with Chi-MVMp/TNF-α and Chi-MVMp/IP-10 at an MOI of 1.5 RU per 
cell for each vector or buffer-treated cells (mock). Total RNA was isolated 24 h and 48 h 
post-infection and reverse transcription-PCR analysis was performed using primers 
specific for IFN-α or -β isoforms. The results are illustrated in Figure 4-7. 
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Figure 4-7: Induction of mIFN-α but not mIFN-β mRNA expression after infection with 
MVMp-derived vectors 
2 x 105 GL261 cells were infected with Chi-MVMp/Δ800, Chi-MVMp/TNF-α, Chi-MVMp/IP-10 
(MOI = 3 RU/cell), coinfected with Chi-MVMp/TNF-α and Chi-MVMp/IP-10 (MOI = 1.5 RU/cell for each 
vector), or buffer-treated cells (mock). Total RNA was isolated 24 h and 48 h post-infection and reverse 
transcription-PCR analysis was performed using primers specific for mIFN-α or -β. GADPH was used as 
loading control and a RT-PCR with all reagents except RNA (-RNA) was included as negative control. 
Whereas no expression of IFN-β could be detected in infected or non-infected cells, the 
expression of IFN-α was induced 48 h post-infection in GL261 cells after parvoviral 
infection. The infection with all cytokine-encoding parvoviruses resulted in an increased 
expression of IFN-α compared to the infection with the empty vector Chi-MVMp/Δ800. 
The expression increased with time as shown by higher levels of mRNA 48 h post-
infection irrespective of the group. No striking difference could be observed between 
cells infected with Chi-MVMp/TNF-α, Chi-MVMp/IP-10, or coinfected with both vectors.  
At the protein level, the induction of IFN-α expression in GL261 cells after infection with 
parvoviral vectors was undetectable by ELISA, meaning that the IFN-α concentrations 
were lower than 12.5 pg/ml.  
 
Together, these results suggest that TNF-α transduced by parvoviral vectors is 
sufficient to induce mIP-10 expression and secretion in the GL261 system. Whether low 
amounts of IFN-α, may also contribute to the induction of mIP-10 by TNF-α remains to 
be elucidated. 
 
We next verified that mIP-10 expression could be induced by TNF-α alone in GL261 
cells and not in the context of parvoviral infection. For this, 1 x 105 GL261 cells were 
treated with increasing concentrations of recombinant mouse TNF-α (0, 1, 10 or 
100 ng/ml) for 24 to 48 h and the secretion of mIP-10 in the culture medium was 
measured by ELISA.  
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Figure 4-8: Increased mIP-10 secretion in GL261 cells treated with recombinant mTNF-α 
1 x 105 GL261 cells were treated with increasing concentrations of recombinant mouse TNF-α              
(0 - 100 ng/ml) for 24 to 48 h, and the levels of mIP-10 released in the culture medium were measured by 
ELISA. Results are expressed as nanograms per 1 x 105 cells and shown as mean of triplicates. Error 
bars represent the standard deviation and statistical analysis was performed using Student’s t test 
(*=p<0.01 versus mock; °=p<0.05 versus 10 ng/ml). 
As shown in Figure 4-8, TNF-α alone is indeed sufficient to induce mIP-10 expression in 
GL261 cells. The treatment of GL261 cells with increasing concentrations of 
recombinant TNF-α induced, in a concentration dependent manner, statistically 
significantly increased levels of mIP-10 secretion in comparison to untreated cells 
(p<0.01). High concentrations of TNF-α (100 ng/ml) were toxic for GL261 cells resulting 
in decreased levels of mIP-10 (p<0.05).  
 
TNF-α was reported to induce IP-10 by itself in various cells. The analysis of the IP-10 
proximal promoter region revealed the presence of an interferon-stimulated responsive 
element (ISRE) and of two Nuclear Factor-kappa B (NF-κB) binding elements, κB1 and 
κB2, conserved among mammalian species (Ohmori and Hamilton, 1993; Yang et al., 
2007). The κB motifs are recognized by members of the NF-κB/Rel homology family 
(Kunsch et al., 1992). Of interest, the TNF-α signaling pathway induces the activation of 
the NF-κB/Rel proteins. Therefore, the induction of mIP-10 by TNF-α most probably 
happens through positive transcriptional regulation of the mIP-10 promoter by the κB 
elements. Whether one or both NF-κB binding elements are involved in the induction of 
mIP-10 in GL261 cells and which members of the NF-κB/Rel protein family may 
participate remains to be elucidated. 
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4.3.2. Analysis of the immune cells infiltration, cell proliferation, and apoptosis in 
established subcutaneous GL261 tumors treated with peritumoral injections 
of parvoviral vectors 
The treatment of established subcutaneous GL261 tumors with repeated peritumoral 
injections of parvoviruses transducing TNF-α, IP-10, or with both vectors was recently 
shown to inhibit tumor growth, while wt MVMp and the control vector Chi-MVMp/Δ800 
had only marginal effects compared to buffer-treated tumors. Whereas synergistical 
antitumor effects were observed when GL261 cells were coinfected in vitro with both 
cytokines-encoding vectors and grafted subcutaneously, the antitumor effects were 
similar whether established tumors were treated with single cytokine-encoding vectors 
or their combination. This suggests that the synergy might be effective only in early 
tumor stages, before tumors become palpable. Alternatively, this could be assigned to 
the lower probability that tumor cells might be coinfected with both viruses in vivo 
(Enderlin et al., 2008).  
To investigate the mechanisms sustaining tumor inhibition by TNF-α- and IP-10-
expressing parvoviral vectors, we examined the infiltration of the major types of 
leukocytes involved in immune responses, including T lymphocytes, macrophages, 
dendritic cells, and natural killer cells. In addition, we also investigated intratumoral cell 
proliferation and apoptosis. 
As the tumors developing from GL261 cells coinfected in vitro with both parvoviral 
vectors encoding TNF-α and IP-10 remained very small and regressed rapidly, we 
rather decided to analyze the antitumor mechanisms after injection of recombinant 
parvoviruses in established GL261 tumors. For this, 1 x 106 GL261 cells were grafted 
subcutaneously in C57BL/6 mice. Small tumors were treated with two peritumoral 
injections, at day 9 and 13 post-implantation, of Chi-MVMp/Δ800, wt MVMp,               
Chi-MVMp/TNF-α, Chi-MVMp/IP-10 (1 x 106 RU per injection), both Chi-MVMp/TNF-α 
and Chi-MVMp/IP-10 (each at 1 x 106 RU per injection), or PBS (mock) (3 mice per 
group). 17 days post-implantation, tumors were resected, cryofixed and tumors sections 
were stained with specific antibodies by immunohistochemistry. Cryosections were 
photographed and digitalized images were processed with an imaging software to 
quantify stained cells.  
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4.3.2.1 Decreased infiltration of CD8+ and CD4+ lymphocytes in subcutaneous 
GL261 treated with parvoviral vectors  
Cellular immune responses were suggested to contribute to the antitumor effects 
observed when GL261 cells coinfected with both TNF-α- and IP-10-encoding vectors 
were grafted subcutaneously in immunocompetent mice. Indeed, when GL261 cells 
coinfected with both vectors were grafted in immunodeficient (nude) mice, all animals 
developed tumors and there was no significant difference in the tumor volume in mice 
implanted with coinfected cells or buffer-treated cells (Enderlin et al., 2008). Moreover, 
IP-10 is known as a potent chemoattractant for activated T cells (Taub et al., 1993), 
especially CD4+ Th1 helper cells, which induce the proliferation of cytotoxic CD8+ 
T cells (Bonecchi et al., 1998; Sallusto et al., 1998).  
In this context, we analyzed the infiltration of lymphocytes in tumor samples, using 
antibodies against CD4 and CD8. These antibodies can detect CD4+ and CD8+ 
T lymphocytes, respectively, as well as NKT cells, which can be CD4+ or CD8+. The 
results are summarized in Figure 4-9. 
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Figure 4-9: Decreased infiltration/proliferation of CD4+ and CD8+ T lymphocytes in 
subcutaneous GL261 treated with MVMp wt and derived vectors  
1 x 106 GL261 cells were grafted subcutaneously in C57BL/6 mice. Small tumors were treated with two 
peritumoral injections (day 9 and 13 post-implantation) of Chi-MVMp/Δ800, wt MVMp, Chi-MVMp/TNF-α, 
Chi-MVMp/IP-10 (1 x 106 RU per injection), with both Chi-MVMp/TNF-α and Chi-MVMp/IP-10 (each at 
1 x 106 RU per injection), or PBS (control) (3 mice per group). 17 days post-implantation, tumors were 
resected, cryofixed, and T lymphocytes were stained by immunohistochemistry using anti-mouse CD8+ 
(A) and CD4+ (B) rat monoclonal antibodies, and counterstained with hematoxylin. Cryosections were 
photographed and digitalized images were processed with an imaging software to measure CD4+ and 
CD8+ positive cells. The number of positive cells is given per mm2 as mean value of three animals per 
group and the error bars represent the SEM. Statistical analysis was performed using Student’s t test  
(*=p<0.05;**=p<0.01 versus mock; °=p<0.05 versus Chi-MVMp/Δ800). Representative picture are shown 
below. 
Both CD8+ and CD4+ cells were found in all subcutaneous GL261 tumors, but 
surprisingly more lymphocytes were found in PBS-treated tumors (control) than in virus-
treated groups. Whereas the infiltration of CD8+ cells was quite similar in all virus-
treated groups, the infiltration of CD4+ cells varied depending on the treatment. Indeed, 
dramatically decreased numbers of CD4+ lymphocytes were observed in tumors treated 
with cytokine-encoding vectors, compared to tumors treated with the empty vector or 
with PBS (p<0.05). The differences observed between Chi-MVMp/TNF-α,                  
0
100
200
300
400
Mock Δ800 TNF-α IP-10 TNF+IP-10 MVMwt
CD
4 
po
si
tiv
e 
ce
lls
/m
m
2
Chi-MVMp/ 
Control 
B 
  Mock                                        Chi-MVMp/Δ800                             Chi-MVMp/TNF-α 
                                                                                                                           RESULTS 
71 
Chi-MVMp/IP-10 or with both cytokine-encoding vectors groups were not statistically 
significant. Thus, in this setting, parvoviral-transduced IP-10 did not seem to mediate 
chemoattraction of T lymphocytes.  
 
A significant tumor inhibition was observed in established subcutaneous GL261 tumors 
treated with parvoviral vectors encoding TNF-α, IP-10, or both, compared with the 
controls (Enderlin et al., 2008). Thus, the infiltration of CD4+ cells is inversely correlated 
with the tumor growth in vivo. Of interest, CD4+ cells comprise helper T cells and 
regulatory T cells (Tregs), which respectively stimulate or suppress immune responses. 
Tregs were indeed shown to be present in high numbers in GL261 subcutaneous 
tumors (El Andaloussi et al., 2006). Thus, we hypothesized that the treatment of GL261 
tumors with cytokine-encoding vectors might inhibit the infiltration and/or proliferation of 
Tregs and hence promote an effective immune response.  
 
 
Gliomas are known to induce an immunosuppressive environment through the secretion 
of several molecules including IL-10, prostaglandin E2 (PGE2), and transforming growth 
factor-β (TGF-β). TGF-β is known as the most immunosuppressive molecule and its role 
in malignant glioma biology is not restricted to immunosuppression but also affects 
tumor growth, invasion, migration, as well as tumor angiogenesis (Platten et al., 2001). 
Interestingly, TGF-β was reported to induce Tregs proliferation and infiltration (Chen 
and Wahl, 2003; Ghiringhelli et al., 2005; Schramm et al., 2004).  
In this context, we investigated the effects of parvoviral infection and of the transgenes 
on the production of TGF-β in GL261 cells. The expression of the TGF-β isoforms 
(TGF-β1, -β2, -β3) was analyzed in virus-infected GL261 cells at the messenger RNA 
level. To this end, 2 x 105 GL261 cells were infected with Chi-MVMp/TNF-α,               
Chi-MVMp/IP-10, Chi-MVMp/Δ800, MVMp wt at an MOI of 3 RU per cell, coinfected 
with Chi-MVMp/TNF-α and Chi-MVMp/IP-10 at an MOI of 1.5 RU per cell for each virus, 
or buffer-treated (mock). Total RNA was isolated 24 h and 48 h post-infection, and 
reverse transcription-PCR analysis was performed using primers specific for TGF-β 
isoforms. Figure 4-10 shows the result of one representative experiment out of two. 
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Figure 4-10: Reduced TGF-β expression by GL261 after infection with MVMp wt and 
derived vectors  
2 x 105 GL261 cells were infected with Chi-MVMp/TNF-α, Chi-MVMp/IP-10, Chi-MVMp/Δ800, MVMp wt 
(MOI = 3 RU/cell), coinfected with Chi-MVMp/TNF-α and Chi-MVMp/IP-10 (MOI = 1.5 RU/cell for each 
virus), or buffer-treated (mock). Total RNA was isolated 24 h and 48 h post-infection, and RT-PCR 
analysis was performed for the expression of TGF-β1, -β2, and -β3 isoforms. GADPH was used as 
loading control and a RT-PCR with all reagents except RNA (-RNA) was included as negative control. 
As shown in mock-infected cells, GL261 cells expressed both TGF-β2 and TGF-β3 
isoforms, but not TGF-β1. TGF-β2 expression was not affected upon parvoviral infection 
or by any of the transgenes, neither at 24 h nor at 48 h post-infection. In contrast,   
TGF-β3 expression was found to be reduced after parvoviral infection, and more 
strikingly with cytokine-encoding vectors. While TGF-β3 mRNA levels remained 
unchanged after infection with Chi-MVMp/Δ800, MVMp wt or Chi-MVMp/IP-10 at 24 h 
post-infection, no TGF-β3 expression could be detected after infection with               
Chi-MVMp/TNF-α. Furthermore, TGF-β3 transcripts were significantly reduced after 
coinfection with both Chi-MVMp/TNF-α and Chi-MVMp/IP-10, suggesting an effect of 
parvoviral-transduced TNF-α. 48 h post-infection, TGF-β3 expression was slightly 
reduced by the parvoviral infection itself, as shown by reduced mRNA levels after 
infection with MVMp wt or Chi-MVMp/Δ800, compared with buffer-treated cells. Most 
strikingly, TGF-β3 expression remained undetectable, not only after infection with      
Chi-MVMp/TNF-α, as already seen 24 h post-infection, but also after infection with    
Chi-MVMp/IP-10 or coinfection of both viruses. This indicates that IP-10 could also have 
an effect on TGF-β3 expression, yet at later times post-infection.  
 
In summary, while parvoviral infection has a only moderate effect on TGF-β3 
expression, the infection with TNF-α- and IP-10-encoding viruses significantly 
decreased the accumulation of TGF-β3 mRNA, indicating a direct role of the cytokines. 
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In contrast, we could not detect an effect on TGF-β2 expression. One should point out 
that all three TGF-β isoforms bind to the same receptors, induce a similar transduction 
pathway and thus have similar functions per se (Graycar et al., 1989). The effects of 
different isoforms depend on the type and differentiation state of target cells and on the 
presence of other cytokines (Nathan and Sporn, 1991).  
 
The inhibition of TGF-β in infected GL261 cells observed at the mRNA level, was 
confirmed at the protein level. For this, the amounts of TGF-β released in the 
supernatants of infected GL261 were assayed using the plasminogen activator  
inhibitor-1 / luciferase (PAI/Luc) bioassay, described by Abe et al., 1994. This assay is 
based on the ability of TGF-β to induce PAI-1 expression, using mink lung epithelial 
cells (MLEC) stably transfected with a luciferase reporter gene under the control of a 
truncated PAI-1 promoter. The assay detects all three TGF-β isoforms. To this end, 
GL261 cells were infected as described here-above with Chi-MVMp/TNF-α,              
Chi-MVMp/IP-10, Chi-MVMp/Δ800, MVMp wt, coinfected with Chi-MVMp/TNF-α and 
Chi-MVMp/IP-10, or buffer-treated (mock). The levels of TGF-β released in the 
supernatants of infected GL261 were measured using the MLEC-PAI/Luc bioassay. 
Figure 4-11 shows one representative experiment out of three.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-11: Decrease of TGF-β secretion after infection with wt and recombinant MVMp 
in GL261 
2 x 105 GL261 cells were infected with Chi-MVMp/TNF-α, Chi-MVMp/IP-10, Chi-MVMp/Δ800, MVMp wt 
(MOI = 3 RU/cell), coinfected with Chi-MVMp/TNF-α and Chi-MVMp/IP-10 (MOI = 1.5 RU/cell for each 
virus), or buffer-treated (mock).Total TGF-β amounts present in the cell supernatants were determined 
using the MLEC-PAI/L bioassay. Results are shown as mean of triplicates from one representative 
experiment and error bars represent the standard deviation. Luciferase activity is reported as relative light 
units (RLU) and TGF-β amounts are normalized per cell number. Statistical analysis was performed using 
Student’s t test (*=p<0.01, **=p<0.001 versus mock; °=p<0.01; °°=p<0.001 versus Chi-MVMp/Δ800). 
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TGF-β secretion by infected GL261 was significantly reduced in all groups compared to 
mock-infected cell. Similarly to the results obtained at the mRNA level, GL261 infection 
with Chi-MVMp/Δ800 and MVMp moderately reduced TGF-β production compared to 
mock-treated cells, whereas the inhibition was greater after infection with cytokine-
encoding vectors. The most potent inhibitions were observed after infection with           
Chi-MVMp/TNF-α and its combination with Chi-MVMp/IP-10, which were statistically 
significant compared to Chi-MVMp/IP-10 used alone (p<0.01). 
 
Taken together, these results show that the infection of GL261 cells with wt and MVMp-
derived vectors inhibits the production of TGF-β in GL261 at the mRNA (TGF-β3) as 
well as at the protein level. This effect is particularly striking for cytokine-encoding 
parvoviruses while the virus alone has only a moderate effect. 
 
Interestingly, the pattern of TGF-β expression strongly correlates with the infiltration of 
CD4+ T cells in subcutaneously implanted GL261 tumors (see Figure 4-9 B). TGF-β was 
reported to induce CD4+ Tregs proliferation and infiltration (Chen and Wahl, 2003; 
Ghiringhelli et al., 2005). The decrease of TGF-β levels observed after infection with 
TNF-α- and IP-10-encoding parvoviruses might thus indeed lead to a decrease in the 
amounts of Tregs infiltrating the tumor, and supports our hypothesis. A decrease of 
Tregs could contribute to the antitumor effects observed, as these cells are potent 
inhibitors of immune responses. 
In addition, TGF-β was reported to impair the function of both CD8+ cytotoxic cells and 
CD4+ helper cells (Gorelik and Flavell, 2002; Thomas and Massague, 2005). The 
reduction of TGF-β expression detected in GL261 cells after infection with cytokine- 
encoding vectors might in turn allow CD4+ helper and CD8+ cytotoxic T lymphocytes to 
exert their functions in vivo while being suppressed in the control groups, becoming 
then the potential effector cells responsible for the antitumor effects mediated with 
cytokine-encoding vectors. 
4.3.2.2 Increased infiltration of CD68+ macrophages in subcutaneous-implanted 
GL261 cells treated with both Chi-MVMp/TNF-α and Chi-MVMp/IP-10 
Macrophages are important components of antitumor responses. They are implied in 
both innate- and adaptative-mediated immunity. Their role in innate immunity implies 
direct killing of tumor cells through phagocytosis and production of various inflammatory 
proteins. Through phagocytosis, macrophages can also process tumor antigens, and 
present them to lymphocytes in order to activate the cellular immune response.  
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The infiltration of macrophages was analyzed by staining of tumor samples with 
antibodies against CD68, also known as microsialin in mouse. CD68 is a glycosylated 
lysosomal antigen restricted to cells of the macrophage lineage (Holness et al., 1993).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-12: Increased infiltration of CD68+ macrophages in subcutaneous GL261 treated 
with both Chi-MVMp/TNF-α and Chi-MVMp/IP-10  
1 x 106 GL261 cells were grafted subcutaneously in C57BL/6 mice. Small tumors were treated with 
repeated peritumoral injection (day 9 and 13 post-implantation) of Chi-MVMp/Δ800, wt MVMp,             
Chi-MVMp/TNF-α, Chi-MVMp/IP-10 (1 x 106 RU per injection), with both Chi-MVMp/TNF-α and             
Chi-MVMp/IP-10 (each at 1 x 106 RU per injection), or PBS (control) (3 mice per group). 17 days post-
implantation, tumors were resected, cryofixed and macrophages were stained by immunohistochemistry 
using an anti-mouse CD68 rat monoclonal antibody, and counterstained with hematoxylin. Cryosections 
were photographed and digitalized images were processed with an imaging software to measure CD68 
positive cells. The number of positive cells is given per mm2 as mean value of three animals per treatment 
group and the error bars represent the standard error of the mean. Statistical analysis was performed 
using Student’s t test (*=p<0.05 versus mock). Representative pictures are shown below. 
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As seen on Figure 4-12, tumor infiltrating macrophages, identified as CD68+ cells, were 
found in all tumor samples, irrespective of the group. Whereas no significant differences 
were observed in tumors treated with TNF-α- or IP-10-encoding viruses, compared to 
Chi-MVMp/Δ800, MVMp wt, or buffer-treated tumors (control), an increased number of 
macrophages was detected in tumors treated with the combination of both cytokine-
transducing vectors, statistically significant compared to buffer-treated tumors (control), 
but not to vector-infected groups.  
Considering the variability between the different groups and the fact that the treatment 
of established GL261 tumors with parvoviral vectors encoding TNF-α, IP-10, or both 
vectors resulted in similar antitumor responses (Enderlin et al., 2008), the increase of 
macrophages observed when using both vectors might not be relevant for the antitumor 
effects observed.  
4.3.2.3 No detectable infiltration of dendritic cells or natural killer cells 
Natural killer cells and dendritic cells are also important components of antitumor 
responses. Whereas natural killer cells are involved in the innate immune response and 
can mediate direct killing of tumor cells, dendritic cells are known as the most efficient 
antigen presenting cells, able to activate both the humoral and cellular adaptative 
responses. The infiltration of natural killer cells and dendritic cells was investigated 
using NKG2D and 33D1 antibodies respectively. Yet, we could not detect any of these 
two types of cells in subcutaneous tumor samples, irrespective of the group. Thus, it 
seems that natural killer cells do not play a key role in the antitumor response in this 
system. Concerning dendritic cells, one possibility may be that at the time point 
analyzed, they may have already left the tumor to the draining lymph nodes.  
4.3.2.4 Effects of MVMp wt and derived vectors on cell proliferation and apoptosis 
The tumor growth of established GL261 tumors treated with peritumoral injections of 
cytokine-encoding parvoviruses was reduced compared to the control groups (Enderlin 
et al., 2008). In addition, parvoviral infection with MVMp wt and derived vectors impaired 
the cellular growth of GL261 cells in vitro (see section 4.2.2). Furthermore, TNF-α is a 
known potent pro-apoptotic factor. This prompted us to investigate whether these 
viruses had an effect on subcutaneous intratumoral cell proliferation or apoptosis. For 
this, tumor cryosections were histomorphometrically examined after staining either for 
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Ki67, used as a marker of cell proliferation, or after staining by terminal deoxynucleotidyl 
transferase Biotin-dUTP nick end labeling (TUNEL) assay to detect apoptotic cells.  
 
 
Treatment group % Ki67 positive cells % TUNEL positive cells 
Control 33.0 ± 6.5 7.5 ± 1.3 
Chi-MVMp/Δ800 33.0 ± 1.5 6.0 ± 2.5 
Chi-MVMp/TNF-α 30.5 ± 4.4 7.3 ± 1.8 
Chi-MVMp/IP-10 29.5 ± 2.3 7.0 ± 1.2 
Chi-MVMp/TNF-α + Chi-MVMp/IP-10 32.5 ± 1.5 6.0 ± 2.2 
wt MVMp 30.3 ± 1.8 6.4 ± 1.5 
 
 
 
 
 
 
 
 
 
 
 
Table 4-1: Effect of MVMp wt and derived vectors on cell proliferation and apoptosis 
1 x 106 GL261 cells were grafted subcutaneously in C57BL/6 mice. Small tumors were treated with two 
peritumoral injections (day 9 and 13 post-implantation) of Chi-MVMp/Δ800, wt MVMp, Chi-MVMp/TNF-α, 
Chi-MVMp/IP-10 (1 x 106 RU per injection), with both Chi-MVMp/TNF-α and Chi-MVMp/IP-10 (each at 1 x 
106 RU per injection), or PBS (control) (3 mice per group). 17 days post-implantation, tumors were 
resected, and cryofixed. Proliferating cells were stained by immunohistochemistry with an antibody 
against Ki67 and apoptotic cells were detected by TUNEL assay. Cryosections were photographed and 
digitalized images were processed with an imaging software to measure Ki67 and TUNEL positive cells 
and counterstained with hematoxylin to quantify the total amount of cells. The percentage of Ki67 and 
TUNEL positive cells are given as mean value of three animals per treatment group ± standard error of 
the mean. The difference between the treated groups was not statistically significant (Student’s t test). 
One representative picture for each stain is shown below. 
As shown in Table 4-1, no significant differences could be observed in the proliferation 
or apoptosis rate between the treated groups. Thus at this time point, the infection of 
GL261 cells with parvoviral vectors did not affect the proliferation nor the apoptosis of 
intratumoral cells in vivo. However, one should point out that these results were 
obtained at only one time point and may perhaps not be representative of the situation 
on a long-term follow up. 
                     Ki67                                                               TUNEL 
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4.4. Analysis of the antitumor effects of cytokine-transducing 
parvoviral vectors on GL261 implanted intracranially in syngeneic 
C57BL/6 mice 
The CNS has long been considered as an immune-privileged site. However, growing 
evidence indicates that the CNS has a significant but tightly regulated capability to 
induce immune responses and many immunotherapeutic approaches, including the use 
of immunostimulatory genes, have already been tried in the treatment of malignant brain 
tumors. This prompted us to investigate the antitumor effects of cytokine-transducing 
parvoviruses on mouse glioma tumor growth and animal survival when glioma cells are 
implanted intracranially in syngeneic immunocompetent mice.  
4.4.1. Establishment of GL261 cells intracranial implantation  
The GL261 glioma model is widely used as subcutaneous but also as intracranial tumor 
model. Of interest, several reports demonstrate that GL261 cells grow well after 
intracerebral implantation in syngeneic C57BL/6 mice and with a highly reproducible 
disease progression (Cha et al., 2003; Szatmari et al., 2006; Zagzag et al., 2000).  
Thus, we decided to test the antitumor effects of cytokine-encoding parvoviral vectors 
on mouse GL261 glioma implanted intracranially. Since this model was not established 
in our laboratory at the time I started, I contributed with S. Paschek (Vet. Med.) to 
implement it in our laboratory. Briefly, mice to be injected intracranially were 
anesthetized, mounted in a stereotactic frame (Figure 4-13 A) and a midline scalp 
incision was made to expose the surface of the skull. The point of junction of the coronal 
and sagittal sutures of the skull, termed bregma, served as reference point for 
stereotactic injections (Figure 4-13 B). A small hole was made at the define position of 
the caudate putamen (2.5 mm lateral to the bregma) and the needle was stereotactically 
introduced into the left striatum (3 mm deep) (Figure 4-13 C). 1 x 105 GL261 cells 
suspended in 4 µl of phosphate buffer (DPBS) were then injected over 16 min with an 
injection rate of 250 nl/min using a microinjection unit (Figure 4-13 A). Following 
injection, the needle was left in place for an additional 5 min to minimize any back-flow 
and the skin was sutured with non-absorbable nylon thread.  
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Figure 4-13: Stereotactic injection of mice in the left striatum 
A: Stereotactic frame with microinjection unit; B: schematic representation of the skull adapted from 
(Cook, 1965); C: Coronal section of the brain adapted from the mouse brain library. 
We first investigated the intracranial tumor growth of buffer-treated GL261 cells 
compared to cells infected with MVM wt and the empty parvoviral vector                   
Chi-MVMp/Δ800, which had only marginal effects on tumor growth and survival in the 
GL261 subcutaneous model (Enderlin et al., 2008). 
To this end, GL261 cells were infected in vitro with either MVMp wt, Chi-MVMp/Δ800 at 
an MOI of 3 RU per cell, or buffer-treated (mock). 1 x 105 cells were stereotactically 
implanted into the left brain hemisphere of C57BL/6 mice (9 animals per group). After 
intracranial tumor inoculation, tumor growth was monitored weekly by magnetic 
resonance imaging (MRI) and the percentage of surviving mice in the different groups 
was recorded daily. Tumor growth and animal survival are illustrated in Figure 4-14. 
In agreement with the literature, almost all mice implanted with buffer-treated cells died 
within four weeks (Szatmari et al., 2006; Zagzag et al., 2000) (Figure 4-14 B). 
Infection of GL261 cells prior implantation with Chi-MVMp/Δ800 or MVMp wt did not 
affect the intracranial tumor growth of GL261 cells up to 23 days post-implantation as 
shown by the similar growth compared with buffer-treated cells (mock) (Figure 4-14 A). 
While the animal survival of mice implanted with Chi-MVMp/Δ800 infected cells was 
slightly, but statistically significantly, prolonged compared to mice implanted with buffer- 
treated cells (p<0.05), there was no statistically significant difference between MVMp wt 
and mock groups. The median survival of mice implanted with Chi-MVMp/Δ800- 
(31 days) or MVMp wt- (30 days) infected cells was only slightly prolonged compared to 
mice implanted with mock-infected cells (28 days) (Figure 4-14 B).  
These results are in agreement with the marginal effects of parvoviral infection on the 
GL261 subcutaneous tumor growth and survival of mice (Enderlin et al., 2008).  
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Figure 4-14: Tumor growth and survival of mice intracranially implanted with GL261 cells 
infected with MVMp wt or the empty parvoviral vector Chi-MVMp/Δ800  
GL261 cells were infected in vitro with MVMp wt, Chi-MVMp/Δ800 (MOI = 3 RU/cell) or buffer-treated, 
and 1 x 105 cells were intracranially implanted in the left striatum of C57BL/6 mice (9 per group). Tumor 
development and animal survival were monitored over time. The tumor growth (A) and the percentage of 
surviving animals per group (B) are plotted as a function of time post-implantation. The tumor size is 
given as mm2 + SEM. Statistical analysis was performed using the Wilcoxon Rank Sum Test. (*=p<0.05 
versus mock). (C) Representative MRI scans of one mice implanted with buffer-treated cells and one 
mice implanted with Chi-MVMp/Δ800 over time.  
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4.4.2. Inhibition of tumor growth and prolonged survival of mice implanted 
intracranially with GL261 transducing TNF-α or both TNF-α and IP-10, but 
not IP-10 alone 
TNF-α- and IP-10-transducing parvoviral vectors were recently shown to inhibit the 
growth of subcutaneously grafted GL261 glioma cells in syngeneic recipient animals. 
The tumor growth of GL261 cells infected in vitro with TNF-α- and IP-10-encoding 
parvoviruses and subsequently implanted subcutaneously in C57BL/6 mice was 
significantly delayed compared to the controls and complete tumor regression was 
observed when glioma were coinfected with both vectors (Enderlin et al., 2008).  
This prompted us to investigate the antitumor effects of TNF-α- and IP-10-transducing 
parvoviruses and their combination on glioma tumor growth and animal survival when 
GL261 cells are implanted intracranially.  
To this end, GL261 cells were infected in vitro with either Chi-MVMp/TNF-α, or          
Chi-MVMp/IP-10 at an MOI of 3 RU per cell, or coinfected with both vectors at an MOI 
of 3 RU per cell for each vector. As control, GL261 were infected with the empty vector 
Chi-MVMp/Δ800 at an MOI of 3 RU per cell. 1 x 105 cells were stereotactically 
implanted into the left brain hemisphere of C57BL/6 mice. After intracranial tumor 
inoculation, tumor growth was monitored weekly and the percentage of surviving mice in 
the different groups was recorded daily. The tumor growth is shown for one 
representative experiment (9 mice per group) out of two in Figure 4-15 A and the animal 
survival is illustrated in Figure 4-15 B based on two independent experiments 
(2 x 9 mice).  
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Figure 4-15: Inhibition of tumor growth and increased survival of mice implanted 
intracranially with GL261 transducing TNF-α or both TNF-α and IP-10, but 
not IP-10 alone 
GL261 cells were infected in vitro with Chi-MVMp/TNF-α, Chi-MVMp/IP-10 (MOI = 3 RU/cell), or 
coinfected with Chi-MVMp/TNF-α and Chi-MVMp/IP-10 (MOI = 3 RU/cell for each vector). GL261 cells 
infected with Chi-MVMp/Δ800 (MOI = 3 RU/cell) served as control. 1 x 105 cells were intracranially 
implanted in the left striatum of C57BL/6 mice. Tumor development and animal survival was monitored 
over time. The tumor growth (A, 9 mice per group), and the percentage of surviving animals (B, 18 mice 
per group from two independent experiments) are plotted as a function of time post-implantation. The 
tumor size is given as mm2 + SEM. Statistical analysis was performed using the using the Koziol test for 
the tumor growth (*=p<0.05 versus delta) and the Wilcoxon Rank Sum Test for the animal survival 
(*=p<0.05, **=p<0.001 versus delta).   
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The intracranial tumor growth was significantly delayed in animals implanted with                    
Chi-MVMp/TNF-α-infected GL261 cells or with cells coinfected with Chi-MVMp/TNF-α 
and Chi-MVMp/IP-10. This tumor inhibition was statistically significant compared to the 
empty vector Chi-MVMp/Δ800 (p<0.05). Surprisingly, the growth of GL261 cells infected 
with Chi-MVMp/IP-10 alone was similar to the empty vector and there was no significant 
differences in tumor growth between parvoviral infections delivering TNF-α or both  
TNF-α and IP-10 (Figure 4-15 A). Furthermore, the survival of mice implanted with 
GL261 cells transducing TNF-α alone (p<0.001) or with both TNF-α and IP-10 (p<0.05) 
was statistically significantly prolonged (median survival: 35 days for both groups) 
compared to mice implanted with Chi-MVMp/Δ800-infected cells (median survival: 
31 days). In contrast, the survival of mice implanted with GL261 cells transducing IP-10 
(median survival: 30 days) was not significantly different from the control. No statistically 
significant differences could be observed between the survival of mice implanted with 
GL261 cells transducing either TNF-α alone or both TNF-α and IP-10 (Figure 4-15 B). 
 
These results differ from the data previously obtained in the subcutaneous model, as 
TNF-α- and IP-10-transducing parvoviral vectors alone were shown to inhibit the growth 
of subcutaneous GL261 and complete tumor regression was achieved when glioma 
were coinfected with both vectors, showing synergistical antitumor effects. Moreover, 
the survival of mice implanted subcutaneously with TNF-α- or IP-10-transducing GL261 
cells was quite similar and prolonged compared to the control (Chi-MVMp/Δ800), while 
all mice implanted with GL261 cells coinfected with Chi-MVMp/TNF-α and                  
Chi-MVMp/IP-10 were long-term survivors (Enderlin et al., 2008). 
Thus, in contrast to the results obtained subcutaneously, treatment with the IP-10-
encoding vector did not reduce the GL261 intracranial tumor growth, and consequently 
did not increase the survival of the animals compared to the control group. No synergy 
between TNF-α and IP-10 could be observed in this setting. In this model, TNF-α alone 
was the most potent antitumor cytokine.  
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4.4.3. Analysis of the mechanisms sustaining the antitumor effects of parvoviral 
vectors transducing TNF-α alone or together with IP-10 in the GL261 
intracranial model 
In order to investigate the mechanisms sustaining the antitumor effects of parvoviral 
vectors expressing TNF-α and to elucidate the lack of effects of IP-10-encoding vectors, 
we analyzed tumor microvascularization, the recruitment of the major types of 
leukocytes involved in immune responses, as well as intratumoral cell proliferation and 
apoptosis by immunohistochemistry on tumors samples from infected GL261 cells 
implanted intracranially. 
For this, GL261 cells infected in vitro with either Chi-MVMp/TNF-α, or Chi-MVMp/IP-10, 
at an MOI of 3 RU per cell, or coinfected with Chi-MVMp/TNF-α and Chi-MVMp/IP-10 at 
an MOI of 3 RU per cell for each virus and 1 x 105 cells were intracranially implanted in 
the left striatum of C57BL/6 mice (3 mice per group). Cells infected with MVMp wt,          
Chi-MVMp/Δ800, or buffer-treated (mock) were used as controls. 21 days post-infection, 
the brains were resected, cryofixed, and tumors sections were stained with specific 
antibodies by immunohistochemistry. Cryosections were photographed and digitalized 
images were processed with an imaging software to quantify positive cells or surface 
area.  
4.4.3.1 Inhibition of tumor angiogenesis in TNF-α-transduced GL261 tumors 
The cytokines used in this model are known to have both immunostimulating functions 
but also to potentially inhibit tumor angiogenesis. Indeed, IP-10 is known for its 
chemoattractive properties and also as a potent angiostatic molecule. TNF-α induces 
immune stimulation and was also reported to inhibit tumor angiogenesis. Therefore, we 
investigated the effects of parvoviral vectors delivering these transgenes on the 
intracranial GL261 tumor microvascularization. For this, tumor cryosections were 
histomorphometrically examined after staining for CD31, used as a marker of 
endothelial cells and microvascularization. The results are illustrated in Figure 4-16. 
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Figure 4-16: Decreased percentage of CD31+ labeled area after infection with TNF-α-
encoding MVMp-based vector 
GL261 cells were infected in vitro with Chi-MVMp/TNF-α, Chi-MVMp/IP-10 (MOI = 3 RU/cell), or 
coinfected with both vectors (MOI = 3 for each vector). GL261 infected with wt MVMp, Chi-MVMp/Δ800 
(MOI = 3 RU/cell) or buffer-treated (mock) were used as controls. 1 x 105 cells were intracranially 
implanted in the left brain hemisphere of C57BL/6 mice (3 per group). 21 days post-infection, brains were 
resected, cryofixed and tumors sections were stained with an antibody against CD31 by 
immunohistochemistry, and counterstained with hematoxylin. Cryosections were photographed and 
digitalized images were processed with an imaging software to quantify CD31+ labeled area. The 
percentage of CD31+ labeled area within the tumor is given as mean value of three animals per treatment 
group. Error bars represent standard deviations. Statistical analysis versus buffer-treated cells (mock) 
was performed using Student’s t test (*=p<0.05, **=p<0.01). Representative pictures are showed below. 
The microvascularization, as shown by CD31 labeling, was significantly decreased in 
tumors derived from GL261 cells infected with Chi-MVMp/TNF-α alone (p<0.01) or 
coinfected with Chi-MVMp/TNF-α and Chi-MVMp/IP-10 (p<0.05) compared to the 
control group (mock). TNF-α-transducing parvovirus had the most potent effect with less 
than 2 % of CD31+ labeled area compared with 6 % in the control (mock). In contrast, 
the effects of Chi-MVMp/IP-10, Chi-MVMp/Δ800 or MVMp wt on tumor 
microvascularization were not statistically significant compared to the control (mock). 
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These results indicate that TNF-α has an antiangiogenic effect on intracranial GL261 
tumor microvascularization while IP-10 has no significant effect. 
The effects of parvoviruses encoding TNF-α or its combination with IP-10 on 
microvascularization correlate with the increased survival of mice and suggest that 
inhibition of tumor angiogenesis by TNF-α may contribute to the antitumor mechanisms.  
4.4.3.2 Increased infiltration of CD8+ and CD4+ lymphocytes in mice intracranially 
implanted with parvovirus-infected GL261 cells 
To investigate the effect of parvoviral vectors on the recruitment of T cells in intracranial 
GL261 cells, we analyzed the infiltration of lymphocytes in tumor samples, using anti-
CD4 and CD8, antibodies respectively. The results are illustrated in Figure 4-17. 
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Figure 4-17: Increased infiltration of CD8+ and CD4+ lymphocytes in mice intracranially 
implanted with parvovirus-infected GL261 
GL261 cells were infected in vitro with Chi-MVMp/TNF-α, Chi-MVMp/IP-10 (MOI = 3 RU/cell), or 
coinfected with both vectors (MOI = 3 RU/cell for each vector). GL261 infected with wt MVMp, Chi-
MVMp/Δ800 (MOI = 3 RU/cell) or buffer-treated (mock) were used as controls. 1 x 105 cells were 
intracranially implanted in C57BL/6 mice (3 per group). 21 days post-infection, tumors were resected, 
cryofixed and T lymphocytes were stained by immunohistochemistry using anti-mouse CD8+ (A) and 
CD4+ (B) rat monoclonal antibodies, and counterstained with hematoxylin. Cryosections were 
photographed and digitalized images were processed with an imaging software to measure CD4+ and 
CD8+ positive cells. The number of positive cells is given per mm2 as mean value of three animals per 
treatment group and the error bars represent the SEM. Statistical analysis was performed using Student’s 
t test (*=p<0.05 versus mock). Representative pictures are showed below. 
Whereas very low numbers of CD8+ lymphocytes and no CD4+ could be detected in 
tumors derived from buffer-treated GL261 cells, a significant, yet limited, infiltration of 
both types of lymphocytes could be observed in all tumors derived from parvoviral 
infected GL261 cells. The lymphocyte infiltration into intracranial GL261 control tumors 
was much less than of the subcutaneous tumors, which is in agreement with the 
literature (Badie et al., 2001).  
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The increase in lymphocyte numbers was statistically significant for CD8+ lymphocytes 
in the case of tumors derived from GL261 infected with Chi-MVMp/TNF-α (p<0.05) 
compared to the mock, but not between the different parvoviral-treated groups, due to 
the large standard deviations observed for all other groups. Similarly the difference of 
infiltration of CD4+ lymphocytes between the different parvoviral-treated groups was not 
statistically significant. 
Thus, the parvoviral infection alone is able to induce the intracranial infiltration of CD4+ 
and CD8+ lymphocytes, but we could not observe a significant effect of any of the 
transgenes on the attraction of these leukocytes. 
Yet, it is worth noting that, as shown in section 4.3.2.1, independently of the numbers of 
infiltrating lymphocytes, the cells might be differentially activated depending on the 
treatment. Indeed, we could show a decrease of TGF-β in GL261 cells infected with 
parvoviral vectors transducing transgenes. Thus, CD4+ and CD8+ might be activated in 
tumors derived from GL261 cells infected with cytokine-encoding parvoviral vectors 
while being suppressed in the control groups (Chi-MVMp/Δ800, MVM wt). 
4.4.3.3 Decreased infiltration of macrophages and/or microglia in mice 
intracranially implanted with parvovirus-infected GL261 cells. 
Both human and animal brain tumors have been shown to be significantly infiltrated by 
blood derived-macrophages and/or by microglia, the latter known as the brain resident 
macrophages (Badie and Schartner, 2000; Roggendorf et al., 1996). Once activated, 
microglial cells acquire morphological and immunophenotypical features similar to 
peripheral macrophages. Hence, it is difficult to distinguish between these two types of 
cells and they are often designated as macrophage/microglial cells (Stoll and Jander, 
1999). The role of glioma-infiltrating macrophages/microglia remains controversial, as 
they were shown to have both pro- and antitumor activities (Badie and Schartner, 2001). 
 
In order to analyze the effect of parvoviral vectors on the infiltration of activated 
macrophages/microglia in intracranially-implanted GL261, tumor cryosections were 
histomorphometrically examined after staining with anti-CD68 antibodies, specific for 
cells of the macrophage lineage. 
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Figure 4-18: Decreased infiltration of macrophages and/or microglia in mice intracranially 
implanted with parvovirus-infected GL261 
GL261 cells were infected in vitro with Chi-MVMp/TNF-α, Chi-MVMp/IP-10 (MOI = 3 RU/cell), or 
coinfected with both vectors (MOI = 3 RU/cell for each vector). GL261 infected with wt MVMp, Chi-
MVMp/Δ800 (MOI = 3 RU/cell) or buffer-treated (mock) were used as controls. 1 x 105 cells were 
intracranially implanted in C57BL/6 mice (3 per group). 21 days post-infection, brains were resected, 
cryofixed and tumors sections were stained for macrophages/microglia using a CD68-specific antibody. 
Cryosections were photographed and digitalized images were processed with an imaging software to 
quantify CD68 labeled area. The percentage of CD68 positive labeled area within the tumor is given as 
mean value of three animals per treatment group. Error bars represent standard deviations. Statistical 
analysis versus buffer-treated cells was performed using Student’s t test (*=p<0.05, **=p<0.01, 
***=p<0.001). Representative pictures are showed below. 
As shown in Figure 4-18, the infiltration of CD68+ macrophages/microglia was 
statistically decreased in all parvovirus-infected cells compared to the control (Mock), 
except for GL261 transducing IP-10. However, the difference between GL261 cells 
infected with Chi-MVMp/IP-10 or Chi-MVMp/Δ800 was not statistically significant. 
The macrophages/microglia numbers were minimal in GL261 cells infected with        
Chi-MVMp/TNF-α (p<0.001) or with both Chi-MVMp/TNF-α and Chi-MVMp/IP-10 
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(p<0.01), suggesting an effect of the transduced TNF-α on the infiltration of 
macrophages. This could be owing to a decreased invasion into the tumor, but also to a 
decreased proliferation or induced cell death within the tumor of macrophages/microglia 
upon treatment with TNF-α-transducing parvoviral vector.  
The degree of macrophages/microglia infiltration inversely correlates with the tumor 
growth and survival in vivo and indicates that these cells might have rather tumor 
promoting features in our experimental setting. Indeed, brain microglia/macrophages 
were reported to secrete many factors including cytokines and matrix proteases which 
directly or indirectly promote glioma proliferation, migration, and angiogenesis (Rao, 
2003; Watters et al., 2005). Thus, this might also be related to the reduced 
vascularization observed in TNF-α-transducing tumors (see section 4.4.3.1). 
4.4.3.4 No detectable infiltration of dendritic cells or natural killer cells  
The infiltration of natural killer cells and dendritic cells was analyzed using anti-NKG2D 
and 33D1 antibodies respectively. At the time point analyzed, we could not detect any of 
these two immune cells in GL261 intracranial tumors, irrespective of the group, similarly 
to the situation in subcutaneous tumors.  
4.4.3.5 No effect of MVMp-derived vectors on cell proliferation and apoptosis 
In order to determine whether parvoviral vectors may affect the intratumoral cell 
proliferation and apoptosis, intracranial tumor cryosections were histomorphometrically 
examined after staining for Ki67 (cell proliferation marker), or after TUNEL assay to 
detect apoptotic cells.  
As shown in Table 4-2, the proliferation rate of tumors was comparable in all groups, 
with about 30% of proliferating cells. The difference between the treatment groups was 
not statistically significant, similarly to what was observed subcutaneously. This 
suggests that at the time point analyzed (21 days post-implantation) neither the infection 
of GL261 cells with parvoviral vectors nor the transduced cytokines did affect the 
proliferation of intracranial GL261 or non tumoral cells. 
Intratumoral apoptosis was evaluated using the TUNEL assay (data not shown). The 
rate of positively stained cells in both cases were very variable between the three 
individual of each group and no significant differences could be observed. Therefore no 
clear effect could be seen on intratumoral apoptosis. 
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Treatment group % Ki67 positive cells  
Mock 29 ± 1.4 
Chi-MVMp/Δ800 31 ± 1.8 
Chi-MVMp/TNF-α 32 ± 4.2 
Chi-MVMp/IP-10 31 ± 5.1 
Chi-MVMp/TNF-α + Chi-MVMp/IP-10 28 ± 5.6 
wt MVMp 29 ± 3.8 
 
Table 4-2: No effect of MVMp-derived vectors on intracranial tumor cell proliferation  
GL261 cells were infected in vitro with Chi-MVMp/TNF-α, Chi-MVMp/IP-10 (MOI = 3 RU/cell), or 
coinfected with both vectors (MOI = 3 RU/cell for each vector). GL261 infected with wt MVMp, Chi-
MVMp/Δ800 (MOI = 3 RU/cell) or buffer-treated (mock) were used as controls. 1 x 105 cells were 
intracranially implanted in C57BL/6 mice (3 per group). 21 days post-infection, brains were resected, 
cryofixed and tumors sections were stained with an antibody against KI67 by immunohistochemistry, and 
counterstained with hematoxylin. Cryosections were photographed using a and digitalized images were 
processed with an imaging software to measure Ki67 positive cells and counterstained with hematoxylin 
to quantify the total amount of cells. The percentage of KI67 positive cells is given as mean value of three 
animals per treatment group ± standard deviation. The difference between the treatment groups was not 
statistically significant (Student’s t test). 
Thus, at the time point analyzed, the infection of GL261 cells with parvoviral vectors did 
not significantly affect the proliferation nor the apoptosis of intratumoral cells in vivo. 
However, one should point out that these results were obtained at only one time point 
and may perhaps not be representative of the situation on a long-term follow up.  
 
4.4.4. Analysis of the antitumor effects of MCP-2- and MCP-3-transducing 
parvoviral vectors on GL261 implanted intracranially in C57BL/6 mice  
Monocyte chemotactic proteins MCP-2 and MCP-3 are known to be potent 
immunoactive cytokines, recruiting a broad range of leukocytes. Their chemotaxis for 
NK cells, T cells and DCs, known to play a critical role in antitumor immunity, makes 
them attractive candidate as antitumor agents. Parvoviral vectors delivering MCP-3 
were previously demonstrated to inhibit the tumor growth of human Hela grafted in nude 
mice (Wetzel et al., 2001) and mouse melanoma implanted subcutaneously in 
syngeneic mice (Wetzel et al., 2007). This prompted us to investigate the antitumor 
effects of parvoviruses delivering MCP-2 and MCP-3 in the GL261 intracranial glioma 
model.  
For this, GL261 cells were infected in vitro with Chi-MVMp/MCP-2, Chi-MVMp/MCP-3 at 
an MOI of 3 RU per cell. As control, GL261 cells were infected with Chi-MVMp/Δ800 at 
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an MOI of 3 RU per cell or buffer-treated. 1 x 105 cells were stereotactically implanted 
into the left brain hemisphere of C57BL/6 mice (8 mice per group) and tumor growth 
was monitored weekly by magnetic resonance imaging (MRI). The percentage of 
surviving mice in the different groups was recorded daily. The tumor growth and the 
animal survival are illustrated in Figure 4-19. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-19: Tumor growth and animal survival of mice intracranially implanted with 
GL261 cells transducing MCP-2 or MCP-3 
GL261 cells were infected in vitro with Chi-MVMp/MCP-2, or Chi-MVMp/MCP-3 (MOI = 3 RU/cell).      
Chi-MVMp/Δ800-infected cells (MOI = 3 RU/cell) and buffer-treated cells (mock) served as control. 
1 x 105 cells were intracranially implanted in the left striatum of C57BL/6 mice (9 per group). Tumor 
development and animal survival were monitored over time. The tumor growth (A) and the percentage of 
surviving animals per group (B) are plotted as a function of time post-implantation. The tumor size is 
given as mm2 + SEM.  
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As observed in Figure 4-19, whereas the tumor growth of GL261 infected with           
Chi-MVMp/Δ800 or buffer-treated was comparable up to 20 days post-implantation, the 
median survival of mice implanted with GL261 infected with Chi-MVMp/Δ800 (27 days) 
was slightly increased compared to mice implanted with buffer-treated cells (24 days). 
The intracranial tumor growth of GL261 cells infected with parvoviral vectors 
transducing MCP-2 or MCP-3 and the corresponding survival (median survival: 28 days 
for MCP-2, and 28.5 days for MCP-3) was similar to that of the empty vector (median 
survival: 27 days). This indicates that the effect observed can be attributed to the 
parvoviral vector alone rather than to the inflammatory cytokines. It might be that these 
two cytokines are processed when produced by GL261, leading to their inactivation by 
cleavage, as it was shown for MCP-2 delivered by parvoviral-derived vectors in 
melanomas (Struyf et al., in press). 
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5. DISCUSSION  
5.1. Mechanisms sustaining tumor inhibition by TNF-α- and IP-10- 
expressing parvoviral vectors in the GL261 subcutaneous model 
Parvoviral vectors transducing hIP-10 and mTNF-α were recently shown to strongly 
inhibit the growth of GL261 glioma, especially when GL261 cells were coinfected in vitro 
with TNF-α- and IP-10-transducing parvoviruses, and subcutaneously implanted in 
syngeneic mice. A synergistic antitumor activity of these cytokines was demonstrated. 
The treatment of established tumors with peritumoral injections of cytokine-encoding 
parvoviruses also inhibited the tumor growth compared to tumors treated with the 
controls but to a lesser extend than in the in vitro setting and the antitumor effects of 
TNF-α- and IP-10-transducing vectors or the combination of both were comparable 
(Enderlin et al., 2008).   
5.1.1. Implication of T lymphocytes and the possible roles of Tregs and TGF-β 
The immunohistochemical analysis of CD4+ lymphocytes infiltrating established GL261 
subcutaneous tumors treated with parvoviral vectors showed a dramatically decreased 
infiltration that inversely correlated with the tumor growth in vivo. Thus, we hypothesized 
that the antitumor response might be related to a decreased tumor invasion and/or 
proliferation of CD4+ Tregs, known to suppress immune responses. Supporting this 
possibility, the depletion of Tregs was shown to prolong the survival of C57BL/6 mice 
bearing intracranial GL261 tumors (El Andaloussi et al., 2006; Grauer et al., 2007).  
This hypothesis would need to be confirmed through the analysis of Treg specific 
markers. Up to now, the most specific marker for mouse Tregs is FoxP3, a member of 
the forkehead transcription factor family. FoxP3 is highly expressed in CD4+ Tregs and 
was shown to be linked to their suppressive activity (Fontenot et al., 2003; Hori et al., 
2003). Other molecules are constitutively expressed on Tregs such as the IL-2 receptor 
α-chain (CD25) and the cytotoxic lymphocyte-associated antigen-4 (CTLA-4), and are 
alternatively used to identify Tregs. However, these molecules can also be found 
temporarily on conventional CD4+ T cells upon activation and are thus not highly 
specific for Tregs (Furtado et al., 2002; Takahashi et al., 2000). Hence, to confirm a 
DISCUSSION 
96 
decrease of CD4+ Tregs upon infection with recombinant parvoviruses, a double 
staining for CD4 and FoxP3 could be performed by immunohistochemistry or 
fluorescence-activated cell sorting (FACS) analysis. Furthermore, we could verify that 
anti-CD25 antibodies-mediated depletion of Tregs reduces the growth of virus-infected 
GL261 implanted subcutaneously.  
 
Moreover, our results revealed that the decrease in CD4+ lymphocytes correlated with 
decreased expression of TGF-β, which is known to induce Treg infiltration and 
proliferation (Chen and Wahl, 2003; Ghiringhelli et al., 2005). To confirm the effect of 
TGF-β on CD4+ Tregs, we could block TGF-β in vivo by means of TGF-β blocking 
antibodies and study its effect on the proportion of CD4+ Tregs infiltrating tumors. 
 
We showed a decreased expression of TGF-β in vitro in GL261 cells infected with 
cytokine-encoding vectors compared to cells infected with the controls (MVMp wt, 
empty vector or buffer-treated cells). Interestingly, TGF-β was also reported to impair 
the function of both CD4+ and CD8+ lymphocytes (Gorelik and Flavell, 2002; Thomas 
and Massague, 2005). This prompted us to consider that the lymphocyte activity might 
be impaired by TGF-β in the controls but not in cytokine-treated tumors. To verify this 
hypothesis, we could test in our experimental setting the activation status of CD4+ and 
CD8+ tumor infiltrating lymphocytes by FACS analysis for lymphocyte activation markers 
such as CD25, CD69 or CD44high. As for cytotoxic CD8+ T lymphocytes (CTL), we could 
also perform RT-PCR on tumors samples for the expression of markers of CTL-
mediated cytotoxicity such as perforin, granzyme A and B, IFN-γ, and Fas ligand 
(Russell and Ley, 2002).  
5.1.2. Implication of macrophages 
The analysis of the macrophage infiltration in established subcutaneous GL261 tumor 
revealed a slight increase in tumors treated with the combination of parvoviral vectors 
encoding TNF-α and IP-10 compared to the control. Since the treatment of established 
tumors with parvoviral vectors transducing TNF-α, IP-10 or both had similar antitumor 
effects, we assume that the contribution of macrophages is only marginal in this setting. 
However, it would be interesting to verify the contribution of macrophages when in vitro 
infected GL261 cells are subsequently grafted subcutaneously, as in this setting, the 
combination of parvoviral vectors encoding TNF-α and IP-10 had the most potent effect. 
This could be tested by depletion of macrophages using anti-CD68 antibodies. 
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5.2. Inhibition of tumor growth and increased survival of mice 
implanted intracranially with GL261 cells transducing TNF-α alone 
or in combination with IP-10, but not IP-10 alone 
We showed that the infection of GL261 cells prior implantation with Chi-MVMp/Δ800 
and MVMp wt did not significantly affect the intracranial tumor growth of GL261 cells 
compared with buffer-treated cells, and only slightly prolonged the survival of mice. 
These results are in agreement with the marginal effects of parvoviral infection in the 
GL261 subcutaneous model (Enderlin et al., 2008).  
The intracranial tumor growth was significantly delayed and the survival prolonged in 
animals implanted with Chi-MVMp/TNF-α-infected GL261 cells or with cells coinfected 
with Chi-MVMp/TNF-α and Chi-MVMp/IP-10 compared to the empty vector               
Chi-MVMp/Δ800. Surprisingly, in contrast to the data obtained subcutaneously, the 
growth of GL261 cells infected with Chi-MVMp/IP-10 alone and the survival of recipient 
mice was similar to the empty vector. Moreover, there were no significant differences in 
tumor growth and survival between mice implanted with parvoviral vectors delivering 
TNF-α alone or together with IP-10.  
Thus, in contrast to the subcutaneous setting, when the glioma cells are implanted 
intracranially, the most potent antitumor effects were obtained with TNF-α-transducing 
parvoviral vector. The effects of TNF-α are in agreement with those of Ehtesham et al., 
who observed a prolonged survival of mice implanted with GL26 glioma cells treated 
with an adenoviral vector encoding TNF-α compared to mice treated with a control 
vector encoding LacZ (Ehtesham et al., 2002). 
 
The lack of antitumor effect of the recombinant parvovirus encoding human IP-10    
(hIP-10) prompted us to investigate the possibility that hIP-10 transduced in GL261 cells 
could be degraded or inactivated. To verify this, hIP-10 produced by parvovirus-infected 
GL261 cells was purified until homogeneity from cell supernatants and was analyzed by 
mass spectrometry in collaboration with S. Struyf (Rega Institute, University of Leuven, 
Belgium). Preliminary results indicate that several forms of hIP-10 are produced by 
infected GL261 cells, some of which might be inactive.  
Yet, Chi-MVMp/IP-10 was shown to be effective as antitumor agent subcutaneously 
when used alone. This suggests that the levels of active hIP-10 transduced are 
sufficient to induce an antitumor response subcutaneously. In the brain, hIP-10 might be 
further modified or degraded due to the presence of modifying enzymes or proteases in 
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the tumor environment. Alternatively, some brain cells might bind and/or trap (decoy 
receptors) IP-10, thus diminishing its availability to attract leukocytes. Indeed, CXCR3 
expression was found to be constitutively expressed in vivo in astrocytes and neurons 
(Goldberg et al., 2001; Xia et al., 2000). 
Moreover, the fact that hIP-10 produced by infected GL261 cells might be partly 
degraded or inactivated supports the hypothesis that the synergistical antitumor effects 
observed subcutaneously, when using both vectors encoding mTNF-α and hIP-10, 
could indeed be related to the increased mIP-10 secretion in GL261 cells infected with 
TNF-α-transducing parvovirus.  
Our hypothesis is that in the brain, but not subcutaneously, the levels of intact hIP-10 
produced by recombinant parvovirus-infected GL261 cells are further processed so that 
only endogenous mIP-10, induced by TNF-α, may be produced in an active form, yet at 
too low levels to be effective. 
To test this, it appears thus relevant to produce a Chi-MVMp-based parvoviral vector 
delivering mouse IP-10 and to evaluate its antitumor effects intracranially, alone or in 
combination with the TNF-α-transducing vector.  
 
 
5.3. Mechanisms sustaining the antitumor effects of TNF-α-
transducing parvoviral vectors in the GL261 intracranial tumor 
model 
The above mentioned observations prompted us to study the mechanisms responsible 
for the antitumor effects of TNF-α-transducing parvoviral vector. TNF-α is a pluripotent 
cytokine, known for its immunostimulatory properties, but also as a potent inhibitor of 
angiogenesis (Lejeune et al., 1998; Mocellin et al., 2005). In addition, it is also able to 
induce direct killing of tumor cells through necrosis or apoptosis (Ashkenazi and Dixit, 
1998; Carswell et al., 1975). Here, we showed an effect of parvoviral TNF-α on 
intracranial tumor vascularization and on the infiltration of macrophages. We also 
investigated the apoptosis of intratumoral cells but could not see any significant 
differences between the different groups. This suggest that at least at the time point 
studied, TNF-α did not induce direct killing of tumor cells, although GL261 cells express 
TNF-α receptors.  
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5.3.1. Parvoviral-transduced TNF-α inhibits GL261 tumor microvascularization 
We observed that parvoviral-transduced TNF-α significantly decreased the 
microvascularization of intracranial GL261 tumors, as shown by reduced CD31 labeling. 
TNF-α was reported to inhibit tumor neovascularization as well as to induce endothelial 
cell death (Lejeune et al., 2006; Mocellin et al., 2005; Polunovsky et al., 1994; Sato et 
al., 1987). Whether inhibition of angiogenesis and/or endothelial cell death contribute to 
the decrease of microvascularization in our system remains to be elucidated.  
The angiogenesis was previously also investigated in the subcutaneous tumor model by 
CD31 labeling but no effect could be detected neither with parvoviruses encoding   
TNF-α, IP-10, or the combination of both. However, this analysis was performed on 
subcutaneous established tumors that were treated in vivo with parvoviruses. Therefore, 
the cytokine levels achieved might have been too low, due to loss of the virus in non-
tumoral cells. Yet, tumor necrosis was shown to be enhanced in the groups treated with 
parvoviral vector encoding TNF-α (Enderlin et al., 2008). Whether this was due to direct 
killing of GL261 cells or to vascular damage remains to ne determined. 
5.3.2. Parvoviral-transduced TNF-α decreases the infiltration of macrophages 
and/or microglia in GL261 brain tumors 
We showed lower numbers of macrophages/microglia in GL261 tumors transducing 
TNF-α. The reduced infiltration with microglia/macrophages correlated with the reduced 
tumor growth and increased survival of mice. These results are in agreement with 
clinical studies indicating that the extend of glioma-associated macrophages/microglia 
positively correlates with poor prognosis (Leung et al., 1997; Roggendorf et al., 1996; 
Rossi et al., 1988). These data are also in accordance with those of Engel et al., who 
showed that inhibition of C6 rat glioma growth correlated with decreased 
macrophages/microglial infiltration (Engel et al., 1999), and of Platten et al., who 
showed that macrophages/microglia infiltration induced by MCP-1-transducing CNS-1 
glioma tumors inversely correlated with animal survival (Platten et al., 2003). 
Macropages/micoglia may indeed contribute to tumor development by secreting growth 
signals, angiogenic factors, matrix-degrading proteinases, and immunosuppressors 
(Badie and Schartner, 2001; Bingle et al., 2002; Graeber et al., 2002).  
Both peripheral macrophages and microglia are CD68+. Thus, we cannot discriminate 
between the relative contribution of both types of cells in our system by means of this 
marker. So far, no specific markers have been identified to differentiate microglia and 
DISCUSSION 
100 
macrophages. Yet, some markers are differentially expressed on both types of cells in 
the mouse, such as CD45 which is highly expressed on macrophages (CD45high) and 
less on microglia (CD45+) (Sedgwick et al., 1991). We could thus consider using such a 
marker to discriminate both cell types by FACS analysis.  
The reduced numbers of macrophages/microglia in TNF-α-transduced intracranial 
GL261 tumors could be due to reduced invasion in the tumor, reduced proliferation, or 
increased cell death within the tumor. Indeed, TNFR-1 and TNFR-2 expression was 
reported on macrophages/microglia (Dopp et al., 1997) and TNF-α could thus directly 
kill these cells. Both types of cells are known to produce TNF-α upon activation 
(Waterston and Bower, 2004; Watters et al., 2005) and have thus evolved to be 
resistant to TNF-α-mediated apoptosis. For instance, macrophages were shown to 
constitutively express NF-κB, and its inhibition induced macrophages apoptosis (Liu et 
al., 2004). It might be that macrophages/microglia are sensitized to TNF-α-induced cell 
death in the glioma microenvironment through inhibition of NF-κB. Alternatively, TNF-α 
may act indirectly by inducing or inhibiting the production of other proteins that would 
lead to macrophages/microglia cell death or decrease their infiltration and/or 
proliferation. 
5.3.3. Slight increased infiltration of lymphocyte in parvovirus-infected brain 
tumors  
We showed a mild increase of CD4+ and CD8+ lymphocytes in parvovirus-infected 
GL261 intracranial tumors compared to the control (mock), but no significant attraction 
due to the cytokines expressed by parvoviral vectors. Yet, as mentioned before, it might 
be that the activation of lymphocytes is higher in tumors transducing cytokines than in 
the controls (MVMp wt and the empty vector) as a result of the decreased TGF-β 
secretion in GL261 transducing cytokines. In agreement with this, inhibition of TGF-β 
signaling using an inhibitor of the TGF-βRI kinase was shown to restore immune 
surveillance and to improve the survival of mice implanted intracranially with SMA-560 
glioma (Tran et al., 2007). Furthermore, the eradication of established intracranial 9L rat 
gliomas was reported after subcutaneous immunizations with 9L cells expressing a 
TGF-β antisense construct (Fakhrai et al., 1996). Thus, it would be interesting to test 
the expression of TGF-β in vivo in our system, for example by RT-PCR on tumor 
samples. 
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5.4. Potential of cytokine-transducing parvoviral vectors for glioma 
therapy 
Our findings illustrate the efficacy of TNF-α-encoding parvoviral vectors as antitumor 
agent in a mouse syngeneic intracranial glioma model. Further studies should be 
performed to exploit the therapeutic potential of cytokine-encoding parvoviral vectors 
and their possible application to malignant gliomas. This would include the injection of 
parvoviral vectors in vivo in established brain tumors or the use cytokine-secreting 
autologous glioma vaccines. As the adult brain is composed of low proliferating glial 
cells and post-mitotic neurons, the application of parvoviral vectors in vivo should 
selectively target glioma tumor cells, as the parvoviral life cycle is strictly dependent on 
host cell proliferation. In agreement with this, preclinical studies showed that normal 
mouse astrocytes and microglia sustain an abortive viral life cycle upon MVMp infection 
(Abschuetz et al., 2006). 
 
Cytokine-transducing parvoviral vectors, like all emerging immunotherapeutic agents, 
should be considered to be applied as adjuvant to the conventional treatment strategy, 
involving surgery, radiation and chemotherapy, to eradicate residual brain tumor cells. 
Of interest, several reports showed that the combination of radiation with intratumoral 
administration of TNF-α-encoding vectors substantially reduced glioma tumor 
progression (Li et al., 1998; Staba et al., 1998). 
Thus, the use of TNF-α-encoding parvoviral vectors in combination with radiotherapy 
and/or chemotherapy appears as a promising therapeutic approach for the treatment of 
malignant gliomas. Whether TNF-α can be combined with IP-10 to increase its efficacy 
in the brain remains to be further investigated. 
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8. LIST OF ABBREVIATIONS  
8.1. Terms 
Amp ampicillin 
ATPase adenosine triphosphatase 
BBB blood brain barrier 
BSA bovine serum albumine 
CD cluster of differentiation 
cDNA complementary DNA 
CNS central nervous system 
CO2 carbone dioxyde 
CMV human cytomegalovirus 
CMR1 chromosome region maintenance protein 1 
DAB diamino-benzidine 
DC dendritic cell 
dCTP Deoxycytidine triphosphate 
DMEM Dulbecco’s modified Eagle medium  
DMEMc DMEM complete 
DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
Dnase deoxyribonuclease 
dNTP deoxynucleotide triphosphate 
DPBS Dulbecco phosphate buffered saline 
ds DNA double stranded DNA 
DTT dithiothreitol 
E. Coli Escherichia Coli 
EDTA ethylenediaminetetraacetic acid  
EGF epidermal growth factor 
ELISA enzyme linked immunosorbent assay 
ER endoplasmic reticulum 
FACS fluorescence-activated cell sorting 
FBS fetal bovine serum  
FGF fibroblast growth factor 
GAPDH glyceraldehyde-3-phosphate dehydrogenase 
GBM glioblastoma multiforme 
h human 
HBSS Hanks’ balanced salt solution  
HRP horseradish peroxidase 
HSV herpes simplex virus 
i.c. intracranial 
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IFN interferon 
Ig immunoglobulin 
IHC immunohistochemistry 
IL interleukin 
IP-10 interferon-γ inducible protein 10 
JNK Jun kinase 
Kan kanamycin 
LB Luria-Bertani  
LPS lipopolysaccharide 
Luc luciferase 
m mouse 
MCP monocyte chemotactic protein 
M-MLV RT Moloney murine leukemia virus reverse transcriptase 
MCS multiple cloning site 
MEM minimum essential medium Eagle 
MEMc MEM complete 
MHC major histocompatibility complex 
MLEC mink lung epithelial cells 
MOI multiplicity of infection 
MPV-1 mouse parvovirus 1 
MRI magnetic resonance imaging 
mRNA messenger RNA 
MVM minute virus of mice 
MVMi MVM immunosuppressive strain 
MVMp MVM prototype strain 
NF-κB nuclear factor kappa B 
NK  natural killer 
NS viral non-structural proteins 
O/N over night 
OCT optimum cutting temperature 
ORF open reading frame 
32P Phosphorus 32 
PBS phosphate buffered saline  
PAI plasminogen activator inhibitor 
PCR polymerase chain reaction 
PFA paraformaldehyde 
PFU plaque forming unit 
p.i. post-infection 
PLA2 phospholipase A2 
PV parvovirus 
RCV replication-dependent virus 
RLU relative light unit 
RNA  ribonucleic acid 
Rnase ribonuclease 
RT room temperature 
RT-PCR reverse transcription-PCR 
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RU replication unit 
s.c. subcutaneous 
SAT small alternatively translated protein 
SD standard deviation 
SDS sodium dodecyl sulfate  
SEM standard error of the mean 
SMN survival motor neuron protein  
SSC saline-sodium citrate 
TAE tris-acetate/EDTA 
TAR transactivating region 
TE tris-EDTA 
Tet tetracyclin 
TGF transforming growth factor 
TK thymidine kinase 
TNF tumor necrosis factor 
TNFR TNF receptor 
TUNEL terminal deoxynucleotidyl transferase biotin-dUTP nick end labeling 
UV ultraviolet 
VEGF vascular endothelial growth factor 
VP viral capsid proteins 
V-TE viral TE 
v/v volume per volume 
w/v weight per volume 
wt wild-type 
WHO world health organization 
x fold, times 
8.2. Units 
bp  base pair 
°C  degree Celsius 
Ci Curie 
cm centimeter 
CPM counts per minute 
g  gram 
h  hours 
kg  kilogram 
l  liter 
µ  micro 
M molar 
m milli 
mm millimeter 
min minute 
n  nano 
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nt nucleotide 
p  pico 
rpm revolution per minute 
s second 
V volt 
U units 
 
 
 
 
 
 
 
